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Chondrosarcoma  
Chondrosarcoma is a malignant cartilage tumour representing 20% of 
malignant bone tumours [1]. It is most common in adults around the age of 
fifty and develops predominantly in the bones of the ribs, pelvis and bones 
of the extremities. The most frequently observed subtype is conventional 
chondrosarcoma, which represents 85% of all the chondrosarcomas, 
followed by rarer chondrosarcoma subtypes dedifferentiated 
chondrosarcoma (10%) [2], mesenchymal chondrosarcoma (2%) [3], clear 
cell chondrosarcoma (2%) [4] and periosteal chondrosarcoma (1%) [1] (see 
figure 1).  
 
  
Figure 1. Chondrosarcoma subtypes and grades. Conventional chondrosarcomas 
are the most common subtype, followed by dedifferentiated chondrosarcomas. Of all 




Conventional chondrosarcoma can be found either as a central subtype, 
when it is located inside the medulla of the bone or as a peripheral subtype 
when it is located next to the bone. Central conventional chondrosarcoma 
accounts for 85% of all conventional chondrosarcomas, while peripheral 
chondrosarcoma is rarer and comprises 15% of all conventional 
chondrosarcomas. Conventional chondrosarcoma can be further subdivided 
into three histologically different grades; Atypical cartilaginous tumour 
/Grade I) (72%), Grade II (20.5%) and Grade III (7.5%) [5], which 
histologically show an increase in cellularity and a decrease in matrix 
deposition with increasing grade (see figure 2). Based on the latest WHO 
classification from 2020 the term Atypical cartilaginous tumour is given to 
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low grade cartilaginous lesions located in the long and short tubular bones, 
while the term Grade I is restricted for low grade cartilaginous lesions 
located in the flat bones. The histological appearance is similar, but lesions 
located at the flat bones represent with a poorer clinical outcome, and need 
more extensive surgery [6]. Histological grade is the most important 
predictor of survival and metastasis. Atypical cartilage tumours rarely 
metastasize and show a relatively good prognosis with a 10-year survival 
rate of 83-88%. Grade II chondrosarcomas show a 10 years survival of 62-
64% and grade III chondrosarcomas show a very poor prognosis with a 10 
years survival rate of 26-29% and a high risk of developing metastasis [1, 5, 
7, 8]. Recurrence of a low-grade tumour into a higher histological grade 
occurs in ~13% of the cases, leading to a worse prognosis for these patients 
[7, 9].  
Central chondrosarcomas can arise de novo or from a pre-existing 
enchondroma, which are benign cartilage lesions that can arise in the 
medulla of the bone. Characteristic mutations identified in 87% of 
enchondromas and 38-70% of central chondrosarcomas are mutations in 
isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2) [10, 
11]. These are enzymes catalysing the conversion of isocitrate to alpha-
ketoglutarate in the Krebs Cycle. A mutation in one of these genes leads to 
a gain of function in which alpha-ketoglutarate is converted to the 
oncometabolite D2HG (See figure 3). This oncometabolite competes with 
alpha-ketoglutarate to bind to alpha ketoglutarate dependent enzymes 
resulting in inhibition of these enzymes. This group of enzymes is involved 
in different important processes such as methylation, collagen folding and 
oxygen sensing [12-14]. 
Peripheral chondrosarcomas always develop from a pre-existing benign 
osteochondroma. Osteochondromas are benign bone tumours developing 
adjacent to the bone, which can progress towards secondary peripheral 
ACT/CS1. Osteochondromas can either occur as sporadic or as hereditary 
disease in which case multiple osteochondromas develop. Alterations in 
Exostosin glycosyltransferase 1 (EXT1) or Exostosin glycosyltransferase 2 
(EXT2) are involved in the development of osteochondromas. Heterozygous 
germline mutations in these genes have been identified in 70-95% of 
patients with multiple osteochondromas [15]. In addition, homozygous 
inactivation of EXT1 is observed in 80% of sporadic osteochondromas [16-
18]. Although homozygous inactivation is observed in osteochondromas, 
only a small percentage (~15%) of peripheral chondrosarcomas show 
homozygous inactivation of the EXT genes [18-22]. This leads to the 
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hypothesis that wildtype cells with functional EXT that are located in or near 
this EXT-null microenvironment are the precursors of secondary peripheral 
chondrosarcoma [23]. EXT1 and EXT2 are involved in biosynthesis of 
heparan sulfate chains of proteoglycans [24]. Proteoglycans are important 
for cell to cell contact and regulate growth plate organization. The absence 
of EXT1 or EXT2 in the developing bone will lead to the formation of an 
osteochondroma [25]. 
 
Rare chondrosarcoma subtypes 
Dedifferentiated chondrosarcoma is a malignant high-grade 
chondrosarcoma subtype. Histologically it shows a mixed appearance of a 
usually low grade cartilaginous component and a high grade dedifferentiated 
component [2] (see figure 2). The 10 years survival is only 28%, and when 
the patient presents with metastasis at diagnosis this if further decreased 
to 10% [26]. Like in conventional central chondrosarcomas IDH1 and IDH2 
mutations have been identified in 54% of the cases [10]. 
Mesenchymal chondrosarcoma is a high-grade tumour with a reported ten 
years survival rate between 27 and 67% [27, 28]. Its histology shows  a 
mixture of differentiated cartilage combined with undifferentiated small 
round cells [3] (see figure 2). Genetically, mesenchymal chondrosarcoma is 
characterized by a fusion between HEY1 (Hes-Related Family BHLH 
Transcription Factor with YRPW Motif 1) and NCOA2 (Nuclear Receptor 
Coactivator 2). The function of HEY1 is as transcription factor downstream 
of Notch signalling. NCOA2 is a nuclear hormone receptor coactivator. Their 
role in development of mesenchymal chondrosarcoma still needs to be 
investigated. 
Clear cell chondrosarcoma is a low-grade chondrosarcoma subtype 
histologically showing malignant cells with clear empty cytoplasm and 
hyaline cartilage matrix (see figure 2). It is mainly found in the epiphysis of 
the femoral or humoral head and the prognosis is relatively good with a 
mortality rate of approximately 15% [29]. No recurrent possible initiating 
mutations have been identified in this subtype.  
Periosteal Chondrosarcoma originates from the periosteum and is a very 
rare chondrosarcoma subtype accounting for less than 1% of the cases [1]. 
Little is known about its development and progression however IDH1 
mutations have been identified in 15% of periosteal chondrosarcomas [30]. 
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Figure 2. Histological appearance of conventional (ACT, Grade II and Grade III) and 
rare chondrosarcoma subtypes. (ACT: atypical cartilage tumour, DCS: 
dedifferentiated chondrosarcoma, MCS: mesenchymal chondrosarcoma, CCS: clear 
cell chondrosarcoma). 
 
Current treatment options for patients with chondrosarcoma 
Surgery 
Chondrosarcomas are relatively resistant towards chemo- and radiotherapy, 
consequently the best treatment option for patients with chondrosarcoma is 
surgery. Complete surgical removal of the tumour provides the only chance 
for cure. Grade II and III chondrosarcoma is treated if possible, by wide, en-
bloc excision of the tumour, while atypical cartilaginous tumour that is 
confined to the tubular bone, is removed by intralesional curettage often 
followed by adjuvant treatment. When the tumour is large or has grown into 
the surrounding soft tissue wide resection is always performed [8].  
 
Radiotherapy 
Chondrosarcomas are considered radioresistant, however after incomplete 
resection or when surgery is not feasible radiotherapy is given to 
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chondrosarcoma patients. This is challenging since high doses are needed 
to achieve an improvement especially when the tumour is located in the 
skull or spine [8]. Proton beam therapy has shown to be a much better 
option compared to conventional radiotherapy [31], especially for tumours 
close to vital organs. This type of radiotherapy can deliver the particles 
precisely to the tumour without damaging the surrounding tissue and since 




Chemotherapy is not standard treatment for patients with chondrosarcoma, 
since there is no evidence whether this is beneficial for these patients. A 
small increase in median overall survival was observed in patients with 
unresectable chondrosarcoma when treated with conventional 
chemotherapy [32]. Mesenchymal chondrosarcoma has been described in 
several reports to be more sensitive to chemotherapy compared to other 
chondrosarcoma subtypes, and has shown a reduced risk of recurrence and 
a better overall survival after chemotherapy [27, 28, 33-38]. However in a 
meta-analysis this could not be confirmed [39]. 
 
Therapy resistance mechanisms 
There are several possible explanations why chondrosarcoma cells are 
resistant to chemo- and radiotherapy; the tumour is slow growing and has 
a large amount of cartilage matrix, which may hamper access to the cells. 
This is however not the case for high grade chondrosarcomas, which 
proliferate faster and have myxoid instead of hyaline cartilaginous matrix, 
and they also show chemo- and radiotherapy resistance. A second possible 
mechanism is the expression of multi-drug resistance pumps, which has 
been shown on chondrosarcoma cell lines and patient tissues. However, 
despite the expression of these pumps doxorubicin was still able to 
accumulate in the nuclei of 3D chondrosarcoma cell pellets [40-42]. Another 
possible mechanism is the expression of anti-apoptotic Bcl-2 family 
members, which has been shown previously as a mechanism of 
chemoresistance in chondrosarcoma cell lines. Inhibition of Bcl-2 family 
members could sensitize conventional, dedifferentiated and, as shown in 
this thesis, mesenchymal chondrosarcoma cells towards doxorubicin and 
cisplatin chemotherapy [41, 43]. Furthermore, upregulation of other pro-
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survival and down regulation of pro-cell death mechanisms are likely to play 
a role in therapy resistance. 
 
Possible new therapeutic options 
IDH1 and IDH2 mutations as therapeutic vulnerability 
Mutations in IDH1 or IDH2 have been identified in 38-70% of central 
chondrosarcomas, 87% of enchondromas, 54% of dedifferentiated 
chondrosarcomas [10, 11] and 15% of periosteal chondrosarcomas [30]. 
Compounds specifically targeting mutant IDH1 or IDH2 have been 
developed by several pharmaceutical companies. Inhibiting mutant IDH1 
using AGI-5198 decreased the production of D2HG in in vitro 
chondrosarcoma cell models, but did not lead to any reduction in viability, 
proliferation and migration, unless used at high, probably toxic dosages [44, 
45]. This indicates that the mutation in IDH1 or IDH2 is an early event in 
tumorigenesis, but after progression chondrosarcomas are not dependent 
on it anymore. Although preclinical studies do not seem promising, clinical 
trials assessing the efficacy of IDH1 and IDH2 mutant inhibitors in 
chondrosarcoma patients are ongoing (NCT022737399, NCT02481154, 
NCT02073994, NCT03684811). 
The oncometabolite D2HG competes with alpha-ketoglutarate to bind to 
alpha ketoglutarate dependent enzymes, which leads to inhibition of these 
enzymes [12-14] (Figure 3). Two groups of alpha ketoglutarate dependent 
enzymes that affect methylation are demethylating enzymes of the ten eleven 
translocation (TET) family and histone demethylases of the jumonji C 
domain containing (JMJD) family. TET enzymes convert 5-methylcytosine 
(5-mC) to 5-hydroxymethylcytosine (5-hmC). Inhibition of TETs will lead to 
an increase in methylation. Indeed IDH1 and IDH2 mutant chondrosarcoma 
cell lines and tissues do show a CpG island methylator phenotype (CIMP) 
[11, 45, 46], however surprisingly no differences in 5-mC and 5 hmC 
immunostaining were observed in a panel of ~100 chondrosarcomas 
between IDH1 or IDH2 mutant and wildtype [47]. Likewise, no difference in 
histone methylation marks H3K27me3, H3K9me3 and H3K27me3 was 
observed in the same cohort. Further studies should determine whether 
IDH1 or IDH2 mutant chondrosarcoma patients should be included in 
clinical trials assessing the effect of demethylating compounds specifically 
in IDH1 and IDH2 mutant tumours (NCT03666559). 
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IDH1 and IDH2 mutated cells produce very high concentrations of D2HG. 
For this process high amounts of alpha ketoglutarate are needed, which can 
be generated either by glycolysis or glutaminolysis. In IDH1 and IDH2 
mutant cells generation of alpha ketoglutarate by glutaminolysis has been 
shown as the most important mechanism [48-50], making targeting 
glutamine metabolism an interesting vulnerability to specifically target IDH1 
or IDH2 mutated cells. In vitro studies in chondrosarcoma cell lines show 
sensitivity towards glutamine pathway inhibitors, however in contrast to 
studies in genetically engineered cell lines [49, 51], no correlation to IDH1 
or IDH2 mutation status was observed [52]. Clinical trials currently 
conducted in IDH1 and IDH2 mutated tumours, including chondrosarcoma, 
aim at inhibiting glutamine metabolism using either CB-839 
(NCT02071862) or metformin or chloroquine (NCT02496741) [53].  
The NAD+ synthesis pathway has been identified using metabolic profiling 
strategies as another IDH1 and IDH2 mutation specific vulnerability [54]. 
Although chondrosarcoma cells were extremely sensitive to inhibition of 
NAD+ synthesis, no correlation with mutation status could be identified [55]. 
Unfortunately phase I clinical trials including FK866 and GMX1778 (and 
prodrug GMX1777) were discontinued due to dose-limiting toxicities [56].  
Another proposed vulnerability in IDH1 and IDH2 mutant cells is the 
increase in reactive oxygen species (ROS) levels due to a decrease in NADPH 
levels. NADPH is important for the reduction of ROS and in addition it is 
important for DNA damage repair. A decrease in NADPH, and consequently 
more ROS and less efficient DNA damage repair will increase sensitivity 
towards chemo and radiotherapy [57]. A better overall survival in IDH1 and 
IDH2 mutated cancers, most likely due to increased therapy sensitivity, has 
been reported in glioma [58] and glioblastoma [59], but not for acute myeloid 
leukaemia [60]. For chondrosarcoma the general consensus is that there is 
no change in outcome although literature studies show conflicting results 
[47, 61].  
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Figure 3. Citric acid cycle and (possible) consequences of IDH1 or IDH2 mutations 
on downstream cellular processes. Wild type IDH1 (cytoplasm) or IDH2 
(mitochondria) converts isocitrate to α-ketoglutarate (α-KG), while mutant IDH1 or 
IDH2 converts α-KG to the oncometabolite D2HG. This process results in an altered 
NADH/NADP+ ratio. Furthermore the produced oncometabolite D2HG competes 
with α-KG to bind to α-KG dependent dioxygenases in the nucleus, resulting in 
altered epigenetics. In the cytoplasm inhibition of α-KG dependent dioxygenases 
results in alterations in collagen maturation and degradation of HIF1-α. In addition 
other not yet investigated enzymes are likely to be affected by the production of 
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Targeting anti-apoptosis proteins to induce chemosensitization 
Apoptosis is a tightly regulated and controlled process of programmed cell 
death to remove damaged or unnecessary cells from the body. Apoptosis can 
be activated by either the intrinsic or the extrinsic pathway (figure 4). By 
upregulating anti-apoptotic proteins, cells can increase  the threshold of 
DNA damage that can accumulate in a cell, and consequently cells can 
continue to divide in the presence of otherwise too much DNA damage [63]. 
As briefly mentioned above, chondrosarcoma cell lines express high levels of 
Bcl-2 and Bcl-xl, and upon inhibition with ABT-737 (inhibiting Bcl-2, Bcl-xl 
and Bcl-w) conventional and dedifferentiated chondrosarcoma cells could be 
sensitized towards doxorubicin and cisplatin [41]. 
Targeting death receptors is another strategy exploited in chondrosarcomas. 
It was shown that chondrosarcoma cell lines were not sensitive towards 
monotherapy with a death receptor inhibitor (TRAIL inhibitor), however they 
could be sensitized towards doxorubicin [64, 65]. Furthermore, clinical trials 
have been conducted investigating the use of death receptor inhibitors 
(PRO95780) in treatment of chondrosarcoma (NCT00543712), and although 
the phase I trial seemed promising, the phase II trial was terminated due to 
low efficacy. Future studies focussing on combination strategies will 
determine whether there is a role for TRAIL inhibitors in future 
chondrosarcoma treatment [66]. 
TP53 mutations have been observed in 20 percent of chondrosarcomas and 
are only found in the more malignant high-grade subtypes [67-69]. As can 
be observed in figure 3 P53 is a main component of the apoptosis pathway 
and its absence is thought to lead to deregulation of apoptosis activation, 
although P53 has a broad range of other functions as well [70]. Clinical trials 
with a mutant P53 inhibitor (APR-246) [71] are ongoing in TP53 mutated 
cancers and first results look promising [72, 73] (NCT02098343, 
NCT03072043, NCT02999893). 
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Figure 4. Apoptosis pathway. Schematic overview of the intrinsic and extrinsic 
apoptosis pathways. The intrinsic apoptosis pathway is activated upon extracellular 
stimuli, resulting in an upregulation of pro-apoptotic family members and a 
downregulation of anti-apoptotic family members. This eventually lead to 
mitochondrial membrane permeabilization (MMP) and the release of cytochrome C. 
This will bind to apaf-1 and the apoptosome is formed, this is able to cleave caspase-
9 which in turn activates caspase 3, 6 and 7. The extrinsic apoptosis pathway is 
activated by death receptors and the formation of a death-inducing signalling 
complex (DISC) will result in activation of caspase 3, 6 and 7 either directly or 
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Upregulated pro-survival mechanisms as possible targets 
Survival pathways in cancer cells are usually up or de-regulated and small 
molecules specifically inhibiting these pathways can serve as possible 
treatment options. In chondrosarcoma several pro-survival pathways have 
been shown to be upregulated (see figure 5). Kinome profiling of 
chondrosarcoma cell lines and primary cultures revealed that the SRC 
pathway was one of the most active pathways in chondrosarcoma [75]. 
Treatment of cell lines with dasatinib resulted in a dose dependent decrease 
in viability and sensitization towards doxorubicin especially in TP53 mutant 
cells. In addition, SRC inhibition slowed down migration of chondrosarcoma 
cell lines.[76]. Treatment of low to intermediate grade chondrosarcoma with 
dasatinib resulted in stable disease for a small subset of patients indicating 
that treatment might be beneficial in some specific patient groups [77].  
One growth factor receptor found to be active in chondrosarcoma is the 
platelet-derived growth factor receptor (PDGFR) and expression of PDGFR-
alpha was correlated with adverse outcome [78, 79]. Although there was 
activation of the pathway, no increase in survival was observed in a phase 
2 clinical study in which chondrosarcoma patients were treated with 
imatinib [80]. Regorafenib, a multi-kinase inhibitor, targeting VEGFR-1, 2, 
3, TIE2, KIT, RET, RAF, PDGFR and FGFR is tested in a phase 2 study 
(NCT02389244) in metastatic bone sarcomas and first results in 
osteosarcoma look promising [81]. Expression of VEGF and presence of 
microvasculature has been shown in high grade chondrosarcoma, indicating 
that angiogenesis inhibition could be a potential therapeutic option for these 
patients [82-84]. A small case series including 10 patients treated with either 
pazopanib or ramucirumab suggests a potential benefit for patients with 
metastatic chondrosarcoma [85]. The current trial testing pazopanib in 
unresectable chondrosarcoma should prove whether inhibition of 
angiogenesis is a viable therapeutic strategy to treat high grade 
chondrosarcoma (NCT01330966). 
Activating mutations in NRAS have been identified in 12% of 
chondrosarcoma samples indicating a role for MAP kinase inhibitors in the 
treatment of chondrosarcoma [86]. No clinical studies have been described 
so far including chondrosarcoma patients.  
Another important pro-survival pathway upregulated in chondrosarcoma is 
the mTOR pathway. This pathway is active in 69% of conventional and 44% 
of dedifferentiated chondrosarcoma as shown by S6 phosphorylation [86]. 
Treatment of chondrosarcoma cell lines with a dual PI3K/mTORC1/2 
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inhibitor (dactolisib) resulted in a dose dependent decrease in viability. In 
addition a reduction in tumour growth was observed in an orthotopic mouse 
model after treatment [86]. Everolimus treatment in a rat chondrosarcoma 
model showed a block in cell proliferation and a decrease in Glut1 and HIF1a 
expression, two genes regulated by mTOR [87]. Combination treatment of 
rapamycin and cyclophosphamide showed a partial response in 1 and stable 
disease in 6 out of 10 patients. Confirmation of these results is currently 
ongoing in a phase II clinical trial (NCT02821507). 
 
 
Figure 5. Survival pathways shown to be deregulated in chondrosarcoma. Simple 
representation of the mTOR pathway (yellow), RAS pathway (blue) and SRC pathway 
(purple) and their crosstalk. The mTOR pathway is activated by several growth factor 
receptor tyrosine kinases that can activate Pi3K. Phosphorylation of 
Phosphatidylinositol 4,5-biphosphate (PIP2) to generate Phosphatidylinositol 3,4,5-
triphosphate (PIP3) activates AKT kinases, which in turn phosphorylate tuberous 
sclerosis protein 1 and 2 (TSC1-TSC2) leading to dissociation of the complex. This 
complex negatively regulates mTORC1, and therefore its dissociation leads to 
activation of mTORC1, which leads to an increase in mRNA translation, lipid and 
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nucleotide synthesis and a decrease in autophagy through the activation of amongst 
others; S6K1, 4E-BP1 and ULK1. The grey lines represent a negative feedback loop 
in which mTORC1 prevents the overactivation of the pathway. mTORC2 is less 
studied, but its activation is caused by PIP3 and growth factors as well as metabolic 
stimuli. mTORC2 activation leads to activation of amongst others AKT, PKC and 
SGK1 and will lead to activation of mTORC1, and an increase in metabolism and 
proliferation and survival. Activation of the Ras-Raf-Mek-Erk pathway is also 
induced by growth factor receptors and activation leads to an increase in 
proliferation and cell cycle progression. Ras can also activate Pi3K, and Erk has also 
the capacity to dissociate the TSC1-TSC2 complex leading to activation of mTORC1. 
SRC kinases show a lot of crosstalk and are regulating several important survival 
pathways. They can activate the RAS as well as mTOR pathways and thereby 
promoting proliferation and cell survival. Activation of SRC kinases also leads to 
angiogenesis, migration, invasion and metastasis trough activation of focal adhesion 
kinase (FAK) and transcriptional factors (for example STAT3). Figure based on [88-
90].  
 
Developmental pathways that play a role in chondrosarcoma development 
During bone development several pathways regulate the differentiation of 
chondrocytes in the growth plate. One pathway particularly important in the 
Indian hedgehog (IHH) pathway. Together with parathyroid hormone-like 
hormone (PTHLH) a gradient is created in which immature chondrocytes are 
able to terminally differentiate. When IHH is constitutively active terminal 
differentiation cannot be achieved and this can result in the development of 
an enchondroma [91]. Mutations in IHH genes are identified in 18% of 
chondrosarcomas suggesting a role for this pathway in development and 
progression of chondrosarcoma [69]. A phase II clinical trial studying the 
effect of IHH inhibition (GDC-0449) showed only modest activity [92]. 
Although good results were obtained in a tumour xenograft model [93], 
treatment with another IHH pathway inhibitor IPI-926 did not show an 
improvement in progression free survival in chondrosarcoma patients [94]. 
 
Targeting the immune micro-environment 
Targeting the immune micro-environment has become a big focus in cancer 
research and also in the sarcoma field more research has been investigating 
the applicability of immune therapy [95, 96]. In conventional 
chondrosarcoma immune infiltrate was found to correlate with prognosis; a 
higher amount of immune infiltrate correlated with a better prognosis [97]. 
Although immune infiltrate was detected in conventional chondrosarcoma, 
in another study immunohistochemical staining showed that there was no 
expression of the immune checkpoint ligand Programmed death ligand 1 
Introduction and Thesis outline 
 
- 23 - 
 
(PDL-1) in conventional chondrosarcoma, but this was only present in 44% 
of dedifferentiated chondrosarcoma. In addition a high amount of immune 
suppressive immune infiltrate was found in the latter chondrosarcoma 
subtype [98]. In a retrospective case study including 2 patients with 
chondrosarcoma a promising response was observed for one of the patients 
with metastatic dedifferentiated chondrosarcoma; a partial response was 
maintained even after 26 cycles with PDL-1 inhibitor nivolumab [99]. A large 
phase 2 clinical trial assessing the safety and activity of PDL-1 inhibitor 
Pembrolizumab included five chondrosarcoma patients of which one showed 
an objective response [100]. In addition, a case report was published 
describing a patient with conventional chondrosarcoma showing a near 
complete response by nivolumab treatment [101]. Clinical trials currently 
ongoing are investigating the effect of combined mTOR and PD-L1 inhibition 
(NCT03190174) or combined CTLA-4 and PD-L1 inhibitors (NCT02982486) 
in sarcoma. Future studies should determine how many and which 
chondrosarcoma patients will benefit from PDL-1 inhibition. 
Other immunogenic cancer specific markers identified in chondrosarcoma 
include MAGE-A3, NYESO-1/LAGE-1a and PRAME antigens that might be 
targetable using T-cells specific for these antigens [102-104]. 
 
Cell cycle regulators in high grade chondrosarcoma 
One of the characteristics of cancer is uncontrolled proliferation, caused by 
a deregulation in the cell cycle and identifying and targeting these proteins 
can be a good strategy to treat cancer. The cell cycle is regulated by a large 
amount of proteins that are active during specific phases in the cell cycle 
(figure 6). Alterations in the retinoblastoma (RB) pathways have been 
identified in 96% of high grade chondrosarcomas, as shown by 
overexpression of CDK4, p16INK4A or cyclin D1 in high grade chondrosarcoma 
tissue samples [105, 106]. In addition higher expression of CDK4 was 
correlated with  a worse overall survival [107]. In vivo studies in an 
orthotopic chondrosarcoma mouse model showed a good response towards 
CDK4/6 inhibitor palbociclib, which has been FDA approved for the 
treatment of breast cancer [107]. A clinical trial assessing the efficacy of 
palbociclib is conducted in sarcoma, although it is unknown if 
chondrosarcoma patients will be included in these studies (NCT03242382). 
As mentioned previously, TP53 mutations are identified in 20% of 
chondrosarcomas [67-69]. Cells with a defective P53 protein depend more 
on the G2 checkpoint to halt cell proliferation in case of DNA damage. This 
gives opportunities to induce synthetic lethality by inhibiting proteins 
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regulating the G2 checkpoint and select patients with defective P53 function 
for treatment with these inhibitors. 
 
Figure 6. Major proteins involved in cell cycle progression. Activation of cyclin 
dependent kinases by mitogenic signals results in progression from G1 to S phase. 
This happens by phosphorylation of retinoblastoma protein 1 (RB1) and subsequent 
activation of E2F transcription factors. This is negatively regulated by growth 
inhibitory signals that activate CIP/KIP and INK4, inhibitors of cyclin dependent 
kinases. Different CDK-cyclin complexes regulate progression through G1-S-G2 and 
M phase. In addition, several other important proteins such as Polo like kinases 
(PLK1) and Aurora kinases (Aurora A and B) also regulate cell cycle progression. Cells 
can exit the cell cycle and go in G0, which can either be reversible of irreversible. 
DNA damage can trigger cell cycle checkpoints (CHK1 or CHK2), which depends on 
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discover new therapeutic targets for chondrosarcoma. For this previously 
established chondrosarcoma cell lines are used and were chosen based on 
genetic background and their utility in terms of transfection efficiency. 
These lines are used to discover new possible targetable vulnerabilities in 
chondrosarcoma and where possible we tried to validate our findings in 
more translatable models. 
 
Outline of the thesis 
The aim of my thesis was to identify new therapeutic targets for patients 
with chondrosarcoma. In addition, we tried to explore the biology of 
chondrosarcoma and tried to find mechanisms that cause chemoresistance 
in these cells.  
Chapter 2 describes the molecular drivers in chondrosarcoma. All known 
genetic alterations and pathway deregulations are described and discussed 
in detail for each chondrosarcoma subtype. 
In chapter 3 and 4 the role of Bcl-2 family members in chondrosarcoma is 
studied. Chapter 3 describes targeting of Bcl-2 family members using ABT-
737 as a possible therapeutic strategy in mesenchymal chondrosarcoma, a 
highly malignant rare chondrosarcoma subtype. In chapter 4 the role of the 
different Bcl-2 family members is assessed separately using a selective Bcl-
2 and a selective Bcl-xl inhibitor, showing that Bcl-xl is the most promising 
Bcl-2 family member in targeted treatment of chondrosarcoma. 
Screening approaches to identify new therapeutic targets are performed in 
chapter 5, 6 and 7. Chapter 5 describes a focussed apoptosis siRNA screen 
identifying Survivin as a potential therapeutic target for chondrosarcoma 
patients. The role of kinases is explored in chapter 6, where a kinase 
focussed siRNA screen and compound screen is performed. We show that 
cell cycle regulators are important in chondrosarcoma cell survival and 
might be potential targets in a subset of high-grade chondrosarcoma 
patients. A metabolic compound screen is described in chapter 7. Here the 
role of the mTOR pathway is assessed in chondrosarcoma cell lines and an 
orthotopic mouse model. 
Chapter 8 focusses on radiation resistance in chondrosarcoma. Cell lines 
and tumour explants are treated with radiotherapy and possible markers 
predicting radio-sensitivity are assessed using sequencing and 
immunohistochemistry.  
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Chapter 9 contains the summary and conclusion and results of different 
studies will be discussed and put in a broader perspective. 
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Introduction 
Chondrosarcoma is a malignant cartilage forming tumour accounting for 
20% of all malignant bone tumours [1]. Only a small percentage of 
chondrosarcomas is found in the skull or spine (2-12%) [2]. Depending on 
the subtype, different molecular pathways are involved in development and 
progression of chondrosarcoma. In the skull or spine, chondrosarcoma 
needs to be distinguished from chordoma, which shows a similar 
presentation and anatomical location, but a different biological behaviour. 
The distinction can be made using brachyury immunohistochemistry, as 
overexpression of brachyury is the hallmark of chordoma [3]. On the other 
hand, chondrosarcomas represent a heterogeneous group of tumours, in 
which different cell signalling pathways are involved in tumorigenesis. In 
this chapter, the most important pathways will be discussed. 
 
Clinicopathological classification of chondrosarcoma 
Chondrosarcomas can be divided in conventional chondrosarcoma (85%), 
and more rare subtypes; dedifferentiated chondrosarcoma (10%), 
mesenchymal chondrosarcoma (2%), clear cell chondrosarcoma (2%) and 
periosteal chondrosarcoma (1%) [4-7]. Central conventional 
chondrosarcoma is the most common in the skull and spine, followed by 
mesenchymal chondrosarcoma [8]. 
 
Conventional chondrosarcoma 
Conventional chondrosarcoma can be further subdivided in central (>85%) 
and peripheral chondrosarcoma (~15%) based on its location in the bone. 
Central chondrosarcomas develop in the bone either directly or from a 
previously developed benign enchondroma [4] (see figure 1). Enchondromas 
can develop as a solitary lesion or as multiple enchondromas in Ollier 
disease or Maffuci syndrome [9]. Ollier disease and Maffuci syndrome are 
both rare non-hereditary disorders caused by somatic mosaic mutations in 
IDH1 or IDH2. In solitary enchondromas ~1% undergoes malignant 
transformation towards a conventional central chondrosarcoma. 
Enchondromas from patients with multiple enchondromas have a much 
higher transformation rate of ~50% [10]. 
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Peripheral chondrosarcomas develop at the surface of the bone from a pre-
existing benign osteochondroma. They develop from bones that are formed 
by endochondral ossification; consequently they are extremely rare findings 
in the skull. Central and peripheral chondrosarcomas show similar 
histological features and are graded using a three tiered scale. Atypical 
cartilaginous tumours (previously chondrosarcoma grade I) show low 
cellularity, do not metastasize, but behave locally aggressive and local 
recurrences can develop. Grade II and III chondrosarcomas are high grade 
tumours with an increased cellularity and mitoses. These tumours show a 
higher metastatic rate and poor patient survival. Patients with atypical 
cartilage tumours show a 10 years overall survival rate of 83%, while 
patients with grade II chondrosarcomas show a 10 years survival rate of 64% 
and patients with a grade III chondrosarcoma show the poorest 10 years 
survival rate of 29% [4, 11] So far, histological grade is the most important 
predictor of prognosis. Upon recurrence of low grade tumours, progression 
towards a higher histological grade can occur in ~13% of the cases [12, 13], 
resulting in a poorer prognosis. Chondrosarcomas are resistant to 
conventional chemo- and radio therapy, leaving surgical removal as the only 
treatment option [14]. This has major implications for patients with 
inoperable disease to whom no treatment options can be offered.  
 
Rare chondrosarcoma subtypes 
Dedifferentiated chondrosarcoma comprises ~10% of all chondrosarcomas 
[5]. It is a high grade chondrosarcoma variant that is characterized by a 
mixed histological appearance of dedifferentiated cells and a cartilaginous 
component. Patients with dedifferentiated chondrosarcoma show a 5 years 
overall survival between 7 and 24% [5, 15]. Like conventional 
chondrosarcoma, dedifferentiated chondrosarcoma is also resistant to 
conventional chemo- and radiotherapy. Mesenchymal chondrosarcoma is a 
rare high grade chondrosarcoma consisting of differentiated cartilage mixed 
with undifferentiated small round cells [7]. Ten years survival rates are 
reported between 27 and 67% [16, 17]. The small round cell component of 
mesenchymal chondrosarcoma may respond better to chemotherapy 
compared to other chondrosarcoma subtypes [17, 18]. Clear cell 
chondrosarcoma is a rare low grade chondrosarcoma mainly found in the 
epiphysis of the humoral or femoral head [11]. Histologically, clear cell 
chondrosarcoma shows malignant cells with clear empty cytoplasm 
surrounded by hyaline cartilaginous matrix [6]. Surgery is the only 
treatment option for patients with clear cell chondrosarcoma. The prognosis 
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is relatively good with a mortality rate of 15% [6]. Periosteal chondrosarcoma 
is the rarest chondrosarcoma subtype accounting for less than 1% of the 
cases and originates from the periosteum [19, 20]. 
 
Molecular drivers in chondrosarcoma  
In this chapter the molecular pathways and mutations in chondrosarcoma 
are discussed for the different chondrosarcoma subtypes, however most 
research has been focussing on central conventional chondrosarcoma. 
Mutations in IDH1 and IDH2 have been found in central as well as 
dedifferentiated and periosteal chondrosarcoma. COL2A1 mutations and 
alterations in Indian hedgehog genes are seen in a small percentage of 
central chondrosarcoma. Deregulation of the hedgehog pathway has been 
found in a large part of chondrosarcomas indicating that it is important for 
the development of these tumours. Peripheral chondrosarcomas are 
characterized by mutations in EXT1 or EXT2. Both central and peripheral 
chondrosarcomas show alterations in p53 and pRb pathways when 
progressing from low to high grade. 
 
Central, dedifferentiated and periosteal chondrosarcoma 
IDH1 and IDH2 mutations  
Mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) have been 
first identified in glioblastoma multiforme [21] and later also in 87% of 
enchondromas, 38-70% of primary central chondrosarcomas, 54% of 
dedifferentiated chondrosarcomas and 15% of periosteal chondrosarcomas 
[9, 19, 22, 23]. The occurrence of IDH1 and IDH2 mutations in enchondroma 
indicates that this is an early genetic event in the development of central 
chondrosarcoma (see figure 1). Also in intracranial chondrosarcomas, but 
not chordomas, IDH1 and IDH2 mutations have been reported, making it a 
good diagnostic marker in the differential diagnosis between the two 
different entities [24, 25]. 
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Figure 1. Progression model of conventional chondrosarcoma  
Enchondromas, located in the medulla of the bone, can develop into central 
chondrosarcoma, while osteochondromas, located at the surface of the bone, can 
progress into peripheral chondrosarcoma. Early driver gene alterations include 
mutations in IDH1 or -2 in enchondroma and EXT1 or -2 in osteochondromas. Upon 
progression towards chondrosarcoma, similar molecular defects in apoptosis and 
survival pathways are observed in central and peripheral subtypes. Deregulation of 
p53 and pRb pathways is observed in the majority of high grade chondrosarcomas. 
 
Cellular consequences of an IDH1 or IDH2 mutation  
IDH1 and IDH2 are enzymes that convert isocitrate to alpha ketoglutarate 
(αKG) in the Kreb’s cycle. IDH1 is located in the cytoplasm and IDH2 in the 
mitochondria and they both convert isocitrate to αKG while meanwhile 
NADPH is produced from NADH+ [26]. Mutations in IDH1 and IDH2 are 
heterozygous and affect only a single amino acid. In chondrosarcoma, the 
IDH1 mutation is always located on the R132 position in exon 4, and the 
IDH2 mutation on R172, which are the active sites of the enzymes. IDH1 and 
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IDH2 mutations are mutually exclusive. When IDH1 or IDH2 are mutated, 
isocitrate cannot be converted to αKG anymore, because affinity for 
isocitrate is reduced. However, affinity for αKG and NADPH is increased, 
which leads to the conversion of αKG to the oncometabolite D2-
hydroxyglutarate (D2HG) which consumes instead of produces NADPH. Also 
the enzyme activity of the wild type IDH is inhibited by the mutant [27, 28].  
D2HG production has major consequences for enzymes that depend on αKG 
as a co-substrate (2-OG-dependent dioxygenases). D2HG and αKG are 
structurally the same, except that the C2 carbonyl group of αKG is replaced 
by a hydroxyl group in D2HG. Because of the similarity of D2HG to αKG, 
D2HG acts as a competitive inhibitor by binding to the αKG binding pocket 
in the active site of the enzymes that depend on αKG [27, 29].  
One group of enzymes affected by increased D2HG levels are the ten-eleven 
translocation (TET) enzymes (Tet 1/2/3). Tet enzymes are demethylating 
enzymes that convert 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine 
(5-hmC), which is the first step in demethylation of cytosines [30-32]. 
Several studies have been conducted investigating the role of Tet enzymes 
and 5-hmC, showing that they play an important role in stem cell 
development and differentiation. Simultaneous knock down of all three Tet 
proteins in mouse ES cells resulted in low levels of 5-hmC, impaired 
differentiation, promoter hypermethylation and deregulated expression of 
genes involved in embryonic development [33].  
JMJC domain containing histone lysine demethylases (JHKDMs) are also 
inhibited by D2HG. These enzymes remove methyl groups from the lysine 
residues of histone proteins, which will affect the histone code leading to 
alterations in chromatin structure and transcription of genes [29, 34, 35].  
Another group of αKG dependent enzymes influenced by D2HG are collagen 
and HIF prolyl-4hydroxylases (PHDs) [29, 36]. Collagen PHDs are important 
for collagen folding and maturation. When these enzymes are inhibited 
collagen cannot be properly folded and accumulates in the endoplasmic 
reticulum (ER). Hydroxylated collagen is part of the extracellular matrix 
(ECM), which can influence proliferation, differentiation and invasion [37]. 
HIF PHDs are oxygen sensing enzymes that hydroxylate HIF1α and HIF2α 
under normoxic conditions, marking them for recognition by the Von Hippel 
Lindau (VHL) protein, which targets them for proteosomal degradation. 
Under hypoxic conditions there is no hydroxylation and HIF1α and HIF2α 
can dimerize with HIF1β to form complete transcription factors targeting 
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genes that function to increase oxygen delivery or enhance angiogenesis 
[38]. Since HIF PHDs need αKG to hydroxylate HIF1α and HIF2α, the 
hypothesis is that IDH1 or IDH2 mutant tumours show a higher frequency 
of HIF1α and HIF2α activation, because they will not be recognized by VHL 
and targeted for degradation. However conflicting results have been shown 
about the role of HIF PHDs in IDH mutant tumours, especially in 
glioblastomas, reporting both up and down regulation of HIF1α and HIF2α 
in IDH1 or IDH2 mutant tumour cells compared to wild type tumour cells 
[29, 36, 38]. This indicates that a more complex mechanism is involved in 
the role of HIF PHDs in IDH1 or IDH2 mutant tumours [39]. 
Mutations in IDH1 or IDH2 are expected to alter the metabolism of cells, 
because IDH1 or IDH2 are involved in the Krebs cycle converting isocitrate 
to αKG or the other way around. Mutations in IDH1 or IDH2 will inhibit this 
process and thereby cause differences in metabolic processes that depend 
on the Krebs cycle, such as glucose and glutamine metabolism as well as 
fatty acid production [40]. 
Mutant IDH1 or IDH2 expressing cells may also have an impaired ability to 
neutralize reactive oxygen species (ROS). This is because the conversion of 
alpha-ketoglutarate to D-2HG consumes one molecule of NADPH, which will 
lead to depletion of NADPH and less formation of GSH (glutathione) which 
is an important antioxidant. Consequently IDH mutant cells remove free 
radicals less effectively, which can lead to DNA mutations [26, 41]. The 
increased ROS in IDH1 or IDH2 mutant tumours can also influence the 
sensitivity to chemo- and radiotherapy. This has already been shown in 
gliomas and can also be of importance in other tumour types with IDH1 or 
IDH2 mutations [42-45]. 
 
IDH1 and IDH2 mutations in enchondroma and chondrosarcoma 
In enchondromas with an IDH1 or IDH2 mutation DNA hyper methylation is 
observed [9] and elevated levels of 2HG were shown in mutated cartilaginous 
tumours compared to wild type tumours [22].  
To assess the influence of the IDH1 or IDH2 mutation on the development of 
enchondroma, mesenchymal stem cells (MSCs) have been used as a model 
system, because the hypothesis is that enchondromas and 
chondrosarcomas result from altered differentiation of MSCs during bone 
development. MSCs are the precursors of bone, cartilage and fat tissue and 
can be forced to differentiate into these specific lineages in vitro, by adding 
2
 
- 44 - 
  
stimulating growth factors. Both D2HG addition, as well as the introduction 
of an IDH1 R132C mutation have been found to cause a block in osteogenic 
differentiation and increased differentiation towards the chondrogenic 
lineage in human MSCs [46, 47]. Also in zebra fish D2HG impairs the 
development of vertebrate rings, indicating a block in osteogenic 
differentiation during skeletogenesis [47]. The introduction of IDH1 R132C 
did not only cause an increase in cartilage differentiation, but also resulted 
in abnormal cartilage formation [46]. This may have something to do with 
the PHD enzymes involved in collagen maturation, which are affected by the 
increased D2HG levels [37]. 
Recently Hirata et al described a conditionally inducible Col2a1 specific 
IDH1 132 knock-in mouse model, which showed multiple enchondroma-like 
cartilage lesions adjacent to the growth plates of the knee after three 
months. Also after six months the same lesions were still present, without 
significant differences in size or amount. Cartilage lesions showed patchy 
expression of Col10a1 indicating deregulated chondrocyte differentiation. 
Chondrocytes cultured from the lesions of those mice showed increased 
expression of hedgehog target genes and genes expressed by hypertrophic 
chondrocytes [48]. A defect in differentiation as well as a hyper methylation 
phenotype was also observed in IDH2 R172 knock in murine 10T1/2 
mesenchymal progenitor cells. Moreover, subcutaneous injection of these 
cells in mice led to the formation of undifferentiated sarcomas in vivo 
indicating that IDH2 R172 also has tumour promoting potential [49]. 
In chondrosarcoma cell lines, and in primary tumours of patients with 
enchondroma and chondrosarcoma with an IDH1 or IDH2 mutation, 
increased levels of DNA methylation are observed compared to wild type cell 
lines. This hypermethylation was only found at CpG islands, but not at other 
regions [49, 50]. 
Increased levels of D2HG were found in chondrosarcoma cell lines with IDH1 
or IDH2 mutations compared to wild type cell lines and could be diminished 
by treatment with  a mutant specific IDH1 inhibitor (AGI-5198), however no 
effect was observed on cell viability, proliferation and migration [50, 51]. 
Likewise, cells cultured for longer periods in the presence of AGI-5198 did 
not show any reduction in cell viability [50]. Only after treatment with 
extremely high concentrations, an effect was observed on colony formation, 
migration and apoptosis [51].  
The minor effects observed after inhibition of IDH1 mutant function and 
consequently D2HG levels, suggests that mutations in IDH1 and IDH2 are 
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not essential for the proliferation and metastasis capacity of malignant 
chondrosarcoma cells and that IDH1 or IDH2 mutations are no driver 




Collagen type II alpha 1 (COL2A1) mutations have been identified in 37% 
[52] and 19.3% of central chondrosarcomas and 31.7% of enchondromas 
[53]. Type II Collagen is the major extracellular component of cartilage and 
is important for the strength and flexibility of the tissue. Mutations in the 
COL2A1 gene can lead to abnormalities in the formation of collagen. 
Immunohistochemical analysis revealed that only a small part of 
chondrosarcomas showed complete loss of the Col2a1 protein, while most 
others still showed focal staining. Mutations in COL2A1 are associated with 
several developmental disorders called type II collagenopathies; however no 
increased incidence of enchondromas or chondrosarcomas is seen in these 
disorders. Also in mice expressing a mutant COL2A1 no increased 
chondrocyte proliferation was observed. However, a disorganized growth 
plate and an aberrant structure of the collagen network was present [54]. 
Down regulation of Col2A1 in cultured mouse chondrocytes resulted in an 
up regulation of Collagen I. Also Hedgehog signalling was affected by knock 
down of Col2A1, which resulted in a defect in chondrocyte differentiation 
[55]. Whether mutations in COL2A1 are drivers of chondrosarcoma 
formation is still to be determined, since proof of principle studies have not 
yet been performed. 
 
Dysregulation of the hedgehog pathway  
The Indian hedgehog (IHH) pathway is important for bone development. 
Chondrocytes located in the growth plate undergo differentiation, resulting 
in longitudinal growth of the bone. This process is regulated by Indian 
hedgehog and parathyroid hormone-like hormone (PTHLH) in a negative 
feedback loop. Chondrocytes are differentiating towards hypertrophic 
chondrocytes after which they will be replaced by osteoblasts. Pre-
hypertrophic chondrocytes produce IHH, stimulating proliferation of 
chondrocytes and stimulating the cells of the perichondrium to produce 
PTHLH. PTHLH in its turn inhibits IHH and thereby terminal differentiation 
of chondrocytes. Constitutive activation of the hedgehog pathway will result 
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in a failure to induce terminal differentiation of growth plate chondrocytes, 
which can result in the development of enchondromas [56]. 
Expression studies showed that the hedgehog pathway members were 
higher expressed in enchondromas as well as in central chondrosarcomas 
maintaining tumour cells in a less differentiated, but proliferative state. 
Levels of expression were variable, but there was no correlation with 
histological grade [57]. Blocking of the hedgehog pathway with triparanol or 
IPI-926 resulted in reduced tumour volume in chondrosarcoma xenografts 
[57, 58], while cyclopamine did not decrease proliferation of 
chondrosarcoma cell lines [59] suggesting that the tumour 
microenvironment may play a role in this pathway. Also the potency of the 
different compounds used in these studies can be different.  
Patients with enchondromatosis show mutations in one of the genes 
involved in the IHH pathway in 8% of the cases [60, 61]. Also mice expressing 
a mutant parathyroid hormone-like hormone receptor specifically in 
chondrocytes show a deregulated growth plate and formation of cartilage 
lesions [61]. 
Hedgehog signalling is activated by binding of hedgehog ligand to the 
Patched receptor, releasing the Smoothened receptor and thereby Gli 
transcription factors are no longer inhibited and can travel to the nucleus 
to activate transcription. Similar to the mutant PTHLH receptor expressing 
mice, mice constitutively expressing Gli2 in their chondrocytes develop 
cartilage lesions [61].  
Primary cilia have been shown to be involved in IHH signalling and to 
regulate its activity [61-63]. Primary cilia are also important for the 
columnar organization of the growth plate [64]. It has been shown that 
chondrosarcoma cells express less cilia, compared to normal chondrocytes, 
which correlated with deregulated hedgehog signalling [65]. Inhibition of the 
hedgehog pathway in enchondromas and central chondrosarcomas can be 
a possible therapeutic strategy to treat patients with inoperable or 
metastatic disease. A phase II clinical trial was conducted investigating the 
efficacy of GDC-0449 Smoothened inhibitor in 45 patients with progressive 
advanced chondrosarcoma, however only modest activity was observed, with 
stable disease in only ten patients with grade I tumours after six months 
[66].  
Recently mutations in IHH genes have been identified in 18% of 
chondrosarcomas using whole exome sequencing [52]. It would be 
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interesting to see whether these patients will respond better to treatment 
with hedgehog pathway inhibitors, making it possible to preselect patients 
for treatment. 
 
P53 and pRb pathway alterations in the progression from low to high grade 
chondrosarcoma 
Mutations in the TP53 gene are the most frequently observed mutations in 
cancer, often associated with a more aggressive phenotype and worse 
prognosis [67, 68]. Mutations in TP53 can either lead to loss of function or 
gain of function [69]. Wild type p53 has important functions in controlling 
cell proliferation and apoptosis, and loss of function mutations lead to 
cancer as was proven by a TP53 knock out mouse model [70]. However, point 
mutations in TP53 will lead to pathogenic accumulation of p53 in the 
nucleus, and mutant TP53 knock-in mice present with highly invasive 
tumours [71, 72]. 
In chondrosarcoma TP53 mutations are observed in 20% of the cases and 
associated with more malignant tumours and a higher histological grade. 
Also increased nuclear p53 expression is correlated with a higher 
histological grade [52, 73, 74] as well as with a worse survival [75]. Mice 
constitutively expressing Gli, crossed with p53 knock out mice, developed 
low grade chondrosarcomas, indicating that deregulation of p53 is 
important in the progression of enchondromas to chondrosarcoma [76]. 
The retinoblastoma (pRb) pathway is important in the control of the cell 
cycle. It is the governor of the restriction point transition (R-Point), and 
decides whether to progress to S-phase or retreat to G0. Mutations are found 
in several cancer types; however in chondrosarcoma no mutations in the RB 
gene have been identified [74]. Also pRb expression was normal in 
chondrosarcomas [77].  
A consistent genomic alteration identified in central chondrosarcomas is the 
amplification of 12q13 [74, 78]. In this region both cyclin dependent kinase 
4 (CDK4) and mouse double minute 2 homolog (MDM2) are located, which 
play important roles in the pRb and p53 pathways. CDK4 forms a complex 
with cyclin D1 and together they control the transition through the G1 
restriction point by inactivating pRb. Consistent with the 12q13 
amplification observed in a subset of chondrosarcomas, CDK4 and Cyclin 
D1 expression has been shown to be upregulated in 62-73% of the high 
grade chondrosarcomas [78, 79]. Furthermore inhibition of CDK4 resulted 
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in a decrease in cell proliferation in chondrosarcoma cell lines [79]. 
CDKN2A/p16 is a negative regulator of the CDK4-cyclin D1 complex and is 
down regulated in 20% of chondrosarcomas, which also correlated with 
histological grade [80]. Moreover, in 28% of chondrosarcomas mutations in 
CDKN2A are observed [52]. However no loss of CDKN2A/p16 was found in 
enchondromas [80-82]. Decreased cell growth, but not apoptosis was 
observed in cells were CDKN2A/p16 was re-expressed [79]. MDM2 is a 
negative regulator of p53, targeting it for proteosomal degradation. MDM2 
has been shown to be overexpressed in 34% of high grade chondrosarcomas 
indicating that p53 is degraded with a higher rate in these tumours [79]. 
The combined incidence of mutations in either the p53 or pRb pathways in 
high grade chondrosarcomas is 96% [79]. This suggests that these pathways 
are important in the progression of chondrosarcoma towards a more 
malignant histological phenotype. 
 
Apoptosis and pro-survival pathways implicated in chondrosarcoma 
A downstream target in the hedgehog pathway is Bcl-2, which is upregulated 
in the growth plate and inhibits differentiation of proliferating chondrocytes 
after binding of PTHrP to its receptor. In conventional chondrosarcoma Bcl-
2 is highly expressed [83, 84] as well as in rare chondrosarcoma subtypes 
[85]. 
By up regulating anti-apoptotic proteins of the Bcl-2 family, 
chondrosarcoma cells can cause resistance to chemotherapy, which is a 
major problem in the treatment of these tumours. This has been shown in 
a cell model where chondrosarcoma cells could be sensitized to 
chemotherapy when treated in combination with a Bcl-2 family inhibitor 
(ABT-737) [85, 86]. 
Another protein highly expressed in chondrosarcoma is Survivin [87-89]. 
Survivin plays an important role in the cell cycle as well as in the apoptotic 
pathway. Furthermore it is expressed at very low levels in normal tissue, 
making it an ideal therapeutic target [90]. In preclinical studies a small 
molecule Survivin inhibitor (YM155) was shown to decrease cell viability in 
chondrosarcoma cell lines, which was dependent on TP53 mutation status 
[91]. Also down regulation of Survivin using siRNAs showed decreased 
viability and increased sensitivity towards chemotherapeutics [87]. 
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Several studies have shown the importance of the Akt-Pi3K-mTOR pathway 
in chondrosarcoma. In 69% of conventional chondrosarcoma and 44% of 
dedifferentiated chondrosarcoma S6 was phosphorylated indicating an 
active PI3K/mTOR activity. Also treatment with a dual PI3K/mTOR inhibitor 
(Bez235) resulted in reduced cell viability in chondrosarcoma cell lines and 
inhibition of tumour growth in a mouse xenografts model [92]. In a rat 
chondrosarcoma model treatment with everolimus resulted in inhibition of 
tumour growth [93]. 
 
Peripheral chondrosarcoma  
EXT1 and EXT2 mutations in osteochondroma and peripheral 
chondrosarcoma 
Multiple osteochondromas (MO) is an autosomal dominant condition in 
which mutations in tumour suppressor genes Exostosin glycosyltransferase 
1 or Exostosin glycosyltransferase 2 (EXT1 and EXT2) have been identified 
[94-96]. Patients with this disease develop osteochondromas at the surface 
of their bones and show heterozygous germline EXT1 or EXT2 mutations, 
with loss of the wildtype allele in the osteochondroma cartilaginous cap at 
least in a subset of the cases [97]. Also homozygous deletions in EXT1 have 
been identified in a subset of sporadic osteochondromas [98]. Both 
hereditary and sporadic osteochondromas can progress towards peripheral 
chondrosarcoma (see figure 1). This occurs in ~1% of sporadic and up to 5% 
of hereditary osteochondromas [99].  
Exostosin-1 and exostosin-2 are both type II glycosyltransferases which 
function in the biosynthesis of heparan sulfate chains of proteoglycans 
[100]. Proteoglycans are molecules that can regulate the signalling of several 
growth factors in many different ways. They can act as receptors or 
coreceptors in signalling pathways, regulate receptor trafficking by endo- 
and exocytosis, facilitate ligand secretion, function as a signal to other cells, 
or act by presenting a ligand to a receptor. In addition, they can regulate the 
structure of the extracellular matrix by providing a signalling gradient to 
ligands [101]. In the growth plate, heparan sulfate is important for the 
establishment of a gradient of IHH (as discussed above). When the 
biosynthesis of heparan sulfate is deregulated, the diffusion of IHH 
signalling is disturbed. This will have consequences for the polar 
organization of growth plate chondrocytes and the formation of the bony 
collar, leading to the formation of an osteochondroma [64]. 
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In a conditional inducible mouse model, where both Ext1 alleles were 
inactivated specifically in chondrocytes, the development of 
osteochondromas was observed, mimicking the human situation. The 
osteochondromas consisted of a mixture of wild type and mutated cells 
indicating that cells need normal heparan sulfate synthesis to survive [102]. 
In another mouse model with a heterozygous loss of both Ext1 and Ext2 a 
decrease in heparan sulfate was observed as well as more exostoses 
compared to mice with heterozygous loss of Ext1 or Ext2 [103]. Zebrafish 
with homozygous loss of Ext2 in their chondrocytes show osteochondroma-
like lesions [104]. In addition, they show altered mesenchymal stem cell 
differentiation [105].  
Osteochondromas can progress into peripheral chondrosarcomas in a small 
percentage of cases. It has been shown that the majority of peripheral 
chondrosarcomas has at least one wild type allele for EXT1 and EXT2, 
indicating that functional EXT is required for cells to survive and to undergo 
malignant progression [106]. Most likely additional genetic alterations are 
needed in order to progress to peripheral chondrosarcoma and they probably 
take place in the EXT1 and EXT2 wild type cells. 
 
p53 and pRb pathway alterations 
In peripheral chondrosarcoma pRb and p53 pathway alterations are also 
found in the majority of the cases, especially in tumours with higher 
histological grade. A mouse model with conditional inducible Ext1 
inactivation specifically in chondrocytes combined with conditional loss of 
Trp53 or Ink4a/Arf showed peripheral chondrosarcoma development from 
Ext-null and Ext mutated cells, mimicking the human situation. Also loss 
of primary cilia and polar organization was observed in these lesions. This 
indicates that an alteration in one of the pathways regulating the cell cycle 
in addition to the EXT mutation is needed for the development of peripheral 
chondrosarcoma from an osteochondroma [107]. 
 
Mesenchymal chondrosarcoma: HEY1-NCOA2 fusion 
Mesenchymal chondrosarcoma is characterized by a specific gene fusion 
between HEY1 (Hes-Related Family BHLH Transcription Factor with YRPW 
Motif 1) and NCOA2 (Nuclear Receptor Coactivator 2) [108]. HEY1 is a basic 
helix-loop-helix transcription factor and downstream of the Notch signalling 
pathway [109, 110]. In rhabdomyosarcoma inhibition of Hey1 resulted in 
Molecular drivers in chondrosarcoma 
 
- 51 - 
 
downregulation of Notch1 and myogenic differentiation [111]. NCOA2, also 
known as SRC2 (steroid receptor co-activator 2), is a nuclear hormone 
receptor co-activator, important for chromatin remodelling [112]. 
Overexpression of NCOA2 was found in prostate cancer and was correlated 
with metastatic disease [113]. Rearrangements involving NCOA2 have been 
identified in other sarcomas as well [114, 115]. The exact mechanism by 
which the HEY1-NCOA2 fusion leads to the formation of mesenchymal 
chondrosarcoma is currently unknown.  
 
Clear cell chondrosarcoma 
Clear cell chondrosarcomas are rare chondrosarcomas subtypes, and 
limited genetic defects have been identified in these tumours. Array-CGH 
analysis was performed, identifying hemizygous loss of the CDKN2A/p16 
locus in four out of twelve clear cell chondrosarcomas. However loss of p16 
protein expression has been identified in 95% of cases, indicating that 
aberrations in the pRb pathway are important for the development and/or 
progression of this tumour type [116].  
 
Summary/conclusion 
Treatment of chondrosarcoma patients is mainly by surgery, since these 
tumours are resistant to conventional chemo and radiotherapy. Therefore it 
is important to understand the molecular pathways involved in the 
development and progression of chondrosarcoma. Chondrosarcomas in the 
skull or spine present a challenge to remove surgically due to their location. 
Especially for these patients new therapeutic options are needed. In table 1 
the most important genetic alterations and pathways that are deregulated 
in chondrosarcoma are listed. The most frequently observed subtype is 
central chondrosarcoma, which is characterized by mutations in IDH1 or 
IDH2 in 38-70 % of the cases (see figure 1). Preclinical research exploring 
the possibility of specifically inhibiting the mutant IDH1 did not lead to a 
decrease in cell proliferation, indicating that this will not be a therapeutic 
target for chondrosarcoma patients. However future studies investigating 
synthetic lethal approaches might provide alternative options exploiting IDH 
mutation induced vulnerabilities. Promising targets for therapy include the 
Bcl-2 family members and mTOR, which are highly active in 
chondrosarcoma. Currently a phase II clinical trial investigating the effect of 
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mTOR inhibition in combination with cyclophosphamide has started, of 
which results will be awaited with great interest. 
Targeting the IHH pathway may offer another strategy to treat 
chondrosarcoma patients, since this pathway is deregulated in 
chondrosarcoma, although a phase II clinical trial did not show promising 
results. However, recently mutations in IHH genes have been identified in 
18% of chondrosarcomas using whole exome sequencing, and perhaps 
patients with these mutations will benefit from treatment. In peripheral 
chondrosarcoma EXT1 and EXT2 mutations have been found in peripheral 
chondrosarcoma, influencing the IHH pathway as well, however in contrast 
to conventional chondrosarcoma this pathway is not activated in peripheral 
chondrosarcoma making it not suitable for treatment. 
Future research will focus on identification of additional molecular 
pathways that are involved in the development and progression of 
chondrosarcoma to find therapeutic targets to treat patients with 
unresectable chondrosarcoma. 
 
Table 1. Genetic alterations and deregulated pathways found in different subtypes 
of chondrosarcoma. CS= Chondrosarcoma  
 
 Gene/Pathway Subtype Reference  
Genetic alterations    









 COL2A1 Enchondroma 
Central CS 
52,53 







Mesenchymal CS 108 
 TP53 Central CS 
Peripheral CS 
52,73,74 
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Clear cell CS 
83,84,85 
 Survivin  Central CS 
Dedifferentiated CS 
Mesenchymal CS 
Clear cell CS 
87,88,89,91 
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Abstract 
Mesenchymal chondrosarcomas are rare and highly aggressive sarcomas 
occurring in bone and soft tissue, with poor overall survival. Bcl-2 
expression was previously shown to be up regulated in mesenchymal 
chondrosarcomas. We here report on a newly derived mesenchymal 
chondrosarcoma cell line, MCS170, in which we investigated treatment with 
the BH3 mimetic ABT-737 alone or in combination with conventional 
chemotherapy as a possible new therapeutic strategy. 
The presence of the characteristic HEY1-NCOA2 fusion was confirmed in the 
MCS170 cell line using FISH, RT-PCR and sequencing. The MCS170 cell line 
was treated with ABT-737 alone or in combination with doxorubicin or 
cisplatin. Cell viability and proliferation was determined using WST-1 
viability assays and the xCELLigence system. Expression of Bcl-2 family 
members was studied using immunohistochemistry. Apoptosis was 
determined using the caspase-glo 3/7 assay and Western blot for PARP 
cleavage. 
The MCS170 cell line was sensitive to doxorubicin treatment with an IC50 of 
0.09 µM after 72 hours, but more resistant to cisplatin treatment with an 
IC50 of 4.5 µM after 72 hours. Cells showed little sensitivity towards ABT-
737 with an IC50 of 1.8 µM after 72 hours. Combination treatments 
demonstrated ABT-737 synergism with cisplatin as well as doxorubicin as 
shown by induction of apoptosis and reduction in cell proliferation.  
Restoration of the apoptotic machinery by inhibition of Bcl-2 family 
members sensitizes MCS170 mesenchymal chondrosarcoma cells to 
conventional chemotherapy. This indicates that combining the inhibition of 
Bcl-2 family members with conventional chemotherapy can be a possible 
therapeutic strategy for patients with mesenchymal chondrosarcoma. 
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Introduction 
Chondrosarcomas are cartilage forming tumors accounting for 20% of all 
the primary bone malignancies [1]. Chondrosarcoma consists of different 
subtypes with conventional chondrosarcoma being the most common (75%). 
More rare chondrosarcoma subtypes include dedifferentiated (10%) [2], 
mesenchymal (3%) [3] and clear cell chondrosarcoma (2%) [4]. Patients with 
chondrosarcoma are mainly treated by surgical removal of the tumor, 
because chemo- and radiotherapy are generally ineffective [5]. 
Mesenchymal chondrosarcoma is an aggressive, high grade 
chondrosarcoma subtype with a reported 10 year survival rate between 27 
and 67% [6-8]. Recently the survival of mesenchymal chondrosarcoma was 
determined using the Surveillance, Epidemiology, and End Results (SEER) 
database, showing that in a group of 205 patients the 10 years survival was 
43% [9]. Genetically, it is characterized by a specific characteristic gene 
fusion between the bHLH domain of HEY1 (Hes-Related Family BHLH 
Transcription Factor with YRPW Motif 1) and the C-terminal transcriptional 
activation domains of NCOA2 (Nuclear Receptor Coactivator 2) [10]. Fusions 
involving NCOA2 have also been identified in other soft tissue tumor 
subtypes including spindle cell rhabdomyosarcoma (SRF-NCOA2 and 
TEAD1-NCOA2) [11] and soft tissue angiofibroma (AHRR-NCOA2) [12] as well 
as in acute myeloid leukemia (ETV6-NCOA2 [13]  and MYST3-NCOA2 [14])  
Histologically mesenchymal chondrosarcoma is characterized by variable 
amounts of differentiated cartilage admixed with small round 
undifferentiated cells [3]. In 1983 Huvos et al. described that patients with 
mesenchymal chondrosarcoma in which the small cell component 
predominated responded better to combination chemo- and radiotherapy 
[8]. In a more recent study, investigating the effect of chemotherapy in 113 
mesenchymal chondrosarcoma patients, it was shown that treatment with 
chemotherapy reduces the risk of recurrence and improves overall survival 
in patients with localized disease [7]. Also in previous smaller case reports, 
patients with mesenchymal chondrosarcoma treated with chemotherapy 
showed a better survival compared to untreated patients [6, 15-18]. 
However, in a recent systematic review of 18 studies including 107 patients 
no correlation between anthracycline based chemotherapy treatment and 
survival was found [19]. 
Conventional chondrosarcomas are resistant to chemotherapy. Low grade 
chondrosarcomas consist of a large amount of cartilage matrix and slowly 
dividing cells, which was for long thought to be the cause of their 
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insensitivity to chemotherapy. However, high grade chondrosarcomas have 
less matrix and more rapidly dividing cells, and are also resistant to 
chemotherapy. Expression of multidrug resistance pumps has been shown 
on chondrosarcoma cell lines and patient tissues [20-22]; however this does 
not prevent doxorubicin from accumulating in the cell nuclei, indicating 
other mechanisms are involved in chondrosarcoma chemoresistance [21].  
Our group has previously shown that Bcl-2 family members play a key role 
in chemoresistance in conventional and dedifferentiated chondrosarcoma 
[21, 23]. Pro- and anti-apoptotic proteins of the Bcl-2 family play important 
roles in initiation of the intrinsic routes of apoptosis, changing the balance 
from anti- to pro-apoptotic, and activating Bak and Bax to facilitate 
mitochondrial outer membrane permeabilization. Anti-apoptotic proteins, 
such as Bcl-2, Bcl-xL and Bcl-w, prevent apoptosis by binding to pro-
apoptotic proteins,  thereby impeding Bak and Bax activation [24]. 
Treatment of different chondrosarcoma cell lines with an inhibitor of the Bcl-
2 family, including Bcl-2, Bcl-xL and Bcl-w (ABT-737) in combination with 
doxorubicin or cisplatin resulted in a synergistic effect, as was determined 
by viability and apoptosis assays [21].  
Since we previously demonstrated high expression of Bcl-2 and Bcl-xL in a 
panel of 23 mesenchymal chondrosarcomas [23], we hypothesized that  Bcl-
2 family members are also important in mesenchymal chondrosarcoma. So 
far, however, no mesenchymal chondrosarcoma cell lines were available for 
functional studies. We here report a novel mesenchymal chondrosarcoma 
cell line, MCS170, carrying the characteristic HEY1-NCOA2 fusion product, 
in which we functionally evaluated the role of Bcl-2 family members in 
chemosensitivity.  
 
Material and methods 
Compounds 
The BH3-mimetic ABT-737 (S1002, Selleckchem, Munich, Germany) is an 
inhibitor of Bcl-2, Bcl-xL and Bcl-w and was dissolved in DMSO to a stock 
concentration of 20 mM. Doxorubicin (DXR) and cisplatin (CDDP) were 
obtained from the in-house hospital pharmacy in a 0.9% NaCl solution in a 
1mg/ml concentration. Z-vad-FMK (550379, BD biosciences, San Jose, CA, 
USA) was used as a general caspase inhibitor and dissolved in DMSO to a 
stock concentration of 20 mM. 
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Cell culture 
The MCS170 cell line was generated from a recurrent mesenchymal 
chondrosarcoma of the spine resected from a 33 year-old man at the 
department of Pathology, Brigham and Women's Hospital and Harvard 
Medical School located in Boston, USA and was cultured in IMDM medium 
(Gibco, Invitrogen Life Technologies, Scotland, UK) supplemented with 15% 
heat inactivated fetal calf serum (Gibco, Invitrogen Life Technologies, 
Scotland, UK) and 1% Penicillin-streptomycin (100 U/ml) (Gibco, Invitrogen 
Life Technologies, Scotland, UK). Cells were grown at 37 °C in a humidified 
incubator with 95% air and 5% CO2. Cells were confirmed bi-monthly for 
absence of mycoplasm infection and cell line identity was confirmed before 
and after experiments by STR profiling using the GenePrint10™ System 
from Promega (Promega Benelux BV, Leiden, The Netherlands). 
 
Molecular analysis 
The presence of the characteristic HEY1-NCOA2 fusion between exon 4 of 
HEY1 and exon 13 of NCOA2 was confirmed on RNA isolated using TRIzol 
(Invitrogen, Carlsbad CA, USA) from the MCS170 cell line and a previously 
published mesenchymal chondrosarcoma patient sample as a positive 
control according to methods described previously [10]. Products were 
purified using MinElute 96 UF PCR purification kit (Qiagen, Venlo, the 
Netherlands) according to the manufacturer’s instructions and Sanger 
sequenced by Macrogen (macrogen.com). 
Fluorescent in situ hybridization was performed as described previously [25] 
using labeled BAC clones RP11-152C15 and RP11-888F10 [10]. MCS170 
cells were screened for mutations in 50 frequently mutated cancer related 
genes using the Ion AmpliSeq™Cancer Hotspot Panel v2 (Life Technologies, 
Thermo Fisher Scientific, USA, catalog number 4475346) according to the 
manufacturer’s instructions. 
 
Cell viability assay 
When cells reached 75-80% confluence they were washed with PBS, 
trypsinized, and counted using a Burker Turk counting chamber. MCS170 
cells were plated in 96 well plates (10.000 cells/well) and allowed to adhere 
overnight. Cells were incubated with concentrations of ABT-737, 
doxorubicin or cisplatin ranging between 0.1 µM to 100 µM for 24, 48 and 
72h after which a WST-1 assay was performed according to the 
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manufacturer’s instructions (Roche diagnostics GmbH, Penzberg, 
Germany). Combination assays were performed 72h after simultaneous 
addition of ABT-737 (0, 125, 500 nM or 1 µM) and doxorubicin (0, 50, 125 
nM or 1 µM) or cisplatin (0, 500 nM, 1 or 5 µM). Results of the WST-1 assay 
were measured at 450 nm using a spectrophotometer (Victor3V, 1420 
multilabel counter, Perkin Elmer, Netherlands). All viability assays were 
performed in triplicate and at least three times. 
 
Cell proliferation measurement 
The RTCA xCELLigence system (Roche Applied Sciences, Almere, the 
Netherlands) was used to measure cell proliferation in real time. MCS170 
cells were plated at a density of 15.000 cells/well, 20 hours before addition 
of either ABT-737 (1 µM), doxorubicin (125 nM or 1 µM) or cisplatin (5 µM) 
or the combination between ABT-737 with doxorubicin or cisplatin. After 96 
hours the measurement was stopped and the results were analyzed using 
RTCA software. Experiments were performed in duplicate and repeated at 
least three times. 
 
Immunohistochemistry 
Protein expression of Bcl-2 (Dako, 124), Bcl-xL (Cell signaling clone 54H6) 
and Bcl-w (Abcam 6C1) was determined using immunohistochemistry on 
paraffin embedded cell pellets of MCS170 cells. Tonsil was used as a positive 
control for Bcl-2, kidney for Bcl-xl and cerebellum for Bcl-w. 
Immunohistochemistry was performed according to standard laboratory 




PARP (clone 46D11, Cell Signaling Technology, Leiden, the Netherlands) 
cleavage was determined after 24 hours of compound treatment. Cells were 
treated with 1 µM ABT-737, 125 nM doxorubicin, 5 µM cisplatin or a 
combination of ABT-737 and doxorubicin or cisplatin. As a loading control 
α-tubulin (clone DM1A, Cell Signaling Technology, Leiden, the Netherlands) 
expression was determined. Cells were harvested using hot SDS buffer (1% 
SDS, 10 mM Tris/EDTA with complete inhibitor and phosSTOP). Of each 
sample, 20 µg protein was separated by using SDS-PAGE and transferred to 
PVDF membranes. Blocking was performed using 5% BSA in PBS/ 0.1% 
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Tween solution. Membranes were incubated with primary antibody 
overnight at 4 degrees Celsius, followed by HRP labelled secondary antibody 
for 30 minutes at room temperature. Blots were developed using ECL 
solution (PierceTM ECL Western Blotting Substrate, Fisher Scientific, 
Landsmeer, the Netherlands). 
 
Apoptosis assay 
Apoptosis was detected using the caspase-glo 3/7 assay (Promega, Madison, 
USA) according to the manufacturer’s instructions. In brief, 10.000 MCS170 
cells were plated into white walled 96 well plates (Corning B.V. Life Sciences, 
Amsterdam, the Netherlands) and the following day cells were treated with 
either 1 µM ABT-737, 125 nM or 1 µM doxorubicin, 5 µM cisplatin or a 
combination of ABT-737 and doxorubicin or cisplatin for 24 hours. Z-vad 
treatment was used as a control. Thereafter the substrate provided with the 
kit was added in a 1:1 dilution and incubated for 30 minutes at room 
temperature. Luminescence was measured using a luminometer (Victor3V, 
1420 multilabel counter, Perkin Elmer, Netherlands). In parallel a viability 




To evaluate synergy between treatment combinations the Bliss 
independence model was used. In this model the assumption is made that 
each drug acts independently of the other on the cells [27]. This is used to 
predict the combined response (C) for the two single compounds (A and B) 
by the formula: C = A + B – A * B. [28]. 
 
Results  
MCS170 as a model to study mesenchymal chondrosarcoma behavior in vitro 
MCS170 cells morphologically show an elongated shape, and they 
predominantly grow in groups of cells (Figure 1A). Using FISH we confirmed 
the presence of the HEY1-NCOA2 intra-chromosomal inversion in all cells 
similar to the positive control (Figure 1B), colocalization of one set of red and 
green probes was observed while the other set of red and green probes were 
at limited distance. Expression of the HEY1-NCOA2 fusion product was 
confirmed using RT-PCR and Sanger sequencing revealed that exon 4 of 
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HEY1 was fused to exon 13 of NCOA2 (Figure 1C). The expression of the 
HEY1-NCOA2 fusion product was variable between different passage 
numbers of the cell line. No mutations were detected in any of the 50 
oncogenes and tumor suppressor genes, including TP53, IDH1 and IDH2, in 
the Ion AmpliSeq™Cancer Hotspot Panel v2. Cell identity as determined by 
the Cell ID GenePrint 10 system (Promega) is available on request. 
 
Figure 1: Characteristics of the MCS170 cell line.  
A) Morphology of MCS170 cells in culture demonstrated elongated cytoplasm. Cells 
are growing predominantly in groups. Picture was taken at passage 31 with a 10 
times objective. B) Interphase FISH using BAC clones RP11-152C15 and RP11-
888F10 on the MCS170 cells and a Mesenchymal chondrosarcoma positive control 
sample C) Sequence showing the fusion of exon 4 of HEY1 to exon 13 of NCOA2 in 
MCS170 cells. 
 
MCS170 cells are sensitive for doxorubicin, while resistant for cisplatin 
To assess chemosensitivity, we treated MCS170 cells with the conventional 
chemotherapeutics doxorubicin or cisplatin. Cells were sensitive to 
doxorubicin treatment, especially after longer incubation periods, with an 
IC50 of 4.5 µM after 24h of treatment which decreased to an IC50 of 0.08 µM 
after 72h of exposure (Figure 2A and Table 1). Cells were resistant to 
cisplatin with an IC50 of 60 µM after 24 hours and 4.5 µM after 72 hours 
(Figure 2B).  
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Figure 2: Sensitivity of MCS170 cells to doxorubicin and cisplatin 
A, B) Dose response curves of MCS170 cells exposed to doxorubicin, cisplatin and 
ABT-737 at 24, 48 or 72 hours. Cells are sensitive for doxorubicin, especially when 
incubated for 72 hours (A), while more resistant for cisplatin (B)  
 
Table 1. IC50 values of MCS170 cells treated with doxorubicin, cisplatin and ABT-
737 for 24, 48 and 72 hours of exposure.  
 
 IC50 24 h IC50 48 h IC50 72 h 
Doxorubicin 4.5 µM 0.2 µM 0.08 µM 
Cisplatin 60 µM 15.8 µM 4.5 µM 
ABT-737 5.5 µM 2.3 µM 1.8 µM 
 
Bcl-2 family members are not essential for survival of MCS170 cells 
Since previous studies indicated that high expression of Bcl-2 and Bcl-xL is 
a hallmark of  mesenchymal chondrosarcoma [23], we determined the 
protein expression of Bcl-2 family members in the MCS170 cell line. Bcl-2 
was expressed in MCS170 (Figure 3A) cells although variable staining 
intensities were observed between different cells. Bcl-xl was highly 
expressed in MCS170 cells (Figure 3C), however only very weak Bcl-w 
expression was observed (Figure 3E). To assess whether these Bcl-2 family 
members are essential for mesenchymal chondrosarcoma cells, these were 
inhibited in MCS170 cells using the BH3 mimetic ABT-737. After 72 hours 
of treatment an IC50 of 1.8 µM was observed (Figure 3G), showing that cells 
are not sensitive for Bcl-2 family member inhibition. 
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Figure 3: Bcl-2 and Bcl-xl are expressed in mesenchymal chondrosarcoma 
A-F) Expression of Bcl-2(A, B) and Bcl-xl (C,D), but only low expression of Bcl-w (E,F) 
was found in paraffin embedded MCS170 cells (A, C, E), compared to expression in 
control tissues tonsil (B), kidney (D) and cerebellum (F) G) MCS170 cells show little 
sensitivity towards ABT-737 treatment after 24, 48 or 72 hours of exposure. 
 
Inhibition of Bcl-2 family members sensitizes towards conventional 
chemotherapy 
To evaluate a functional role for Bcl-2 family members in the response to 
chemotherapy MCS170 cells were incubated for 72 hours with ABT-737 and 
either doxorubicin or cisplatin. Compared to single treatment, a reduction 
in viability was observed when ABT-737 was combined with doxorubicin or 
cisplatin for 72 hours. (Figure 4A, B). To assess synergy the excess over Bliss 
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score was calculated. An excess over Bliss score of more than 12% 
(indicating synergy) was observed when 1 µM ABT-737 was used in 
combination with 125 nM doxorubicin or when 0.5 or 1 µM ABT-737 was 
combined with 5 µM cisplatin pointing towards a small synergistic effect 
(Table 2). Real time measurement of proliferation using the xCELLigence real 
time cell proliferation assay demonstrated an early significant reduction in 
cell index when 1 µM ABT-737 was combined with 1 µM doxorubicin, as 
compared to single treatment. Consistent with the viability assay, combining 
1 µM ABT-737 with 125 nM doxorubicin or 5 µM cisplatin resulted in a 
reduction in cell viability at 72 hours of incubation and persisted until 96 
hours (Figure 4C, D).  
 
Figure 4: Combination treatment of ABT-737 and doxorubicin or cisplatin in 
MCS170 cells.  
A,B) Viability after treatment of MCS170 cells for 72h with ABT-737 and doxorubicin 
(A) or ABT-737 and cisplatin (B). Combination treatment shows a larger reduction in 
viability compared to single treatment after 72 hours. C, D) Real time proliferation 
assay with the xCELLigence system of MCS170 cells treated with ABT-737 and 
doxorubicin (C) or ABT-737 and cisplatin (D). The combination of 1 µM ABT-737 and 
1 µM doxorubicin is most effective and shows a faster reduction in cell index, 
compared to single treatment. The combinations of 1 µM ABT-737 and 125 nM or 5 
µM cisplatin show a similar reduction in cell index and are more effective compared 
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Table 2. Excess over Bliss calculations of MCS170 cells treated with combinations 
of ABT-737, doxorubicin or cisplatin showing highest percentages when 1 µM ABT-
737 was used in combination with 125 nM doxorubicin or when 1 or 0.5 µM ABT-
737 is combined with 5 µM cisplatin. 
 
Excess over Bliss (%) ABT-737 
1 µM 0.5 µM 0.125 µM 
Doxorubicin  
 
1 µM 8.9 9.4 8.8 
0.125 µM 12.6 7.0 6.3 
0.05 µM 7.5 6.1 4.4 
Cisplatin 5 µM 14.4 14.1 2.8 
1 µM 7.6 4.4 -1.5 
0.5 µM -5.5 -8.9 -12 
 
Combination of ABT-737 with doxorubicin or cisplatin increases apoptosis 
To assess if treatment with ABT-737 and combination with chemotherapy 
resulted in apoptosis, caspase 3/7 activity was measured after 24h of 
treatment (Figure 5A). Combination treatment of ABT-737 with doxorubicin 
or cisplatin for 24 hours substantially increased caspase 3/7 dependent 
apoptosis. This effect was inhibited by the pan caspase inhibitor Z-vad-FMK, 
confirming that the effect was caspase dependent (Figure 5A). Consistent 
with results obtained using xCELLigence, combining 1 µM ABT-737 with 1 
µM doxorubicin resulted in a large reduction of cell viability, after 24 hours 
(Figure 5B). However this effect could not completely be restored by adding 
z-vad, indicating that additional mechanisms that reduce viability, besides 
caspase dependent apoptosis, may be operable. PARP cleavage was also 
measured using western blot (Figure 5C), confirming that combination 
treatment results in activation of apoptosis.  
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Figure 5: Apoptosis activation after combining ABT-737 and doxorubicin or cisplatin 
in MCS170 cells.  
A, B) Caspase 3/7 activity (A) and viability (B) measured after 24 hours of treatment 
with doxorubicin, cisplatin or ABT-737 and the combination showing highest 
caspase 3/7 activity and lowest viability in MCS170 cells treated with 1 µM ABT-737 
combined with 1 µM doxorubicin. Pan-caspase inhibitor Z-vad-FMK inhibits all the 
caspase 3/7 activity and restores part of the viability reduction observed after 
treatment with 1 µM ABT-737 and 1 µM doxorubicin. C) Western blot image showing 
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Discussion 
We here present the first mesenchymal chondrosarcoma cell line; MCS170, 
in which we could demonstrate that inhibition of Bcl-2 family members, can 
restore chemosensitivity. Mesenchymal chondrosarcoma is an aggressive 
chondrosarcoma subtype, with a poor prognosis. There is an urgent need 
for alternative treatment strategies, as the current prognosis is very poor 
with reported 10 years survival rates between 27% and 67% [6-9].  
The generation of the MCS170 cell line as a model for mesenchymal 
chondrosarcoma will give the opportunity to perform more preclinical 
research to identify possible therapeutic candidates to treat patients with 
mesenchymal chondrosarcoma, as well as to study the functional role of the 
HEY1-NCOA2 fusion. The presence of the HEY1-NCOA2 fusion gene was 
confirmed at the DNA level and at the RNA level. As expected in translocation 
driven sarcomas, a low mutational burden was found, as no additional 
mutations were found in 50 oncogenes or tumour suppressor genes 
frequently mutated in cancer. 
Preclinical studies on mesenchymal chondrosarcoma are rare, and only few 
possible therapeutic options have been described based on expression 
analysis in small sample groups. A small study investigating a panel of 
different proteins in three mesenchymal chondrosarcoma cases identified 
PKC-α, PDGFR, Bcl-2 [29] and mTOR [30] as potential therapeutic targets. 
In a larger study including 23 cases of mesenchymal chondrosarcoma TGF-
β, Bcl-2 and Bcl-xL were identified as possible therapeutic targets in 
mesenchymal chondrosarcoma [23]. No mutations in hot spot regions of 
TP53 were identified in a panel of 33 mesenchymal chondrosarcomas; 
however 61.3% showed nuclear overexpression of the p53 protein [31]. 
In this study we focused on evaluating the role of Bcl-2 family members and 
conventional chemotherapy in mesenchymal chondrosarcoma. The anti-
apoptotic proteins Bcl-2 and Bcl-xL were found to be highly expressed in 
chondrosarcoma, especially in the mesenchymal subtype, suggesting an 
important role for these proteins in mesenchymal chondrosarcoma 
chemoresistance and thereby a possible novel treatment strategy [23].  
The MCS170 cell line was sensitive for doxorubicin, especially when cells 
were treated for 72 hours, but resistant for cisplatin. This is in line with a 
recently published retrospective study including 119 patients, showing that 
mesenchymal chondrosarcoma patients with localized disease have reduced 
risk of recurrence when treated with anthracycline based chemotherapy 
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suggesting that it is beneficial to add adjuvant chemotherapy to the 
standard treatment regimen [7]. However, a recent analysis of the available 
literature could not confirm these data [19]. Also the study of Xu et al. did 
not detect a difference in overall survival when patients with localised 
disease were compared with patients that showed metastasis.  
Bcl-2 and especially Bcl-xL were found to be highly expressed in the 
MCS170 cell line, which is consistent with the known high expression of 
these Bcl-2 family members in mesenchymal chondrosarcoma primary 
tumours [23]. To investigate the role of Bcl-2 family members in 
mesenchymal chondrosarcoma, the BH3 mimetic ABT-737 was used to 
inhibit the anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w in MCS170. While 
ABT-737 monotherapy was ineffective, combination of ABT-737 and 
doxorubicin resulted in a synergistic induction of apoptosis, and reduction 
in viability, suggesting a role for Bcl-2 family members in resistance to 
chemotherapy in mesenchymal chondrosarcoma. 
Induction of apoptosis is important for the effectiveness of many therapies, 
which can be prevented by high levels of anti-apoptotic proteins or down 
regulation of pro-apoptotic proteins. By directly targeting the intrinsic 
apoptotic pathway using BH3 mimetic ABT-737, more pro-apoptotic 
proteins will be available to activate Bak and Bax, resulting in higher efficacy 
of other therapies that induce apoptosis [24].  
The combination of Bcl-2 family protein inhibitors and chemotherapeutics 
has activity in vitro in a wide variety of tumours [32], including conventional 
as well as dedifferentiated chondrosarcoma [21, 23]. Now that the MCS170 
cell line is available, we had the opportunity to show this experimentally in 
a mesenchymal chondrosarcoma model as well, indicating that patients with 
mesenchymal chondrosarcoma might also benefit from this treatment 
combination.  
ABT-263 (Navitoclax) is an orally available derivative of ABT-737 with the 
same working mechanism, which makes it a more attractive compound 
compared to ABT-737. ABT-263 is currently under evaluation in clinical 
trials, however due to side effects caused by the high Bcl-xL expression on 
platelets, only low doses could be administered [33]. Here we demonstrate 
that treatment with BH3 mimetics can sensitize mesenchymal 
chondrosarcoma for conventional chemotherapy, while single agent 
administration is not effective. This raises the possibility to administer these 
agents in combination, increasing the activity, while lowering toxicity in 
mesenchymal chondrosarcoma.  
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Mesenchymal chondrosarcoma is a rare aggressive chondrosarcoma 
subtype with a poor prognosis. In this study we describe the first 
mesenchymal chondrosarcoma cell line; MCS170, containing the 
characteristic HEY1-NCOA2 fusion, that can be used as a model to identify 
new therapeutic targets. As mesenchymal chondrosarcoma is known to have 
high Bcl-2 and Bcl-xl expression [23], we used this cell line to functionally 
investigate the role of Bcl-2 family members in chemosensitivity. We 
demonstrate that inhibition of Bcl-2 family members restores the apoptotic 
machinery in mesenchymal chondrosarcoma, rendering the cells sensitive 
to conventional chemotherapy, especially doxorubicin. 
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Abstract 
Chondrosarcomas are malignant cartilage tumors showing relative 
resistance to conventional chemo- and radiotherapy. Previous studies 
showed that chondrosarcoma cells could be sensitized to chemotherapy by 
inhibiting the Bcl-2 family members Bcl-2, Bcl-xl and Bcl-w using ABT-737. 
In this study we explored the specific role of Bcl-2 family members to identify 
the most important player in chondrosarcoma cell survival and chemo 
resistance. Immunohistochemistry was performed on tissue microarrays 
containing 137 conventional chondrosarcomas of different grades. Selective 
inhibition of Bcl-2 (S55746) or Bcl-xl (WEHI-539 or A-1155463) and the 
combination with doxorubicin or cisplatin was investigated in a panel of 8 
chondrosarcoma cell lines using presto blue viability assays and caspase 
3/7 glo apoptosis assays. In addition Bcl-2 and Bcl-xl inhibition was 
investigated in an orthotopic Swarm Rat Chondrosarcoma (SRC) model. Bcl-
2 and Bcl-xl were most abundantly expressed in the primary tumors, and 
expression increased with increasing histological grade. A subset of 
chondrosarcoma cell lines was sensitive to selective inhibition of Bcl-xl, and 
synergy was observed with doxorubicin or cisplatin in 3 out of 8 
chondrosarcoma cell lines resulting in apoptosis. Conversely, selective 
inhibition of Bcl-2 was not effective in chondrosarcoma cell lines and could 
not sensitize to chemotherapy. In vivo, selective inhibition of Bcl-xl, but not 
Bcl-2 resulted in a decrease in tumor growth rate, even though no 
sensitization to doxorubicin was observed. These results suggest that among 
the Bcl-2 family members, Bcl-xl is most important for chondrosarcoma 
survival. Further research is needed to validate whether single or 
combination treatment with chemotherapy will be beneficial for 
chondrosarcoma patients.  
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Introduction 
Chondrosarcomas are malignant primary bone tumors characterized by the 
production of a hyaline cartilage matrix, with poor vascularization [1]. 
Histologically chondrosarcomas can be subdivided into conventional, 
dedifferentiated, mesenchymal, clear cell and periosteal chondrosarcoma. 
Conventional chondrosarcoma is the most frequent subtype found in 85% 
of the cases and can either be found in the medulla of the bone (central 
subtype) or at the surface of the bone (peripheral subtype). The 10-year 
survival rate for patients with conventional chondrosarcoma depends on the 
histological grade. Atypical cartilage tumors (previously grade I) show a 10-
year survival of 83%, patients with grade II chondrosarcomas show 64% 
survival and patients with grade III tumors show a 10-year survival rate of 
29% [1]. Chondrosarcomas show relative resistance to conventional chemo- 
and radiotherapy leaving surgery as the only treatment option. As such the 
10-year survival rate of chondrosarcoma patients has remained unchanged 
for the last four decades [2]. Therefore, new treatment options are urgently 
needed, especially for patients with inoperable or metastatic disease. 
Apoptosis is a form of programmed cell death, eliminating damaged or 
unnecessary cells from the body. The intrinsic apoptosis pathway is 
regulated by B-cell lymphoma-2 (Bcl-2) family of proteins that comprises of 
anti- and pro-apoptotic and BH3-only proteins. Under stress conditions the 
BH3-only proteins inhibit the anti-apoptotic proteins Bcl-2, Bcl-xl, Bcl-w 
and Mcl1 leading to mitochondrial outer membrane permeabilization 
(MOMP) through Bax and Bak oligomerization, activating the caspase 
cascade. Increased expression of anti-apoptotic proteins is a widely used 
strategy by cancer cells to increase the threshold for caspase activation and 
thereby prevention of apoptotic cell death [3]. Previously we already showed 
the importance of Bcl-2 family members in chondrosarcoma. Up regulation 
of Bcl-2 family members is an important mechanism causing chemo 
resistance, and combined inhibition of Bcl-2, Bcl-xl and Bcl-w with the BH3-
mimetic ABT-737 [4] successfully induced sensitization of chondrosarcoma 
cell lines of all different subtypes to the chemotherapeutic agents 
doxorubicin and cisplatin [5-7]. Moreover, the anti-apoptotic protein Bcl-2 
is up regulated in conventional chondrosarcoma, while expression of Bcl-xl 
and Bcl-w has not been studied [8]. In dedifferentiated and mesenchymal 
chondrosarcoma, Bcl-2 and Bcl-xl are highly expressed [7]. Unfortunately 
inhibition of Bcl-2 family members with the orally available derivative of 
ABT-737, ABT-263 resulted in a high toxicity rate (most significantly 
thrombocytopenia) in lymphoid malignancies and solid tumors [3]. 
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Our aim was to further unravel the role of the separate Bcl-2 family 
members, and to investigate whether selective inhibition of the separate Bcl-
2 family members with possible lower toxicity could serve as an alternative 
to ABT-737. We evaluated the expression of the Bcl-2 family members Bcl-
2, Bcl-xl and Bcl-w using immunohistochemistry on tissue microarrays 
containing 137 conventional chondrosarcomas. Since Bcl-2 and Bcl-xl were 
most abundantly expressed, we assessed the anti-tumoral effect of selective 
Bcl-2 inhibition using a novel BH3-mimetic, S55746 [9], which binds to the 
BH3-binding groove of Bcl-2, and selective Bcl-xl inhibition, using WEHI-
539 [10] or its structurally related compound A-1155463 [11], in 
combination with chemotherapy. Studies were performed in vitro using a 
panel of chondrosarcoma cell lines of different histological subtypes, and in 
vivo in the orthotopic Swarm Rat Chondrosarcoma (SRC) model.  
 
Material and methods 
Compounds 
The selective Bcl-2 inhibitor S55746 was kindly provided and developed by 
Servier (Suresnes, France). For in vitro experiments S55746 was dissolved 
in phosphate buffered saline (PBS). ABT-737 (S1002, Selleckchem, Houston, 
TX, USA), WEHI-539 (ApexBio Technology, Houston, TX, USA) and Z-vad-
FMK [22] (550377, BD biosciences, San Jose, CA, USA) were dissolved in 
DMSO and stored at -20°C. The animal experiments were performed with 
freshly dissolved S55746 according to the manufacturer’s indications at 30 
mg/mL in a solution of 40% polyethylene glycol (Sigma-Aldrich, St Louis, 
MO, USA), 10% ethanol (Sigma-Aldrich) and 50% sterile water for injection 
(B. Braun, Melsungen, Germany). A-1155463 (S7800, Selleckchem, 
Houston TX USA) was dissolved in 5% DMSO, 10% ethanol, 20% PEG 35 
and 65% sterile water as recommended by the manufacturers.  Doxorubicin 
(2 mg/ml in a 0.9% NaCl solution) and cisplatin (1 mg/ml in a 0.9% NaCl 
solution) were obtained from the in house hospital pharmacy from the 
Leiden University Medical Centre for in vitro experiments or Centre Léon 
Bérard for in vivo experiments. 
 
Cell culture 
Chondrosarcoma cell lines JJ012 [23], SW1353 (ATCC), CH2879 [24], L2975 
[25] and NDCS1 [26] and control cell lines HeLa (ATCC) and HL-60 (ATCC) 
were cultured in RPMI-1640 (Gibco, Invitrogen Life-Technologies, Scotland, 
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UK) containing 10% Fetal Calf Serum (Gibco, Invitrogen Life-Technologies, 
Scotland, UK). Chondrosarcoma cell lines CH3573 [27], L3252 [25] and 
L835 [25] were cultured in RPMI-1640 containing 20% Fetal Calf Serum. 
Mesenchymal chondrosarcoma cell line MCS170 [5] was cultured in IMDM 
medium (Gibco, Invitrogen Life-Technologies, Scotland, UK) supplemented 
with 15% Fetal Calf Serum. JJ012 and L835 cell lines are known to contain 
an IDH1 mutation, while SW1353 and L2975 show a mutation in IDH2. All 
other cell lines are IDH1 and IDH2 wild type [28]. Cell lines were cultured in 
a humidified incubator (5% CO2) at 37°C. Before and after completion of the 
experiments cell identity was confirmed using the Cell ID Gene Print 10 
system (Promega Benelux BV, Leiden, The Netherlands).Mycoplasma 
negativity was confirmed on a regular basis. 
 
Swarm rat chondrosarcoma model 
All animal experiments were performed in accordance with European and 
French regulations and protocols were authorized by the animal ethical 
evaluation committee C2EA-UCBL55, (protocol number: DR2014-49). All 
experiments were conducted in the pathogen-free animal facilities SCAR 
(Faculté de Médecine Rockefeller, Université Claude Bernard Lyon 1, Lyon, 
France) at the Rockefeller Medicine faculty (Agreement # A 69 388 10 01). 
The Swarm rat chondrosarcoma model (SRC) is a transplantable in vivo 
model which has been described previously [29]. It mimics the 
aggressiveness and chemo-resistance observed in human chondrosarcoma 
as well as histological features and it is classified as a grade II 
chondrosarcoma. [30]. Tumor fragments of 10 mm3 were grafted on the right 
posterior tibia of one month old Spraque-Dawley rats. Before 
transplantation rats underwent periosteal abrasion. Palpable tumors were 
observed after approximately 10 days upon which rats were randomly 
divided into treatment groups consisting of 5-6 rats in each group. 
Treatment was given for a period of 10-14 days until tumors reached 2,500 
mm3. Treatment response was evaluated by monitoring tumor growth by 
regular visual inspection and tumor dimensions were measured every 2–3 
days (no blinding was done). Calculation of the tumor volume was performed 
using the following formula: Volume = (longest tumor diameter × (shortest 
tumor diameter)2)/2. Rats were sacrificed when tumors reached 2,500 mm3 
or after completion of the treatment period. Tumors were harvested and fixed 
in 10% formalin for Immunohistochemical analysis. The following 
treatments were given twice a week either by IP administration or per oral 
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gavage (S55746): S55746 (25, 50, 100 or 150 mg/kg), A-1155463 (5 mg/kg;) 
and / or Doxorubicin (1 mg/kg).  
 
Immunohistochemical analysis  
Previously constructed tissue micro arrays (TMAs) containing 137 
conventional chondrosarcomas (92 central of which 42 grade I, 36 grade II, 
14 grade III and 45 peripheral including 31 grade I, 11 grade II, 3 grade III) 
[31] were stained for Bcl-2 (Dako, clone 124, Agilent Technologies, Santa 
Clara, CA, USA), Bcl-xl (Cell signaling, clone 54H6, Danvers MA, USA) and 
Bcl-w (Abcam, clone 6C1 ) protein expression. Tonsil was used as a positive 
control for Bcl-2, prostate for Bcl-xl and cerebellum for Bcl-w. Cytoplasmic 
staining was scored separately by two observers (JVMGB, YDJ) using a 
scoring system assessing intensity (0= no, 1=weak, 2=moderate, 3=strong) 
and percentage of staining (0=no, 1=1-24%, 2=25-49%, 3=50-74%, 4=75-
100%) [7] and discrepancies were discussed to reach consensus. IDH 
mutation status was determined for 70 central chondrosarcomas in a 
previous study [32], and correlation towards Bcl-2, Bcl-xl and Bcl-w 
immunohistochemistry expression was assessed. The protocol was validated 
and approved by the medical ethical evaluation committee (protocol number: 
B17.020). Immunohistochemical analysis of rat chondrosarcomas was 
performed to determine Bcl-2 and Bcl-xl expression using the following 
primary antibodies: anti-Bcl-2 (polyclonal rabbit; Bio Vision, Milpitas, USA) 
and anti-Bcl-xl (clone 54H6, Cell Signaling, Danvers, USA). Goat anti-rabbit 
antibody (AI-1000; Vector Lab, Burlingame, CA, USA; dilution 1:100) was 
used as a secondary antibody and detection was performed using avidin-
biotin complex and visualization with DAB peroxidase. (VECTASTAIN Elite 
ABC Reagent, ImmPACT reagent; Vector Lab).  
 
Viability assay 
Chondrosarcoma cells were seeded in 96 well plates (3000-20000 cells 
depending on the cell line) and were treated with increasing concentrations 
of S55746 (0-1000 nM) or WEHI-547(0-10 uM) for 72 hours. HL-60 cells 
were used as positive control cells. Combination treatments with 
doxorubicin or cisplatin where performed with either 0.5 µM of S55746 or 5 
or 0.5 µM of WEHI-547. Presto blue reagent (Invitrogen, Life-Technologies, 
Scotland, UK) was used as described by the manufacturer to measure cell 
viability. Fluorescence was measured at 590 nm as a read out for cell 
viability on a victor3V mutilabel reader.(Perkin Elmer, the Netherlands). 
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Three technical replicates were included in each experiment and assays 
were repeated 2-3 times. 
 
Caspase assay 
The caspase-glo 3/7 assay from promega (Madison, USA) was used to 
measure apoptosis induction. Chondrosarcoma cell lines CH2879, L835 and 
L3252 were plated in white walled 96 well plates (Corning B.V. Life Sciences, 
Amsterdam, the Netherlands). After overnight attachment cells were treated 
for 24 hours  with either WEHI-539, doxorubicin, cisplatin or a combination. 
To measure caspase 3/7 activity  the substrate was added in a 1:1 dilution 
with medium and incubated for half an hour at room temperature. Cells 
treated with a combination of ABT-737 and doxorubicin were included as a 
positive control. As an additional control treatment with pan-caspase 
inhibitor Z-VAD-FMK was performed. Luminescence was measured with a 
victor V3 multilabel reader (, Perkin Elmer, Netherlands). Each experiment 
was performed in triplicate and the assay was repeated three times. 
 
Western blotting 
Western blotting was performed for Bcl-xl (Cell signaling, clone 54H6), Bcl-
w (Abcam, clone 6C1), Mcl-1, Bak (Cell signaling, clone D4E4) and bax (Cell 
signaling, clone D2E11). Western blotting for Bcl-2 was performed with two 
different clones (Cell signaling, clone D55G8 and clone 50E3) of which clone 
D55G8 was proven to give the most reliable results and was therefore chosen 
to be used for experiments. Cells were lysed using hot-SDS buffer (1% SDS, 
10 mM Tris/EDTA with complete inhibitor and phosSTOP) and 20 µg protein 
was loaded for each sample. Otherwise the procedure was performed as 
previously described [33]. α-tubulin (clone DM1A, Sigma-Aldrich Chemie 
B.V. Zwijndrecht, the Netherlands) expression was determined as a loading 
control.  
 
Statistical analysis  
Results were analyzed using a 2way ANOVA followed by Turkey’s multiple 
comparisons test using GraphPad Prism v6. software (GraphPad Software, 
Inc., La Jolla, CA, USA). Correlation tests were performed using the 
Spearman correlation test in graphpad Prism v6.  Results are given as mean 
± SD and results with p<0.05 were considered significant. The Bliss 
independence model was used to evaluate synergy between treatment 
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combinations. [34]. Using the formula C = A + B – A * B,  in which C 
represents combined response and A and B the two single compounds, 
predictions were made to assess synergy [35]. The heatmap figure was 
generated using the MORPHEUS online tool. 
 
Results 
Bcl-2 family members Bcl-2 and Bcl-xl are highly expressed in conventional 
chondrosarcoma 
Protein expression of Bcl-2, Bcl-xl and Bcl-w was determined in a panel of 
137 conventional chondrosarcomas. Expression of Bcl-2 was variable and 
found in 100 out of 110 chondrosarcomas (27 were lost from the TMA) and 
correlated with histological grade in central as well as peripheral 
chondrosarcoma (figure 1A). Bcl-2 was significantly higher expressed in 
grade II (P=0.0022) and grade III (P=0.0002) central chondrosarcoma 
compared to ACTs. The same correlation with grade was observed in 
peripheral chondrosarcoma (ACT vs. grade II: P=0.0332, ACT vs. grade III: 
P=0.0021). Bcl-xl was expressed in 101 out of 102 chondrosarcomas (35 
were lost from the TMA) and the extent and intensity significantly correlated 
with histological grade in central chondrosarcoma (ACT vs. grade II: 
P=0.0035, ACT vs. grade III: P=0.0034) (figure 1B). Expression of Bcl-w was 
found in 48 out of 120 chondrosarcomas and was higher in grade III central 
chondrosarcomas compared to ACTs (P=0.0104) (figure 1C). No statistical 
differences were observed for Bcl-xl or Bcl-w in the peripheral 
chondrosarcomas, probably due to the smaller sample size. Examples of 
different ranges of Bcl-2 family member expression within one tumour are 
shown in supplementary figure 1A Correlation between Bcl-2 and Bcl-xl was 
assessed using the Spearman correlation test showing a positive correlation 
(r=0.5829 P<0.0001) (supplementary figure 1B). The correlation was 
stronger in high grade chondrosarcomas (grade 2 and grade 3)(r=0.6301 
P<0.0001) compared to low grade chondrosarcomas (r=0.3393, P=0.03461). 
For the central chondrosarcomas, IDH mutation status was known for 70 
tumors, and there was no correlation between expression of Bcl-2 or Bcl-xl 
and IDH1 or 2 mutation status (supplementary figure 1C). Taken together, 
Bcl-xl shows the highest expression in chondrosarcoma, followed by Bcl-2, 
suggesting that these two Bcl-2 family members are the most important, 
and were therefore selected for further functional validation. 
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Figure 1. Bcl-2 and Bcl-xl are highly expressed in conventional chondrosarcoma. 
A, Protein expression of Bcl-2 as detected by immunohistochemistry significantly 
increased with increasing histological grade, in peripheral as well as in central 
chondrosarcoma. B, Bcl-xl is highly expressed in conventional chondrosarcoma and 
is increased in high grade (grade II and III) compared to ACT. C, Expression of Bcl-w 
is low in conventional chondrosarcoma, but higher expression is observed in grade 
III chondrosarcoma compared to ACT. Each dot represents one tumor and mean 
value with standard deviation is shown for each group. 
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Chondrosarcoma cell lines show minimal sensitivity for selective Bcl-xl 
inhibition and are not sensitive for selective Bcl-2 inhibition. 
Protein expression analysis of apoptotic family members Bcl-2, Bcl-xl, Bcl-
w, Mcl-1, Bak and Bax revealed that Bcl-xl was highly expressed in all nine 
chondrosarcoma cell lines, while Bcl-2 expression was variable (Figure 2A). 
Bcl-2 was expressed in three conventional and two dedifferentiated 
chondrosarcoma cell lines and is not correlated to IDH mutation status [12]. 
Bcl-w expression was variable and was highest in L2975. Bak and Bax are 
both expressed in all chondrosarcoma cell lines although expression of Bax 
is variable. Interestingly the same trend is observed as shown with 
immunohistochemical staining; Bcl-xl is highly expressed in all cell lines. 
Inhibition of Bcl-xl using WEHI-539 resulted in a reduction in cell viability 
in a subset of chondrosarcoma cell lines (Figure 2B). The most sensitive 
chondrosarcoma cell lines were conventional chondrosarcoma cell line 
CH2879 and dedifferentiated chondrosarcoma cell lines L2975 and NDCS1. 
In contrast, no sensitivity for Bcl-2 inhibition using S55746 was observed in 
any of the chondrosarcoma cell lines tested, while the positive control cell 
line HL-60 showed a dose dependent decrease in viability (figure 2C). 
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Figure 2. Bcl-xl can sensitize for chemotherapy in a subset of chondrosarcoma cell 
lines 
A, Western blots showing expression of apoptotic regulators Bcl-2, Bcl-xl, Bcl-w, Mcl-
1, Bak and Bax in chondrosarcoma cell lines. HeLa-83 and HL-60 cell lines are used 
as positive controls. Results for Bcl-2 where obtained in a separate experiment 
compared to the other protein expression analysis. B, Dose response viability curves 
of chondrosarcoma cell lines after 72h treatment with Bcl-xl inhibitor WEHI-539. 
Chondrosarcoma cell lines NDCS1, L2975 and CH2879 show minimal sensitivity 
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towards treatment with Bcl-xl inhibitor WEHI-539. C, Dose response viability curves 
of chondrosarcoma cell lines after 72h treatment with Bcl-2 inhibitor S55746 show 
that chondrosarcoma cell lines are not sensitive for S55746, as compared to the 
positive control HL-60. D, Excess over Bliss percentages of chondrosarcoma cell lines 
treated with doxorubicin or cisplatin in combination with WEHI-539 or S55746 for 
72 hours. Values were obtained by addressing the viability using presto blue assays. 
Chondrosarcoma cell lines L835 and L3252 show increased sensitivity towards 
doxorubicin and cisplatin when co-treated with WEHI-539. In addition CH2879 and 
SW1353 show increased sensitivity towards cisplatin when treated in combination 
with WEHI-539. A small increase in sensitivity is observed in CH2879 when S55746 
is combined with doxorubicin E, Caspase 3/7 activity of CH2879, L835 and L3252 
cell lines after treatment with WEHI-539 (0.5 or 5 µM), Doxorubicin (1 µM), Cisplatin 
(10 µM) or a combination. As a positive control cells have been treated with ABT-737 
and doxorubicin. Addition of pan-caspase inhibitor Z-vad showed that measured 
activity was specific. (DXR=doxorubicin, CDDP=cisplatin). 
 
Selective Bcl-xl but not Bcl-2 inhibition can sensitize for conventional 
chemotherapy in a subset of chondrosarcoma cell lines. 
Inhibition of Bcl-xl with WEHI-539 led to increased sensitivity to doxorubicin 
or cisplatin treatment in a subset of chondrosarcoma cell lines, while 
combination treatment with Bcl-2 inhibitor S55746 and chemotherapy did 
not result in a difference in sensitivity compared to single treatment (Figure 
2D., supplementary figure 2 and supplementary figure 3). Combination 
treatments with chemotherapy were performed with either 1 µM S55746 or 
0.5 µM WEHI-539 for the sensitive cell lines (CH2879, L2975 and NDCS1) 
or 5 µM WEHI-539 for the more resistant cell lines (JJ012, SW1353, L835, 
L3252 and CH3573). Bliss independence values were calculated and showed 
that the most chemo resistant cell lines L835 and L3252 could be sensitized 
for doxorubicin and cisplatin by inhibition of Bcl-xl using WEHI-539. In 
addition, CH2879 and SW1353 showed an increase in sensitivity towards 
chemotherapy after Bcl-xl inhibition (Figure 2D and supplementary figure 
2). Inhibition of Bcl-2 using S55746 in combination with doxorubicin or 
cisplatin only showed a small effect in CH2879 cell line, while in all other 
cell lines no difference was observed (Figure 2D and supplementary figure 
3). In addition, an increase in caspase activation was observed when 
CH2879, L835 or L3252 was treated with WEHI-539 (0.5 µM WEHI-539 
CH2879, 5 µM L835 and L3252) and chemotherapy compared to single 
treatment (Figure 2E). Single treatment with WEHI-539 or doxorubicin or 
cisplatin resulted in a 200-500% increase in caspase dependent apoptosis 
compared to the 100% control in all cell lines. The only exception was 
CH2879 treated with cisplatin which resulted in a 1700% increase. 
Combination treatment resulted in an increase of 1500-3500% compared to 
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the control indicating that the sensitizing effect we observe is depending on 
an increase in caspase dependent apoptosis. 
 
Figure 3. Bcl-xl inhibition is more effective in Swarm rat chondrosarcoma compared 
to Bcl-2 inhibition.  
High protein expression of Bcl-xl (A) and Bcl-2(B) in the SRC tissue determined by 
immunohistochemistry C, Tumor growth rate (TGR) of tumors orthotopically 
implanted in rats on day 3, 7 and 10 compared to day 0. Rats were treated with 
doxorubicin, A1155463 or a combination. Treatment with A1155463 resulted in a 
significant decrease in TGR compared to control mice D, TGR of tumors 
orthotopically implanted in rats on day 3, 7 and 10 compared to day 0. Rats were 
treated with doxorubicin, S55746 or a combination. No statistical difference is 
observed between the different treatment groups. 
 
Inhibition of Bcl-xl but not Bcl-2 results in a decrease in tumor growth in a 
Swarm Rat chondrosarcoma model  
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Expression of Bcl-2 and Bcl-xl was determined in Swarm rat 
chondrosarcoma to evaluate their suitability as a representative model to 
study Bcl-2 family member inhibitors. Figure 3A and B show that Bcl-xl as 
well as Bcl-2 are highly expressed in these tumors as determined by 
immunohistochemistry, mimicking the human situation. The effect of Bcl-
xl inhibition was studied using A-1155463, a structurally related compound 
to WEHI-539, shown to cause less toxicity in vivo. A concentration of 5 
mg/kg was used, since this had shown on target activity before in mice [11]. 
Inhibition of Bcl-xl showed a significant (P=0.0055) decrease in tumor 
growth compared to control or doxorubicin treated rats (figure 3C), however 
no difference was observed when A-115463 was combined with doxorubicin, 
indicating that single Bcl-xl inhibition is more effective. Since Bcl-2 inhibitor 
S55746 was never tested in rats before a dose escalation study was 
performed (25, 50, 100 and 150 mg/kg). A biweekly administration of 50 
mg/kg S55746 resulted in the smallest increase in tumor volume (1218 ± 
403mm3 in treated group versus 2033 ± 647 mm3 in the PBS control group 
at day 14) and was selected for further experiments (supplementary figure 
4). Inhibition of Bcl-2 did not lead to a significant reduction in tumor growth 
as a single agent nor in combination with doxorubicin. (Figure 3D). 
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Discussion 
Bcl-2 family members have been investigated as therapeutic targets in a 
large variety of solid tumors as well as in chondrosarcoma. Previously we 
showed that chondrosarcoma cell lines of all different subtypes can be 
sensitized to chemotherapy by inhibiting Bcl-2 family members using ABT-
737 [5-7]. In this study we investigated whether single Bcl-2 or Bcl-xl 
inhibition could be an alternative therapeutic strategy for patients with 
chondrosarcoma, since inhibition of Bcl-2, Bcl-xl and Bcl-w using ABT-263, 
showed toxicity problems when used in the clinic for other malignancies [3]. 
Bcl-2 and especially Bcl-xl were highly expressed in chondrosarcoma tissue 
samples, which correlated with an increased histological grade. Bcl-w was 
also expressed but not as abundantly, and also correlated with histological 
grade. In addition a positive correlation between Bcl-2 and Bcl-xl expression 
was observed, especially in high grade chondrosarcomas. These results are 
in line with previously published smaller studies, conducted by us as well 
as others, in which Bcl-2 and Bcl-xl also showed an increased expression 
with increasing histological grade [8, 13-15]. Selective Bcl-xl inhibition with 
WEHI-539 was effective at relatively high doses in a subset of 
chondrosarcoma cell lines, which did not correlate with expression of Bcl-2 
or Bcl-xl. These doses were comparable with concentrations obtained in 
osteosarcoma cell lines [16]. Our in vivo data confirm that tumor growth can 
be slowed down by selective inhibition of Bcl-xl by A-1155463, a structurally 
related Bcl-xl inhibitor showing less toxicity in vivo [11]. When the 
combination with chemotherapy was investigated the two cell lines that were 
most resistant to doxorubicin or cisplatin (L835 and L3252) could be 
sensitized for these agents when combined with WEHI-539. In addition, we 
confirmed that the combination treatment induced apoptosis. Interestingly 
those two cell lines did not show Bcl-2 and low Bcl-w expression. In the SRC 
model, the combination of selective Bcl-xl inhibition and doxorubicin did not 
show a sensitizing effect, and thus did not confirm the advantage of 
combination treatment suggested by the in vitro data. However, while the 
cell lines show a heterogeneous response with respect to chemo-
sensitization, with a preference for chemo-resistant cell lines with high Bcl-
xl and low Bcl-2 and Bcl-w expression, the SRC model represents only a 
subset of the chondrosarcomas. 
Although half of the chondrosarcoma cell lines showed Bcl-2 expression, 
none of the cell lines was sensitive for selective Bcl-2 inhibition with S55746 
and only one cell line (CH2879) showed a small increase in sensitivity for 
doxorubicin when treated in combination with the Bcl-2 inhibitor. In line 
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with this, in the orthotopic Swarm rat chondrosarcoma model, S55746 also 
showed no beneficial effect regarding inhibition of tumor growth. These data 
indicate that Bcl-2 is not essential for the survival of chondrosarcoma cells, 
and its function might be taken over by other apoptosis proteins. Bcl-xl is 
essential only in a subset of chondrosarcoma cell lines, and also seems 
important in the rat chondrosarcoma model. This means that  the previously 
observed effects of combined inhibition of Bcl-2, Bcl-xl and Bcl-w using ABT-
737 cannot be substituted by selective inhibition of Bcl-2 alone, not even in 
the cell lines that highly express Bcl-2. This can be caused by the high Bcl-
xl expression observed in all chondrosarcoma cell lines, which has been 
reported previously as a possible cause of resistance to selective Bcl-2 
inhibition [17, 18]. In the majority of the high grade chondrosarcomas high 
Bcl-2 and Bcl-xl expression is observed, which might suggest that selective 
Bcl-2 inhibition could be problematic due to high Bcl-xl expression or vice 
versa. However, high Bcl-2 expression does not confer resistance towards 
Bcl-xl inhibition as shown in a study by Punnoose et al. in multiple myeloma 
pointing towards Bcl-xl as a more promising target in tumours expressing 
both Bcl-2 and Bcl-xl [18]. No difference in sensitivity for Bcl-2 or Bcl-xl 
inhibition was observed between IDH1 or -2 mutant cell lines and wild type 
cells. This is different from acute myeloid leukaemia in which Bcl-2 
inhibition was identified as synthetic lethal to elevated levels of the 
oncometabolite D-2HG caused by mutations in IDH1 or IDH2. The authors 
propose a model in which D-2HG inhibits the activity of cytochrome c 
oxidase (COX) in the mitochondrial electron transport chain, which lowers 
the threshold to trigger apoptosis after Bcl-2 inhibition [12]. In addition, 
IDH1 mutant gliomas were more sensitive for Bcl-xl inhibition, which was 
shown to be dependent on D-2HG, which lowers Mcl-1 expression in mutant 
gliomas compared to wild type gliomas thereby increasing sensitivity for Bcl-
xl inhibition [19]. The different results in these different tumour types 
sharing a mutation in IDH emphasize that these mutations may have a 
tissue specific effect which hampers the development of a common therapy 
for IDH mutant tumours.  
The importance of Bcl-xl over Bcl-2 regarding chemo resistance is in line 
with results found in several other solid tumours. One study testing ABT-
263, Bcl-2 and Bcl-xl selective inhibitors in a panel of breast cancer, non-
small lung cancer and ovarian cancer cell lines, showed that only ABT-263 
and the Bcl-xl selective inhibitors where able to induce sensitization to 
docetaxel, indicating that Bcl-xl is the most important protein causing 
chemo resistance [20]. Also in osteosarcoma cell lines a selective Bcl-2 
inhibitor could not sensitize for doxorubicin, whereas WEHI-539 treatment 
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resulted in a synergistic effect [16]. A correlation between Bcl-xl and chemo 
resistance has been shown before in a study in which they found a strong 
correlation between Bcl-xl mRNA expression and the sensitivity of 60 cell 
lines towards 122 standard chemotherapy agents [21]. No clinical trials have 
been performed using selective Bcl-xl inhibitors, however the Bcl-xl inhibitor 
A-1155463 that we tested in vivo and its orally available related compound 
A-1331852 seem promising in pre-clinical studies in rodents [11, 20]. 
Furthermore a study by Leverson et al shows that in rodents higher 
concentrations of Bcl-xl inhibitors in combination with docetaxel can be 
administered before thrombocytopenia becomes dose limiting, in 
comparison with combination therapy using ABT-263, in which, because of 
Bcl-2 inhibition, suppression of granulopoiesis and neutropenia becomes 
dose limiting at much lower concentrations [20]. Although a clear biomarker 
to predict sensitivity still needs to be identified, we show that among the Bcl-
2 family members, Bcl-xl is most important for chondrosarcoma survival. 
Further research is needed to validate whether single or combination 
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Supplementary figure 2. Inhibition of Bcl-xl with WEHI-539 results in an increased 
sensitivity for doxorubicin (DXR) and cisplatin (CDDP) in L835 and L3252 cell lines. 
In addition SW1353 and CH2879 show a small increase in sensitivity for cisplatin. 
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Supplementary figure 3. Inhibition of Bcl-2 with S55746 does not result in an 
increased sensitivity for doxorubicin (DXR) or cisplatin (CDDP) in all 
chondrosarcoma cell lines. Only CH2879 shows a small increase in sensitivity for 
doxorubicin. 
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Supplementary figure 4. Dose escalation study of S55476 in Swarm Rat 
chondrosarcoma model. (n=3-4 Rats/group).  
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Abstract 
Chondrosarcomas are malignant cartilage-forming bone tumours, which are 
intrinsically resistant to chemo- and radiotherapy, leaving surgical removal 
as the only curative treatment option. Therefore our aim was to identify 
genes involved in chondrosarcoma cell survival that could serve as a target 
for therapy. 
siRNA screening for 51 apoptosis related genes in JJ012 chondrosarcoma 
cells identified BIRC5, encoding survivin, as essential for chondrosarcoma 
survival. Using immunohistochemistry, nuclear as well as cytoplasmic 
survivin expression was analyzed in 207 chondrosarcomas of different 
subtypes. Nuclear survivin has been implicated in cell cycle regulation while 
cytoplasmic localization is important for its anti-apoptotic function. RT-PCR 
was performed to determine expression of the most common survivin 
isoforms. Sensitivity to YM155, a survivin inhibitor currently in phase I/II 
clinical trial for other tumours, was examined in ten chondrosarcoma cell 
lines using viability assay, apoptosis assay and cell cycle analysis. 
Survivin expression was found in all chondrosarcoma patient samples. 
Higher expression of nuclear and cytoplasmic survivin was observed with 
increasing histological grade in central chondrosarcomas. Inhibition of 
survivin using YM155 showed that especially TP53 mutant cell lines were 
sensitive, but no caspase 3/7 or PARP cleavage was observed. Rather, 
YM155 treatment resulted in a block in S phase in two out of three 
chondrosarcoma cell lines indicating that survivin is more involved in cell 
cycle regulation than apoptosis. 
Thus, survivin is important for chondrosarcoma survival and 
chondrosarcoma patients might benefit from survivin inhibition using 
YM155, for which TP53 mutational status can serve as a predictive 
biomarker.  
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Introduction 
Chondrosarcoma is a malignant cartilage forming tumour accounting for 
20% of all malignant bone tumours [1]. Chondrosarcomas represent a 
heterogeneous group as different histological subtypes are recognized, 
including conventional, dedifferentiated, mesenchymal, clear cell and 
periosteal chondrosarcoma. The conventional subtype is most frequent 
(85%) [1] and can be further categorized in central chondrosarcoma 
(>85%)(in medullar cavity) and peripheral chondrosarcoma (at the bone 
surface) [2]. Histologically, atypical cartilaginous tumours (previously 
referred to as grade I chondrosarcomas), show low cellularity and are locally 
aggressive, but do not metastasize. High-grade chondrosarcomas comprise 
grade II and III chondrosarcomas and show higher cellularity, mitoses and 
less cartilaginous matrix. Histological grading represents the most 
important prognostic factor; patients with atypical cartilaginous tumours 
show a 10 year overall survival rate of 83%, patients with grade II tumours 
show 64% survival and patients with grade III chondrosarcomas show 29% 
10 year survival rate [1, 2]. Dedifferentiated chondrosarcomas comprise 10% 
of all chondrosarcomas and are characterized by a high grade 
dedifferentiated component juxtaposed to a low grade cartilaginous 
component. Patients with dedifferentiated chondrosarcoma show a 5 year 
overall survival between 7 and 24% [3]. Mesenchymal chondrosarcoma is a 
rare (<3%) high grade chondrosarcoma subtype with reported 10 year 
survival rates between 27 and 67% [4, 5]. Histologically it consists of 
differentiated cartilage mixed with undifferentiated small round cells [6]. 
Chondrosarcomas are intrinsically resistant to conventional chemo- and 
radiotherapy, and therefore surgical removal of the tumour is the only 
curative treatment option. Several studies have been performed 
investigating possible new therapeutic targets for the treatment of 
chondrosarcoma. This has led to several discoveries including mTOR [7, 8], 
Src [9, 10] and Bcl-2 family members [11, 12] as possible targets but still no 
targeted therapies are available for chondrosarcoma patients. Therefore, 
there is still an urgent need for novel therapeutic targets that can be easily 
and rapidly applied in the treatment of patients with high-grade metastatic 
or inoperable chondrosarcoma.  
To identify new cancer drug targets, high throughput RNA interference 
(RNAi) screens are widely used and have led to several important findings 
regarding new cancer gene discoveries [13]. Loss of function RNAi screens 
have led to the identification of important oncogenes in several different 
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cancer types, such as the identification of Brd4 as a therapeutic target in 
acute myeloid leukaemia [14] and MED12 as a determinant of drug response 
to tyrosine kinase inhibitors in non-small cell lung cancer [15]. Since RNAi 
is a powerful tool to discover survival related genes in a specific manner we 
performed a siRNA screen targeting 51 genes involved in apoptosis 
regulation to identify genes involved in survival of chondrosarcoma cells, 
that could serve as a potential target for therapy for patients with inoperable 
or metastatic chondrosarcoma. To validate our results we used a unique 
panel of chondrosarcoma cell lines including conventional, dedifferentiated 
and mesenchymal subtypes, reflecting the heterogeneity of chondrosarcoma 
of bone. 
 
Materials and methods 
Cell culture 
Central conventional chondrosarcoma cell lines SW1353 (ATCC), JJ012 
[41], CH2879 [18], OUMS27 [42], CH3573 [43] and L835, and 
dedifferentiated chondrosarcoma cell lines L3252B, L2975 [20] and NDCS1 
[44] were cultured in RPMI-1640 (Gibco, Invitrogen Life-Technologies, 
Scotland, UK) supplemented with 1% penicillin/streptomycin (100 U/mL) 
and 10 or 20 % Fetal Calf Serum (Gibco, Invitrogen Life-Technologies, 
Scotland, UK). Mesenchymal chondrosarcoma cell line MCS-170 was 
cultured in IMDM medium (Gibco, Invitrogen Life-Technologies, Scotland, 
UK) supplemented with 1% penicillin/streptomycin (100 U/mL) and 15% 
Fetal Calf Serum (Supplementary table 1). All cell lines were cultured at a 
temperature of 37⁰C in a humidified incubator (5% CO₂). Identity of cell lines 
was confirmed using the Cell ID GenePrint 10 system (Promega Benelux BV, 
Leiden, The Netherlands) before and after completion of the experiments. 
Mycoplasma tests were performed on a regular basis. 
 
Mutation analysis 
Mutations in TP53, IDH1 and IDH2 were confirmed with Ion 
AmpliSeq™Cancer Hotspot Panel v2 (Life Technologies, Thermo Fisher 
Scientific, USA, catalog number 4475346) according to the manufacturer’s 
instructions. Sanger sequencing was performed when validation was 
necessary (Supplementary table 1). TP53 mutations identified were analyzed 
using prediction software Align GVGD and Sorting Intolerant From Tolerant 
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(SIFT). Also entries in the Catalogue of Somatic Mutations in Cancer 
(COSMIC) database were analyzed. 
 
Compounds 
The survivin inhibitor YM155 (Catalog No.S1130, Selleckchem) and BH3 
mimetic ABT-737 (Catalog No.S1002, Selleckchem) were dissolved in DMSO 
according to the manufacturer’s instructions. Doxorubicin and cisplatin 
were obtained from the in house hospital pharmacy in a 0.9% NaCl solution. 
Z-vad-FMK (550377, BD biosciences) was used as a general caspase 
inhibitor and dissolved in DMSO. 
 
siRNA screen 
To identify critical genes for chondrosarcoma cell survival, a focused 
targeted siRNA screen was performed on the JJ012 central chondrosarcoma 
cell line targeting 51 apoptosis related genes (Dharmacon, GE life sciences, 
Landsmeer, the Netherlands) (Supplementary table 2). In the primary 
screen, reverse transfection of SMARTpools of 4 different siRNAs in a final 
concentration of 50 nM for each gene was performed using DharmaFECT 3 
transfection reagent (Thermo Fisher Scientific Inc. Waltham, MA USA,T-
2003). Deconvolution confirmation screens were performed where each of 
four individual siRNAs was transfected separately. A gene was considered 
as a hit when three out of four individual siRNAs mimicked the SMARTpool. 
GFP or GAPDH siRNAs were used as negative and KIF11 siRNAs were used 
as positive controls. Mock (no siRNA) transfection served as an additional 
control. The transfection was performed in duplo in u-clear 96 well black 
clear bottom plates (Corning B.V. Life Sciences, Amsterdam, the 
Netherlands) using 7000 cells/well. After one day the medium was replaced. 
After 5 days cells were fixed with formalin and stained with Hoechst. Nuclei 
present in each well were imaged using a BD-pathway microscope. 
Quantification was performed by determining the total Hoechst area using 
Image Pro analyzer software and normalizing towards negative controls. 
Z’factor analysis was performed as a quality control using the mean of siGFP 
and siGAPDH as a negative and siKIF11 as a positive control.  
 
Immunohistochemistry 
Survivin and p53 expression were evaluated in human primary 
chondrosarcoma tumour tissue using previously constructed tissue 
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microarrays containing 137 conventional chondrosarcomas (92 central of 
which 42 grade I, 36 grade II, 14 grade III and 45 peripheral including 31 
grade I, 11 grade II, 3 grade III) [10] and ten chondrosarcoma cell lines. 
Additionally, survivin expression was evaluated in 20 clear cell, 21 
mesenchymal, and 25 dedifferentiated chondrosarcomas [12]. For 
dedifferentiated chondrosarcoma the well-differentiated and the 
dedifferentiated component were scored separately. To visualize survivin, 
the 71G4B7 antibody (Rabbit mAb #2808, Cell Signaling Technology) was 
diluted 1:100, and placenta was used as a positive control. p53 expression 
was determined using an antibody from DAKO (M700101) in a 1:800 
dilution with tonsil as positive control tissue. Immunohistochemistry was 
performed according to standard laboratory methods, using citrate (pH 6) as 
antigen retrieval method, as previously described [45]. Survivin is known to 
be expressed in the nucleus as well as in cytoplasm displaying different 
functions and prognostic significance [46]. Therefore, nuclear and 
cytoplasmic expression was scored separately for each core by two 
independent observers (JVMGB,GA) using a scoring system assessing 
staining intensity (0= no, 1=weak, 2=moderate, 3=strong) and percentage of 
staining (0=no, 1=1-24%, 2=25-49%, 3=50-74%, 4=75-100%) [12]. p53 
expression was considered as high when added scores were ≥ 4, as 
previously described [27]. Cores that were lost from the TMA section were 
excluded from analysis (n=39 for conventional chondrosarcomas, n=3 for 
clear cell chondrosarcoma, n= 7 for mesenchymal chondrosarcoma and n=4 
for dedifferentiated chondrosarcoma). Slides were scanned using a Philips 
intellisite pathology scanner and pictures were taken using Philips IMS 
viewer.  
 
RNA isolation and Quantitative real time PCR 
RNA was isolated from fresh frozen tissue of 34 conventional 
chondrosarcoma primary tumour tissues (supplementary table 3) and six 
cartilage control tissues, i.e. three growth plate, and three articular cartilage 
tissues. RNA was also isolated from untreated and YM155 treated cell lines. 
For isolation TRIzol (Invitrogen, Carlsbad CA) was used followed by RNA 
clean up using the RNeasy mini kit (Qiagen) according to the manufacturer's 
instructions. All patient samples were handled according to the ethical 
guidelines described in ‘Code for Proper Secondary Use of Human Tissue in 
The Netherlands’ of the Dutch Federation of Medical Scientific Societies. Q-
PCR was performed for; wild type (wt) survivin, survivin 2b and survivin Δex3 
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with primers described previously [47]. Expression was normalized towards 
housekeeping genes PPIA, CPSF6 and GPR108, as previously described [48].  
 
Viability assay 
Chondrosarcoma cell lines were plated in 96 well plates so as to achieve 50-
70% confluency the following day. Dose response curves were performed 
using concentrations from 0.01 till 1000 nM. Concentrations used for 
combination studies were 10 and 50 nM doxorubicin, 250 and 1000 nM 
cisplatin and 1 and 5 nM YM155 and combinations of drugs were added at 
the same moment. After 72 hours of incubation a presto blue assay (Life-
Technologies, Scotland, UK) was performed according to the manufacturer’s 
instructions. Fluorescence was measured reading the plate at 590 nm on a 
fluorometer (Victor3V, 1420 multilabel counter, Perkin Elmer, Netherlands). 
Experiments were performed at least three times in triplicate. 
 
Apoptosis 
To measure apoptosis the caspase-glo 3/7 assay (Promega, Madison, USA) 
was used according to the manufacturer’s instructions. In brief, cells were 
plated into white walled 96 well plates (Corning B.V. Life Sciences, 
Amsterdam, the Netherlands) and incubated with IC75 concentrations of 
YM155 (determined using 72h viability assays). After 24 hours the substrate 
was added in a 1:1 dilution and incubated for 30 minutes at room 
temperature. As a positive control MCS-170 cells treated with ABT-737 and 
doxorubicin were used. Luminescence was measured using a luminometer 
(Victor3V, 1420 multilabel counter, Perkin Elmer, Netherlands). 
Experiments were performed at least two times in duplicate. 
 
Western blotting 
Western blotting for PARP (Cell Signaling Technology, Leiden, The 
Netherlands) was performed on lysates obtained using hot-SDS buffer (1% 
SDS, 10 mM Tris/EDTA with complete inhibitor and phosSTOP) as 
previously described [9]. For PARP and cleaved PARP detection Jurkat cell 
lysates treated with 25 µM etoposide obtained from Cell Signaling 
Technology (#2043) were used as a positive control. Of each sample, 20 µg 
protein was loaded on the gel. As loading control, α-tubulin (clone DM1A, 
Sigma-Aldrich Chemie B.V. Zwijndrecht, the Netherlands) expression was 
determined. Proteins were blotted on a PVDF membrane and detected using 
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enhanced chemo luminescence (PierceTM ECL Western Blotting Substrate) 
followed by exposure of 1 minute and development of the film (ECL 
hyperfilm, Amersham).  
 
Cell cycle analysis 
Cells were plated in T25 flasks in amounts ensuring 70% confluency when 
harvested. For knock down experiments cells were seeded in 6 well plates. 
After 48 hours of treatment with YM155 IC50 concentrations or BIRC5 or 
GAPDH siRNA, cells were prepared for cell cycle analysis using methanol 
and propidium iodide staining as previously described [49]. Cell cycle data 
analysis was performed using WinList 7.1 (Verity Software House, Topsham, 
ME). Experiments were performed at least two times in duplicate. 
 
Statistical analysis 
Mann-Whitney testing was applied using Prism Graph path software to 
assess significant differences between survivin expression levels. Bonferroni 
correction was used to correct for multiple testing. Dose response curves 
and IC50 values were determined using Prism Graph path software. 
 
Results 
BIRC5 is an essential survival gene in chondrosarcoma cells 
A siRNA screen targeting 51 apoptosis related genes revealed that HRK 
(Harakiri, BCL2 Interacting Protein), BIRC5 (Baculoviral IAP Repeat 
Containing 5), BCL2L1 (B-cell/Lymphoma 2 like 1), BCL-10 (B-
cell/Lymphoma 10) and CRADD (CASP2 And RIPK1 Domain Containing 
Adaptor With Death Domain) were essential genes in the JJ012 
chondrosarcoma cell line (Figure 1A). Across the primary screen, 
transfection with control siRNAs led to a slight (~13%) reduction in viability 
compared to mock whereas positive control siKIF11, caused a very strong 
(>90%) loss of viability indicating successful gene silencing and a good 
experimental window (Figure 1B). The average Z’factor was 0.61, which 
indicates a qualitatively good screen. Deconvolution was performed for 
selected hits and BCL2L1, BIRC5, CRADD and HRK were confirmed 
(Supplementary figure 1). Identification of HRK and CRADD is surprising 
since these encode pro-apoptotic proteins. A role for BCL2L1 in 
chondrosarcoma has been previously described by us [11]. Here, we focused 
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on BIRC5 (Figure 1C), which encodes the survivin protein, an anti-apoptotic 
protein overexpressed in human cancers [16].  
Survivin is highly expressed in chondrosarcoma tumour tissue and cell lines. 
Survivin protein expression and its subcellular localization was determined 
in 207 chondrosarcomas of different subtypes. Nuclear expression, 
suggesting a role for survivin in cell cycle progression, was found in 90/98 
conventional chondrosarcomas. Cytoplasmic expression, reflecting its 
function in apoptosis regulation, was found in 97/98 conventional 
chondrosarcomas. Expression levels were variable. Both nuclear and 
cytoplasmic survivin expression increased with increasing histological grade 
in central chondrosarcoma (Figure 2A, B). Cytoplasmic survivin expression 
was significantly higher in grade II (P≤0.001) and III (P≤0.01) central 
chondrosarcomas compared to ACTs. Also, higher expression of nuclear 
survivin was observed in grade III chondrosarcomas compared to ACTs 
(P≤0.05). No correlation was found with IDH1 or -2 mutation status (not 
shown). Moreover, survivin was also highly expressed in dedifferentiated, 
clear cell and mesenchymal chondrosarcoma. Survivin expression was 
significantly higher in nuclei compared to the cytoplasm in the well 
differentiated part of dedifferentiated chondrosarcoma (P≤0.001) (Figure 2C, 
D). Also in clear cell chondrosarcoma nuclear expression was significantly 
higher (P≤0.001) compared to cytoplasmic expression (Figure 2C). 
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Figure 1. Screening for apoptotic regulators identifies BIRC5 as an important 
survival gene in chondrosarcoma cell line JJ012.  
A) Occupied area of cells present in the well as a percentage to control siRNA of 51 
apoptosis related genes. Mean values and range of duplicates are shown. B) Raw 
data measured as Hoechst area of controls used in the siRNA screen. Dots indicate 
individual measurements and mean values are shown for each control. siCTR 
indicates control siRNA of either GFP or GAPDH. C) Area of cells as a percentage to 
control siRNA of selected hits. BIRC5 shows 4/4 siRNAs that mimic the smart pool. 
Data represent means of duplicate values with range. Black bars represent the smart 
pool and grey bars represent individual siRNAs. 
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Figure 2. Survivin is highly expressed in high grade chondrosarcoma.  
A) Immunohistochemical analysis of Survivin in conventional chondrosarcoma 
showing higher cytoplasmic expression in grade II and III central chondrosarcoma 
compared to ACTs. Also higher expression of nuclear survivin is observed in grade 
III chondrosarcomas compared to ACTs. Each dot represents one patient and mean 
value with standard deviation is shown for each group. B) High cytoplasmic Survivin 
expression in a grade III chondrosarcoma. C) Immunohistochemical analysis of 
nuclear and cytoplasmic survivin in dedifferentiated, clear cell and mesenchymal 
chondrosarcoma. Nuclear survivin is higher expressed in nuclei of the well 
differentiated part of dedifferentiated chondrosarcoma and clear cell 
chondrosarcoma compared to the cytoplasmic part. Each dot represents one patient 
and mean value with standard deviation is shown for each group. D) High nuclear 
Survivin expression in dedifferentiated chondrosarcoma (dedifferentiated part).  
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Nuclear survivin expression is associated with p53 overexpression in high 
grade conventional chondrosarcoma 
Since p53 is a known effector of survivin expression [17], we investigated a 
possible correlation between p53 overexpression (indicative of a mutated 
TP53 gene) and survivin expression using the conventional chondrosarcoma 
TMA. p53 overexpression was observed in 0/50 grade I, 20/41 grade II and 
9/17 grade III conventional chondrosarcomas (Figure 3A, B). In high grade 
chondrosarcomas (grade II and III) with overexpression of p53, the 
expression of nuclear survivin was higher as compared to high grade 
chondrosarcomas without overexpression of p53 (P≤0.01 for grade 3) (Figure 
3C). No difference between peripheral and central conventional 
chondrosarcoma was observed (data not shown).  
 
Figure 3. P53 is higher expressed in high grade conventional chondrosarcoma and 
correlated with nuclear survivin in grade III chondrosarcoma.  
A) Immunohistochemical analysis of p53 expression in conventional 
chondrosarcoma. Grade II and III chondrosarcomas show significantly higher 
expression compared to grade I chondrosarcoma (P<0.0001). Each dot represents 
one patient and mean value with standard deviation is shown for each group. B) 
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High nuclear p53 expression in a high grade chondrosarcoma. C) Low nuclear p53 
expression in a high grade chondrosarcoma. D) Correlation between nuclear survivin 
and p53 overexpression in conventional chondrosarcoma. P53 is considered as 
overexpressed when it reached a sum score of 4 (indicated by +). Grade I 
chondrosarcomas did not show p53 overexpression. In grade II chondrosarcoma 
higher nuclear survivin was seen in p53 overexpressing chondrosarcomas, as well 
as in grade III chondrosarcoma (P<0.01) compared to low p53 expressing tumours. 
Each dot represents one patient and mean value with standard deviation is shown 
for each group. 
 
Survivin isoforms are higher expressed in high grade chondrosarcoma 
The three most common survivin isoforms; wt survivin, survivin 2b and 
survivin Δex3 were all expressed significantly higher in high grade 
chondrosarcomas (grade II and III) compared to low grade chondrosarcomas 
(P≤0.001 for wt survivin, P≤0.01 for survivin 2b and P≤0.05 for survivin Δex3) 
(Figure 4A, B, C). No significant difference in survivin expression was 
observed between IDH wild type and IDH1 or -2 mutant chondrosarcomas 
(not shown). Furthermore, a correlation was found between all different 
survivin isoforms (Supplementary figure 2). 
 
 
Figure 4. Survivin wt, 2b and Δex3 isoforms are highly correlated and show higher 
expression in high grade chondrosarcoma as determined by Q-PCR analysis.  
A, B, C) Survivin isoforms wt (A), 2b (B) and Δex3 (C) are higher expressed in high 
grade (grade II and III) chondrosarcoma compared to low grade (ACT) 
chondrosarcoma. No expression is found in cartilage while variable expression is 
seen in growth plate tissue. Each dot represents one measurement and mean values 
are shown for each group. 
 
Chondrosarcoma cell lines highly express survivin, predominantly in the 
nucleus 
We confirmed that all cell lines showed high expression of survivin protein, 
predominantly in the nucleus (Figure 5A and supplementary figure 3). All 
5
 
- 120 - 
  
survivin isoforms where highly expressed compared to normal articular 
cartilage (Figure 5B). Using the Ion AmpliSeq™Cancer Hotspot Panel v2 the 
IDH1 or -2 mutation status was confirmed (Supplementary table 1). For 
TP53 the use of this highly sensitive targeted next generation sequencing 
technique provided novel insights for CH2879 and L2975, which were 
previously reported to be wild type [18-20] (Supplementary table 1). In 
CH2879 a sub clonal pathogenic mutation was found with a frequency of 
17%, which corresponded to the mosaic staining pattern of nuclear p53 
observed in the cell pellet and primary tumour (Supplementary figure 4). 
The mRNA expression levels of survivin were not correlated with TP53 or 
IDH1 or -2 mutational status (not shown). 
 
Chondrosarcoma cell lines are sensitive to survivin inhibition using YM155  
YM155 is a compound currently in phase I/II clinical trial, that represses 
survivin promoter activity [21]. We first assessed the effect of YM155 on 
survivin RNA down regulation (Figure 5B). JJ012, SW1353 and L835 cell 
lines showed clear down regulation of all three survivin isoforms after 
YM155 treatment. NDCS1 only showed down regulation of survivin Δex3 
after YM155 treatment and L2975 only showed down regulation of survivin 
2b. Chondrosarcoma cell lines were highly sensitive to YM155 showing IC50 
values below 5 nM in four out of ten chondrosarcoma cell lines (SW1353, 
OUMS27, NDCS1, L2975) (Figure 5C,D). JJ012 showed an IC50 of 8.2 nM 
and CH3573 showed an IC50 of 12.32 nM. The least responsive cell lines 
were L835, CH2879, L3252B and MCS-170. Interestingly, three of these are 
TP53 wild type (P = 0.033) (Figure 5E and supplementary table 1). There was 
no relation between YM155 sensitivity and histological subtype or IDH1 or -
2 mutation status. Combination treatment of YM155 with doxorubicin and 
cisplatin did not show a synergistic effect in JJ012 and SW1353 cell lines 
(Supplementary figure 5). 
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Figure 5. Chondrosarcoma cell lines are sensitive to YM155, which is p53 
dependent.  
A) JJ012 cell line showing strong survivin expression B) Normalized RNA expression 
of three survivin isoforms in 8 chondrosarcoma cell lines. JJ012, SW1353 and L835 
show a clear reduction in survivin expression after YM155 treatment. Growth plate 
and cartilage are taken as a control. Bars represent mean with standard deviation. 
C, D) Dose response curves for YM155 (72h) in conventional subtypes (C) and rare 
chondrosarcoma subtypes (D). Error bars are shown for three experiments 
performed in triplicate. E) IC50s determined for TP53 wild type and mutant cell lines 
showing a significantly increased sensitivity of TP53 mutant cell lines towards 
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The survivin inhibitor YM155 does not induce caspase 3/7 or PARP dependent 
apoptosis in chondrosarcoma cells. 
No activation of apoptosis was found in chondrosarcoma cell lines after 
treatment with IC75 concentrations of YM155. Caspase 3/7 activation was 
not observed after 24 or 48 hours of treatment (Figure 6A and data not 
shown). Furthermore, treatment with pan-caspase inhibitor z-VAD could 
not restore the reduction in viability observed after treatment with YM155 
(Figure 6B). PARP expression, but not cleaved PARP was observed in 
CH2879 and NDCS1 cell lines (Figure 6C), however not in SW1353 and only 
low expression was observed in JJ012.  
 
YM155 deregulates the cell cycle in a subset of chondrosarcoma cell lines 
Because no activation of apoptosis was found in chondrosarcoma cell lines 
treated with YM155, we evaluated its effect on the cell cycle (Figure 6D). A 
large increase in S phase and a reduction in G1 was observed in JJ012 cells 
after 48 hours of treatment. CH2879 showed only minor effects in cell cycle 
distribution after YM155 treatment and NDCS1 cells did not show any 
change in cell cycle distribution after treatment with YM155. Knock down of 
BIRC5 in JJ012 cells also resulted in a deregulation of the cell cycle 
(Supplementary figure 6).  
Targeting survivin in chondrosarcoma  
 
- 123 - 
 
 
Figure 6. YM155 does not cause caspase 3/7 and PARP dependent apoptosis, but 
cell cycle deregulation in chondrosarcoma cell lines.  
A,B) Caspase 3/7 activity (A) and viability (B) after 24h as percentage to untreated 
control measured in nine chondrosarcoma cell lines by caspase glo assay and presto 
blue viability assay. No caspase 3/7 activity is seen after YM155 treatment in all cell 
lines. Pan Caspase inhibitor z-vad was not able to rescue the YM155 dependent 
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reduction in viability. MCS-170 cells treated with doxorubicin and ABT-737 were 
used as a positive control. Error bars are shown for two independent experiments 
performed in duplicate. C) Western blot analysis for PARP and cleaved PARP 
expression in four chondrosarcoma cell lines. No differences are seen between 
treated (+) and untreated (-) samples. Alpha tubulin was used as a loading control. 
Jurkat cell lysates treated with 25 µM etoposide obtained from cell signaling were 
used as a positive control. D) FACS analysis of three chondrosarcoma cell lines 
treated with YM155 for 48 hours. JJ012 and CH2879 show a reduction in G1 and 
increase in S-phase after treatment with YM155. NDCS1 is not showing a difference 
in cell cycle distribution.  
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Discussion 
For patients with inoperable or metastatic chondrosarcoma no treatment 
options are available resulting in a 10 years survival rate below 30% [1]. By 
using a focused RNAi screen targeting core apoptosis machinery 
components we identified BIRC5 as an important player in chondrosarcoma 
survival and we here show that survivin inhibition using YM155 could be a 
promising novel treatment strategy for this malignant tumor. 
BIRC5 encodes the survivin protein which is part of the inhibitor of apoptosis 
family, and is involved in a large variety of cellular processes in the nucleus 
as well as in the cytoplasm. Nuclear survivin functions in the cell cycle as 
an essential mitotic regulator being a member of the chromosomal 
passenger complex. On the other hand, cytoplasmic survivin is 
predominantly involved in preventing apoptosis [16]. Overexpression is 
found in many tumor types including osteosarcomas [22] and soft tissue 
sarcomas [23]. Moreover, survivin up regulation was previously shown in 
small series of conventional chondrosarcomas [24-26]. We here demonstrate 
high survivin expression in conventional as well as rare chondrosarcoma 
subtypes in a large panel of >200 chondrosarcomas. Expression was found 
both in the nucleus as well as in the cytoplasm in high grade conventional 
chondrosarcomas suggesting a function both in the cell cycle and as an anti-
apoptotic protein. In contrast, in dedifferentiated and clear cell 
chondrosarcomas, survivin was predominantly expressed in the nucleus, 
suggesting a more prominent role for survivin in cell cycle regulation. 
We also show a positive correlation between nuclear survivin and p53 
overexpression in conventional chondrosarcoma. High p53 expression is 
known to correlate with increasing histological grade in chondrosarcoma 
[27] and is suggestive for mutated TP53 [28]. Wild type p53 was shown to be 
able to repress survivin expression [17], which may explain the higher 
survivin expression in chondrosarcomas with high, probably mutated, p53 
expression.  
Survivin isoforms are differentially expressed in different types of cancer 
correlating with survival, depending on the isoform. In chondrosarcoma we 
found increased expression of all three isoforms with increasing histological 
grade. SurvivinΔΕx3 has been most extensively studied and has been 
associated with a worse prognosis in breast, colon and cervical cancer [29]. 
In soft tissue sarcomas, all survivin transcripts were strongly overexpressed 
compared to non-malignant control tissue and elevated expression of 
survivinΔΕx3 was correlated with a worse survival [30]. Survivin was 
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expressed in normal growth plate tissue, suggesting a role for survivin in 
endochondral ossification. This is in concordance with the role for survivin 
described in tissue development and its down regulation with differentiation 
[31]. No survivin expression was detected in normal articular cartilage, 
which is in concordance with the low expression levels observed in other 
normal adult tissues [31], rendering survivin a very attractive therapeutic 
target [32]. 
We here show for the first time that survivin inhibition using YM155 could 
be a promising novel treatment strategy for chondrosarcoma as YM155 was 
highly potent in reducing cell viability. YM155 is already in phase I and II 
clinical trials, so could be readily applicable in clinical trials for 
chondrosarcoma patients. It is an indirect inhibitor of survivin, that blocks 
the survivin promoter region by binding and disrupting the RNA binding 
protein ILF3/NF110, thereby preventing survivin transcription [33]. Another 
proposed mechanism is disruption of binding of zinc transcription factor 
SP1 to the survivin promoter by YM155 [34]. Interestingly, TP53 mutant cell 
lines were more sensitive to YM155 as compared to TP53 wt cell lines, 
suggesting that the TP53 mutation status could be a predictive biomarker. 
This was also found in other cancer cell lines [35]. In TP53 wt cell lines, 
mechanisms other than survivin may dominate tumor cell proliferation and 
survival.  
YM155 does not induce apoptosis in the chondrosarcoma cell lines, as 
shown by the absence of caspase 3 and 7 activity and of PARP cleavage. In 
previous studies YM155 was shown to induce apoptosis in leukaemia, 
prostate cancer and breast cancer [36]. However, in merkel cell carcinoma, 
YM155 did not induce apoptotis but inhibited DNA synthesis [37]. Survivin 
is predominantly expressed during G2/M phase of the cell cycle [38], and 
its inhibition is expected to cause a G2/M arrest. G2/M phase cell cycle 
arrest has been described by Lechler et al. in two chondrosarcoma cell lines 
after siRNA knock down of survivin [26], however Yang et al showed a 
decrease in S-phase after knock down of survivin in the same cells [24]. We 
found an increase in S phase after treatment with YM155 in two of our 
chondrosarcoma cell lines and an increase in G2/M phase in JJ012 cells 
after BIRC5 knock down. This inconsistency can be caused by several issues 
including different confluency of the cells, different methods to inhibit 
survivin and different incubation times before the measurement. 
Consistent with our findings, Brun et al. also observed a block in S phase 
after treatment with YM155 in sonic hedgehog driven medulloblastoma [39]. 
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We did not observe a difference in cell cycle distribution in all cell lines, 
which shows that chondrosarcoma cell lines show a heterogeneous response 
towards YM155 treatment. 
In our hands, combination treatment of YM155 with doxorubicin or cisplatin 
did not result in synergistic inhibition of viability in two chondrosarcoma 
cell lines, suggesting that survivin is not involved in chondrosarcoma chemo 
resistance. However, Lechler et al. previously reported on a synergistic 
induction of apoptosis after combining survivin siRNA with doxorubicin 
treatment in two chondrosarcoma cell lines [26]. This can possibly be 
attributed to the different cell lines and the different mechanism of inhibition 
used to target survivin.  
Phase I and II clinical trials have already been conducted for YM155 as a 
single agent as well as in combination with chemotherapy for a few tumour 
types [36]. Phase I studies show that YM155 is well tolerated, however larger 
phase II studies in diffuse large B-cell lymphoma, non-small cell lung 
cancer, melanoma and prostate cancer do not show very promising results 
regarding anti-tumour activity [36]. This does not necessarily mean that this 
will also be the case for chondrosarcoma, especially since we show here that 
in chondrosarcoma instead of the induction of apoptosis, YM155 causes a 
block in the cell cycle, and that patients can be preselected based on TP53 
mutation status. New survivin inhibitors, for example antisense 
oligonucleotides and survivin based vaccines, are in development and some 
already reached clinical trials [40].  
In conclusion, we show that survivin is essential for chondrosarcoma cell 
survival and is highly expressed in high grade chondrosarcomas and absent 
in normal cartilage. Chondrosarcoma cell lines are highly sensitive for 
treatment with YM155, especially if TP53 is mutant, indicating that survivin 
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Supplementary figure 1: Results of deconvolution.  
Area of cells as a percentage to control siRNA. BCL2L1, BIRC5, CRADD and HRK all 
show 3/4 or 4/4 siRNAs that mimic the smart pool. Data represent means of 
duplicate values with range. Black bars represent the smart pool and grey bars 
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Supplementary figure 2: Correlation survivin expression  
A, B, C) Survivin expression of all three isoforms was correlated in chondrosarcoma 
tissues and cell lines. Expression is plotted as log2 and r2 was determined to assess 
correlation. Black dots indicate high grade chondrosarcoma, white dots indicate low 
grade chondrosarcoma and crosses indicate chondrosarcoma cell lines. 
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Supplementary figure 3. Survivin staining in chondrosarcoma cell lines.  
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Supplementary figure 4. Mosaic staining pattern of P53 protein in CH2879. 
A, B) Negative (A) and positive control (B) tonsil tissue. C, D) Mosaic P53 staining in 
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Supplementary figure 5. No synergistic effects of YM155 combined with 
doxorubicin or cisplatin are observed in JJ012 or SW1353 cell lines as determined 



























































































































































   

























   
   





   
   
   
   
   
   






























































































































































































































































































































































































































































































































































































































































































































Supplementary table 3 Patient samples subjected to survivin expression analysis 
by Q-PCR 
 

















Growth plate Not applicable N/A 3 
Cartilage Not applicable N/A 3 
Information of RNA samples used to evaluate survivin expression. Shown are grade, 
mutation status and amounts.  
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Abstract 
Chondrosarcomas are malignant cartilage tumors that are relatively 
resistant towards conventional therapeutic approaches. Kinase inhibitors 
have been investigated and shown successful for several different cancer 
types. In this study we aimed at identifying kinase inhibitors that inhibit the 
survival of chondrosarcoma cells and thereby serve as new potential 
therapeutic strategies to treat chondrosarcoma patients. 
An siRNA screen targeting 779 different kinases was conducted in JJ012 
chondrosarcoma cells in parallel with a compound screen consisting of 273 
kinase inhibitors in JJ012, SW1353 and CH2879 chondrosarcoma cell lines. 
AURKA, CHK1 and PLK1 were identified as most promising targets and 
validated further in a more comprehensive panel of chondrosarcoma cell 
lines. Dose response curves were performed using tyrosine kinase 
inhibitors: MK-5108 (AURKA), LY2603618 (CHK1) and Volasertib (PLK1) 
using viability assays and cell cycle analysis. Apoptosis was measured at 
24h after treatment using a caspase 3/7 assay. Finally, chondrosarcoma 
patient samples (N=34) were used to examine the correlation between 
AURKA, CHK1 and PLK1 RNA expression and documented patient survival. 
Dose dependent decreases in viability were observed in chondrosarcoma cell 
lines after treatment with MK-5108, LY2603618 and volasertib, with cell 
lines showing highest sensitivity to PLK1 inhibition. In addition increased 
sensitivity to conventional chemotherapy was observed after CHK1 
inhibition in a subset of the cell lines. Interestingly, whereas AURKA and 
CHK1 were both expressed in chondrosarcoma patient samples, PLK1 
expression was found to be low compared to normal cartilage. Analysis of 
patient samples revealed that high CHK1 RNA expression correlated with a 
worse overall survival. 
AURKA, CHK1 and PLK1 are identified as important survival genes in 
chondrosarcoma cell lines. Although further research is needed to validate 
these findings, inhibiting CHK1 seems to be the most promising potential 
therapeutic target for patients with chondrosarcoma. 
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Introduction 
Chondrosarcomas account for 20% of primary bone tumors and are 
characterized by malignant cartilage producing cells [1]. Depending on the 
morphology and the location, chondrosarcoma can be subdivided into 
conventional chondrosarcoma and more rare subtypes; dedifferentiated 
chondrosarcoma, mesenchymal chondrosarcoma, clear cell 
chondrosarcoma and periosteal chondrosarcoma. Conventional 
chondrosarcoma accounts for 85% of all chondrosarcoma cases [1] and is 
further classified into central chondrosarcoma, located in the medulla of the 
bone, and peripheral chondrosarcoma, found at the surface of the bone [2]. 
These two different conventional chondrosarcoma subtypes show the same 
histological features: however a distinct molecular background is observed 
[1].Conventional chondrosarcoma is classified into three different grades, 
which is the most important prognostic factor. Atypical cartilaginous tumors 
(ACT)/chondrosarcoma grade I show a low cellularity, a large amount of 
cartilage matrix, rarely metastasize, and have a relatively good prognosis. 
Grade II and grade III chondrosarcomas behave more aggressive and show 
a more cellular histology with reduced cartilage matrix and a poor prognosis. 
Patients with grade II chondrosarcomas show 64% overall survival and 
patients with grade III chondrosarcomas show a very poor 10 years overall 
survival of only 29% [1, 2]. As chondrosarcomas are resistant to 
conventional radio- and chemotherapy, the only treatment option to date for 
patients with chondrosarcoma is surgical removal. This is a major problem 
especially for patients with tumors in inoperable locations and patients with 
metastatic disease [2]. 
Protein kinases are important for cellular processes and are often found 
deregulated in cancer [3]. Kinome profiling in chondrosarcoma cell cultures 
previously revealed that the AKT, Src and Ras/Raf/MEK pathways were 
most active in chondrosarcoma [4]. In addition, Src kinases were shown to 
be important for chemoresistance, as shown by sensitization for doxorubicin 
upon inhibition with dasatinib, as well as a high expression of Src kinase 
family members in chondrosarcoma patient tissues [5]. Using phospho-RTK 
arrays the phosphorylation status of 42 RTKs was investigated in 
chondrosarcoma cell lines, which led to the observation of a heterogeneous 
RTK activation pattern in these cells. P-S6 activation was found in 69% of 
conventional chondrosarcoma and 44% of dedifferentiated chondrosarcoma 
indicating that the downstream PI3K/mTOR pathway might be an important 
therapeutic target [6]. Furthermore, we previously showed a role for 
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mTORC1 and C2 as an important regulator of chondrosarcoma metabolism 
[7]. 
To further unravel the role of kinases in chondrosarcoma we chose a 
screening-based approach using siRNAs targeting 779 different kinases and 
kinase related genes. In addition a compound screen was performed 
consisting of 273 compounds targeting kinases implicated in survival 
pathways often deregulated in cancer. By comparing the hits we aim at 
identifying kinase regulated pathways that are important for 
chondrosarcoma survival.  
 
Material and methods 
Cell culture 
Conventional chondrosarcoma cell lines SW1353 (ATCC), JJ012 [8], 
CH2879 [9], CH3573 [10] and L835, and dedifferentiated chondrosarcoma 
cell lines L3252B, L2975 [11] and NDCS1 [12] were cultured in RPMI-1640 
(Gibco, Invitrogen Life-Technologies, Scotland, UK) supplemented with 10 or 
20 % Fetal Calf Serum (Gibco, Invitrogen Life-Technologies, Scotland, UK). 
Mesenchymal chondrosarcoma cell line MCS170 [13] was cultured in IMDM 
medium (Gibco, Invitrogen Life-Technologies, Scotland, UK) supplemented 
with 15% fetal Calf Serum. All cell lines were cultured at 37⁰C in a 
humidified incubator (5% CO₂). Identity of cell lines was confirmed using the 
Cell ID Gene Print 10 system (Promega Benelux BV, Leiden, The 
Netherlands) before and after completion of the experiments. Mycoplasma 
tests were performed on a regular basis. 
 
Compounds 
MK-5108 (S2770), LY2603618 (S2626), Volasertib (S2235) and ABT-737 
(S1002) (positive control apoptosis assay) were purchased from Selleckchem 
and dissolved in DMSO to a working stock of 10 mM according to the 
manufacturer’s instructions. Z-VAD-FMK was obtained from BD biosciences 
(550377). Doxorubicin and Cisplatin were obtained in a solution of 0.9% 
NaCl from the inhouse pharmacy of the Leiden University Medical Centre.  
 
siRNA screen 
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To identify critical genes for chondrosarcoma cell survival, a focused 
targeted siRNA screen was performed on the JJ012 central chondrosarcoma 
cell line targeting kinases and kinase related genes (Dharmacon, GE life 
sciences, Landsmeer, the Netherlands, G-003505). Hits were selected for 
further validation, when both duplicates showed a reduction in cell numbers 
of 80% or more. A secondary screen including 35 most promising hits was 
performed in JJ012 and CH2879 chondrosarcoma cell lines (figure 1A). 
Reverse transfection was performed using SMARTpools of 4 different siRNAs 
targeting the same gene in a final concentration of 50 nM DharmaFECT 3 
(Thermo Fisher Scientific Inc. Waltham, MA USA, T-2003) was used as a 
transfection reagent according to the manufacturer’s instructions. 
Deconvolution confirmation screens, including 9 hits identified in both cell 
lines were performed on JJ012 and CH2879 cells where each of the four 
individual siRNAs was transfected separately. A gene was considered as a 
hit when three out of four individual siRNAs mimicked the SMARTpool in 
both cell lines or when one cell line showed at least three out of four the 
other at least two out of four siRNAs mimicking the SMARTpool. Mock (no 
siRNA), GFP, and GAPDH siRNAs were used as a negative control and KIF11 
siRNA as a positive control. Transfection was performed using 7000 
cells/well for JJ012 and 10000 cells/well for CH2879 cells in µ-clear 96 well 
black clear bottom plates (Corning B.V. Life Sciences, Amsterdam, the 
Netherlands). 24 hours after transfection the medium was replaced with 
medium containing either 1 µM doxorubicin, 5 µM cisplatin or PBS and after 
five days cells were fixed with formalin and stained with Hoechst. Imaging 
was performed using a BD-pathway microscope. To quantify the amount of 
nuclei the total Hoechst area was determined using Image Pro analyzer 
software and normalized to mock treated cells as described previously [14]. 
 
Compound screen 
A compound screen was performed in JJ012, SW1353 and CH2879 cells 
using a kinase library from Selleckchem (2014, L1200) containing 273 
compounds targeting different pathways. SW1353 and JJ012 were plated at 
an optimal density of 5000 cells/well and CH2879 cells were plated at a 
density of 7000 cells/well. The screen was performed in duplicate in µ-clear 
96 well black clear bottom plates (Corning B.V. Life Sciences, Amsterdam, 
the Netherlands). After overnight attachment of the cells, compounds were 
added in a concentration of 1 µM as single treatment or in combination with 
0.05 µM doxorubicin or 0.8 µM cisplatin. A high concentration of 
doxorubicin (5 µM) was used as a positive control. After 72 hours of 
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Optimal cell amounts for each cell line were seeded in triplicate in 96-well 
plates. After 24h, increasing concentrations from 0–1000nM of MK-5108 
and Volasertib or 0–1250nM LY2603618 were added to the appropriate wells 
and cells were incubated for an additional 72h. After the incubation period, 
a Presto Blue assay (Thermo Fisher Scientific Inc. Waltham, MA USA, 
A13262) was carried out according to the manufacturer’s instructions. After 
1 hour, viability results were measured by fluorescence at 590 nm on a 
fluorometer (Victor3V, 1420 multilabel counter, Perkin-Elmer, Groningen, 
the Netherlands). All experiments were performed in triplicate at least 3 
times.  
 
RNA isolation and Quantitative real time PCR 
RNA was isolated from fresh frozen tissue of 34 conventional 
chondrosarcoma primary tumor tissues and six cartilage control tissues: 
three growth plates, and three articular cartilage tissues (Supplementary 
table 1). RNA was isolated using TRIzol (Invitrogen, Carlsbad CA) followed 
by RNA clean up using the RNeasy mini kit (Qiagen) according to the 
manufacturer's instructions. All samples were handled as approved by the 
LUMC ethical board (B17.021). AURKA, CHK1 and PLK1 expression was 
normalized towards housekeeping genes PPIA and CPSF6 as previously 
described [15]. Primer pairs are described in supplementary table 2. 
 
Cell cycle analysis 
Optimal cell amounts for each cell line were seeded in 6-well plates and 
allowed to attach overnight. Cells were treated with IC50 concentrations of 
LY2603618, MK-5108 or Volasertib. After 24h, cells were stained with 
Solution 18 Ao-DAPI (Catalog no.910-3018, Chemometec, Denmark) 
according to the manufacturer’s instructions and cells were counted using 
an automated cell analyzer (NucleoCounter NC-250, Chemometec, 
Denmark). Remaining cells were centrifuged for 5 minutes at 500g at 4°C. 
Supernatant was removed and the cells were washed with PBS (B. 
BraunMelsungen AG, Melsungen, Germany). Methanol fixation was carried 
out, after which cells were washed with PBS/Tw 0.05%. The samples were 
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centrifuged using the same settings and were then washed with PBA/Tw 
0.05% (PBS/1.0% BSA/Tw 0.05%). After the final centrifugation of the cells, 
cells were stained with10 µM DAPI in PBA/Tw 0.05%. The cells were stored 
at 4 degrees and analysis was carried out next day using the NC-250 
nucleoCounter. Results were analyzed using, Winlist 3D and ModFit LT 




The caspase glo 3/7 assay (Promega, Madison, WI, USA) was used to detect 
apoptosis, according to the manufacturer’s instructions. Cells were plated 
in a white 96-well plate and treated the next day with IC50 concentrations 
(obtained from dose response curves) of MK-5108, LY2603618, Volasertib 
for 24 hours. ABT-737 and Doxorubicin were added to the cells as a positive 
control. Z-vad-FMK, a caspase inhibitor was used as a positive control. After 
treatment period, caspase glo 3/7 assay was added to cells, which were 
incubated for an additional 30 minutes at room temperature. Caspase 
activity was measured by luminescence using a luminometer (Victor3V, 
1420 multilabel counter, Perkin-Elmer) according to the manufacturer’s 
instructions. Experiments were performed three times in duplicate. 
 
Western blotting 
Protein expression of Chk1 (Cell signaling technology #2360) and p-
Chk1(S345) (Cell signaling technology, #2348) was determined in JJ012, 
SW1353 and CH2879 in control conditions and after treatment for 2 or 24 
hours with IC50 concentrations of LY2603618 (JJ012 1µM, SW1353 441 
nM, CH2879 449 nM). In addition PARP cleavage (Cell signaling technology 
#9532) was assessed after treatment of JJ012, SW1353 and CH2879 for 2 
or 24h with IC50 concentrations of MK-5108, LY2603618 or Volastertib 
(MK-5108; SW1353: 1 µM, JJ012: 513 nM, CH2879: 847 nM, Volasertib: 
SW1353: 34 nM, JJ012 11nM, CH2879: 24 nM, LY2603618 as described 
above). Lysates were obtained of cells grown until 70% confluence using hot-
SDS buffer (1% SDS, 10 mM Tris/EDTA with complete inhibitor (Roche 
#11697498001) and phosSTOP (Roche #04906837001) as previously 
described [4]. Expression of gapdh (Cell signaling technology #5174)  was 
determined as a loading control. A total of 10 µg was loaded on the gel for 
each sample and blocking was performed using 5% milk. Primary antibodies 
were diluted in 5% BSA (bovine serum albumin) and incubated overnight. 
6
 
- 148 - 
  
Blotting was performed on PVDF membranes and detection was done using 
enhanced chemo-luminescence (west Pico Plus chemiluminescent 
Substrate, Thermo Fisher Scientific, Waltham, MA, USA) followed by 
visualization using the ChemiDoc imaging system of Biorad. 
 
Statistical analysis 
Dose response curves and IC50 values were determined using Prism 7 
GraphPad software. Statistically significant differences were assessed by 
performing a 2-way ANOVA test, correcting for multiple comparisons using 
Turkey’s test. To assess synergy access over Bliss was calculated and 
percentages above 12 were considered as synergistic [16, 17]. Overall 
survival was determined using SPSS software by performing a Kaplan Meyer 
analysis and assessing significance using a Mantel Cox Log Rank test. 
 
Results  
siRNA screen identifies PLK1, AURKA, COPB2, CHEK1, and CNKSR1 as most 
important survival genes in chondrosarcoma cells. 
A siRNA screen targeting 779 kinases and kinase related genes identified 35 
genes that decreased survival of JJ012 chondrosarcoma cells more than 
80% upon inhibition in both duplicate measurements (see figure 1A, B and 
supplementary table 3). No siRNAs were identified that could sensitize 
JJ012 cells to doxorubicin or cisplatin. Transfection with control GFP 
siRNAs led to a slight reduction in cell amounts compared to mock 
conditions in most plates, however silencing of GAPDH led to a large 
reduction in cell amounts, indicating that this cannot be used as a control 
for CS siRNA screens (supplementary figure 1). Knock down of KIF11 led to 
a strong reduction in cell amounts, indicating successful knock down in all 
plates except plate 7 which was treated with doxorubicin or cisplatin. This 
did not influence the hit selection process. A second validation screen was 
performed in JJ012 and CH2879 cell lines including the 35 most promising 
siRNAs to select genes important for both cell lines. This reduced the 
number of candidates to eight that were found in both JJ012 and CH2879 
cells (Figure 1C). The remaining 19 targets, from the first JJ012 screen, 
could not be reproduced/identified in JJ012 and were absent as well in 
CH2879 cells. The eight hits identified in both JJ012 and CH2879 were 
selected for deconvolution and PLK1, AURKA, CHK1, COPB2 and CNKSR1 
were confirmed (Figure 1D). 
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Compound screening identifies cell cycle regulators as most promising targets 
in chondrosarcoma cell lines. 
In parallel with the siRNA screen a compound screen including 273 
compounds targeting kinases and kinase related pathways was performed 
in three different chondrosarcoma cell lines. The top 50 compounds, that 
showed the highest reduction in cell numbers as compared to DMSO treated 
controls, of each cell line were compared and 34 compounds were found to 
be effective in all three cell lines (Figure 1E), while in total 48 compounds 
were shared between at least 2 cell lines. The percentage of compounds 
targeting a specific pathway as compared to the total of 48 hit compounds 
are represented in figure 1F. Inhibitors of cell cycle regulators Aurora 
kinases (13/16), Polo like kinases (5/5) and Cyclin dependent kinases 
(4/12)represent a substantial portion (figure 1F), confirming the findings of 
the siRNA screen. Also, inhibitors of the Pi3K and mTOR pathway (12 / 25) 
are one of the major hits. Furthermore, inhibitors of cMET (2/13), ALK (1/2), 
SRC (1/3), SYK (1/5), JAK (1/13), IKK (1/2) and CHK (1/3) are also 
represented (see supplementary table 4 for a list of selected compounds). 
Similar to the siRNA screen, no pathways were identified that upon 
inhibition clearly sensitized for either doxorubicin or cisplatin 
(supplementary table 5). Based on the overlap between the siRNA and the 
kinase inhibitor screen we chose to continue with PLK1, AURKA and CHK1 
as most promising targets. In addition, previous studies already showed that 
mTOR, CDK and Src are important therapeutic targets for patients or 
subsets of patients with chondrosarcoma [4, 18, 19]. 
 
Inhibition of AURKA, CHK1 and PLK1 in chondrosarcoma cells results in a 
dose dependent decrease in viability, which is not related to RNA expression 
levels 
Dose dependent decreases in viability were observed when different 
chondrosarcoma cell lines were treated with inhibitors for AURKA (MK-
5108), CHK1 (LY2603618) or PLK1 (Volasertib) (Figure 2A). Lowest IC50 
values were obtained when cell lines were treated with PLK1 inhibitor 
volasertib, however treatment with CHK1 inhibitor LY2603618 also led to 
low IC50 values (see Table 1). These values have previously been shown as 
clinically achievable in human plasma in phase I and phase II trials [20-22]. 
L835, L3252 and MCS170, which are slower growingTP53 wildtype cell lines 
showed higher IC50 values for all compounds compared to the other faster 
growing cell lines. RNA expression analysis showed a variable expression 
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pattern of AURKA, CHK1 and PLK1 across the cell lines, with highest 
expression of all three in CH2879 (Figure 2B). Only few cell lines responded 
to inhibition of AURKA, which was not correlated to the level of AURKA 
expression. Likewise, no correlation was observed between sensitivity to 
CHK1 inhibition and CHK1 expression levels. Interestingly, of the three lines 
showing low PLK1 expression, L835 and MCS-170 showed a poor response 
to PLK1 inhibition, whereas L2975 exhibited a response, which although 
PLK1 expression was lower, still resembled the response patterns of high 
PLK1 expressors, but never reached 0% cell viability. Combination treatment 
with doxorubicin or cisplatin and MK-5108 and LY2603618 was performed 
in three conventional chondrosarcoma cell lines and results showed a 
synergistic effect between doxorubicin and cisplatin with the CHK1 inhibitor 
LY2603618 in JJ012 and SW1353 cell lines as shown by more than 12% 
increase in Excess over Bliss score (Figure 2C). This shows that 
chondrosarcoma cells are more sensitive towards treatment with 
chemotherapy when CHK1 is inhibited. Increased phosphorylation of CHK1 
on Ser345 was observed after treatment with LY2603618 in JJ012, SW1353 
and CH2879, indicating that inhibiting CHK1 under these conditions leads 
to activation of ATM/ATR (Figure 2D). No basic CHK1 phosphorylation was 
observed on Ser345.  
 
Cell cycle regulators 
 
- 151 - 
 
 
Figure 1. SiRNA screen and compound screen identify PLK1, AURKA and Chk1 as 
potentially important kinases for survival of chondrosarcoma cells.  
A. Set-up of siRNA screen. Primary screening was performed on 779 SMARTpools 
targeting kinases and kinase related genes. The secondary screen was performed in 
JJ012 and CH2879 cells and consisted of 35 SMARTpool siRNAs identified in the 
primary screen (decreased cell proliferation below 20% compared to mock 
conditions). Deconvolution consisted of 4 separate siRNAs and the SMARTpool 
targeting 9 different genes. B. Hoechst area as a percentage to mock for JJ012 cells. 
Each dot represents one SMARTpool targeting one Kinase or kinase related gene. 
Duplicates are shown for each gene and only when both screens showed a percentage 
below 20% it was considered as a hit. C. Kinases that showed cell killing in both 
JJ012 and CH2879 were selected for deconvolution (AURKA, CHK1, CNKSR1, 
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COPB2, EPHA6, IRAK3, STK39, TRAT1, PLK1). D. Deconvolution results in JJ012 
and CH2879 cells showing that AURKA, CHK1, COPB2, CNKSR1 and PLK1 are 
important for cell survival in both cell lines. E. Compound screen results in JJ012, 
CH2879 and SW1353 showing 35 hits in common in the top 50 compounds in each 
cell line. In addition, 8 compounds were found in JJ012 and CH2879, 6 in JJ012 
and SW1353 and 2 in CH2879 and SW1353. F. Compounds that were identified in 
all three or two out of three cell lines were selected and showed that Aurora kinase, 
Pi3K-mTOR, mTOR, PLK, CDK and multi-target comprised the largest groups. In 
addition, compounds targeting c-MET, ALK, SRC, SYK, JAK, IKK and CHK were 
identified. 
 
Table 1. IC50 values and 95% confidence intervals for nine different chondrosarcoma 
cell lines treated with inhibitors for AURKA (MK-5108), CHK1 (LY2603618) or 
PLK1(Volasertib). 
 
 MK-5108 Ly2603618 Volasertib 
JJ012 513.4 (464.2-570.1) >1000 10.98 (10.31-11.73) 
SW1353 >1000 441.2 (386.6-502.8) 33.67 (31.76-35.66) 
CH2879 847.6 (723.3-1049) 449.3 (401-504.6) 24.28 (20.69-28.18) 
CH3573 >1000 815.2 (730.2-918.4) 8.382 (7.083-9.809) 
L835 >1000 >1000 >1000 
L2975 520.8 (440.5-631) 826.1 (781.3-875.8) 11.33 (9.109-13.92) 
Ndcs1 >1000 442.6 (420.5-465.8) 3.166 (2.54-4.003) 
L3252 >1000 >1000 252.4 (187.1-363.9) 
MCS170 >1000 >1000 276.1 (181.2-482) 
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Figure 2. Chondrosarcoma cell lines are sensitive for compounds targeting AURKA, 
CHK1 and PLK1.  
A. Dose response curves showing viability measured after 72h using presto blue 
viability reagent for 9 chondrosarcoma cell lines targeting AURKA (MK-5108), CHK1 
(LY2603618) or PLK1 (volasertib). The top three panels represent the conventional 
chondrosarcoma cell lines and the bottom panel the rare chondrosarcoma cell lines 
including three dedifferentiated cell lines (L2975, L3252 and NDCS1) and one 
mesenchymal chondrosarcoma cell line (MCS-170). Highest sensitivity is observed 
after inhibition with Volasertib. Experiments were performed in triplicate at least 
three times. B. RNA expression in chondrosarcoma cell lines for AURKA, CHK1 and 
PLK1. No correlation between expression and sensitivity for the different inhibitors 
is observed. C. Excess over Bliss percentages of combination treatment of 100 nM 
LY2603618 and doxorubicin (DXR) or cisplatin (CDDP) showing that JJ012 and 
SW1353 can be sensitized to conventional chemotherapy after Chk1 inhibition. D. 
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Western blot showing Chk1 and P-chk1 (S345) expression after treatment for 2 or 
24h with IC50 concentrations of LY2603618. Gapdh expression is assessed as a 
loading control. Hela cells treated with Hydroxyurea have been used as a positive 
control for p-Chk1 expression. 
 
Cell cycle analysis reveals a block in G2 after AURKA inhibition 
Cell cycle analysis was carried out after 24 hours of treatment with MK-
5108, LY2603618 or Volasertib and showed that inhibition of AURKA with 
MK-5108 caused a block in G2/M in both JJ012 (p<0.0001) and CH2879 
(p<0.0001) cell lines (Figure 3A, Supplementary figure 2). Treatment with 
CHK1 inhibitor LY2603618 did result in an increase in S-phase (p=0.0003) 
and debris (p=0.0004) in JJ012, but not in CH2879.Thus, while inhibiting 
AURKA clearly showed a G2/M arrest in both cell lines, only JJ012 showed 
a clear S-phase arrest after CHK1 inhibition. To assess whether this cell 
cycle arrest led to apoptotic cell death, caspase 3/7 dependent apoptosis 
was evaluated after 24 hours of treatment with MK-5108, LY2603618 or 
Volasertib (Figure 3B). Results were variable, but small increases were 
observed after treatment with MK-5108 or Volasertib in SW1353. PARP 
cleavage was assessed to determine general cell death and showed a small 
amount of PARP cleavage, especially in MK-5108 treated JJ012 and CH2879 
cells, but no clear differences were observed (Figure 3C). These results 
indicate that even though the cell cycle inhibitors successfully caused cell 
cycle arrest in both cell lines, this did not directly lead to an increase in cell 
death after 24hrs.  
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Figure 3. Cell cycle and apoptosis analysis after AURKA, CHK1 or PLK1 inhibition. 
A. Cell cycle analysis after 24 hours of treatment with MK-5108, LY2603618 or 
Volasertib in JJ012 or CH2879 cells. Both cell lines show a decrease in G1 and an 
increase in G2 phase after treatment with MK-5108. In addition, CH2879 cells show 
a decrease in S phase after treatment with MK-5108. JJ012 cells show a decrease in 
G1 after inhibition with either MK-5108, LY2603618 or Volasertib and an increase 
in S-phase and debris after LY2603618 treatment. B. Apoptosis induction measured 
using the caspase-glo 3/7 kit in JJ012, CH2879 and SW1353 after treatment for 
24h with IC50 concentrations of MK5108, LY2603618 or Volasertib. Z-vad was added 
as a control. Only the positive control showed significant caspase induction in all cell 
lines. SW1353 showed significant upregulated caspase activity after treatment with 
MK-5108 and Volasertib compared to dmso treated controls. For both cell cycle and 
apoptosis experiments mean values are shown of three experiments performed in 
duplicate. P-values were calculated using a 2way ANOVA test, correcting for multiple 
comparisons using Tukeys test. C PARP cleavage assessed after 24h of treatment 
using IC50 concentrations of MK-5108, LY2603618 and Volasertib. As a positive 
control CH2879 cells treated with the combination of ABT-737 and doxorubicin has 
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High CHK1 RNA expression in chondrosarcoma tissue samples is correlated 
with a worse overall survival  
Expression of AURKA, CHK1 and PLK1 was investigated in a panel of 
chondrosarcoma tissue samples and revealed that both AURKA and CHK1 
showed higher RNA expression compared to cartilage in a subset of 
chondrosarcoma patients (Figure 4A). PLK1 expression was lower compared 
to normal cartilage in all samples tested, but high in chondrosarcoma cell 
lines. Most samples that showed higher AURKA or CHK1 expression 
compared to normal cartilage were in the high-grade group, but this was not 
significantly different. Samples were divided into high and low expression 
based on expression compared to normal cartilage (>1=high expression, 
<1=low expression) and survival analysis was performed (Figure 4B). No 
significant difference in survival was observed between low or high 
expression of AURKA (p=0.131), but high CHK1 expression was significantly 
correlated with a worse overall survival compared to low CHK1 expression 
(P=0.018). These results show that CHK1 expression is correlated towards a 
poor prognosis in chondrosarcoma patients. 
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Figure 4. Gene expression analysis shows that high expression of CHK1 is correlated 
to a worse survival in chondrosarcoma patients.  
A.RNA expression of AURKA, CHK1 and PLK1 in chondrosarcoma patient samples 
and chondrosarcoma cell lines compared to expression in normal articular cartilage 
samples. Each dot represents one sample. B. Kaplan Meyer analysis of patient 
samples with low and high expression of AURKA and CHK1. High CHK1 expression 
shows a significant correlation with a worse overall survival in chondrosarcoma 
patients. Samples with <1 expression were considered as ‘low’ expression and 
samples >1 expression were considered as high expression. P values were calculated 
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Discussion 
Chondrosarcoma patients suffer from limited treatment options due to 
relative chemo- and radio resistance. In this study we sought to identify new 
targetable pathways in chondrosarcoma cells by performing a kinase 
focused siRNA and compound screen. By comparing the hits that were 
identified in both screens we identified AURKA, PLK1 and CHK1 as 
important survival regulators in chondrosarcoma cells. AURKA, PLK1 and 
CHK1 are all involved in cell cycle regulation and often deregulated in cancer 
cells [23]. 
Previous studies in chondrosarcoma already revealed that Src kinases could 
be a potential therapeutic target in chondrosarcoma [5]. In addition mTOR 
was shown to be active in a large portion of chondrosarcoma patient 
samples, as well as an important regulator of chondrosarcoma metabolism 
[6, 7]. These hits were also confirmed in our compound screen data. 
Cell cycle progression is tightly regulated and controlled by cyclin dependent 
kinases (CDKs). Activity of CDKs is induced by mitogenic signals but can be 
inhibited by cell cycle checkpoints in response to DNA damage. Proteins that 
function in regulating the cell cycle are often deregulated in cancer and can 
function as possible therapeutic targets as mono therapy or combination 
with chemotherapy [24]. In this study we show a possible role for targeting 
the cell cycle in chondrosarcoma. 
AURKA and PLK1 are involved in G2 to M phase progression and are 
essential during mitosis and cytokinesis. AURKA phosphorylates PLK1 to 
activate Cyclin B-CDK1 complexes leading to progression from G2 to M-
phase. During mitosis AURKA and PLK1 form several complexes with other 
proteins that regulate the maturation and separation of centrosomes and 
the assembly of the bipolar spindle. Furthermore PLK1 is a member of the 
chromosomal passenger complex (CPC) that regulates chromosome 
dynamics and cohesion, kinetochore microtubule attachments, spindle 
assembly checkpoint and cytokinesis [25]. Overexpression of both AURKA 
and PLK1 has been shown in a variety of different tumors [26, 27]. 
A subset of chondrosarcoma cell lines showed a dose dependent decrease in 
viability after inhibiting AURKA using MK-5108, which was not related 
towards AURKA RNA expression. A clear block in G2/M phase of the cell 
cycle was observed after 24 hours of treatment with MK-5108. We did not 
find any correlation between expression of AURKA and survival, in contrast 
to a study from 2012 by Liang et al. in which they showed a correlation 
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between high AURKA expression and a worse overall survival in 
chondrosarcoma patients [28]. A clinical study including 6 chondrosarcoma 
patients investigating the efficacy of Aurora Kinase A inhibition using 
Alisertib showed a partial response in one patient with dedifferentiated 
chondrosarcoma [29]. However a phase III study in lymphoma was 
discontinued because of lack of response compared to the other study arm 
[30]. Different studies testing combination strategies show different adverse 
effects and maximum tolerated dose, which indicates that results might vary 
between tumor types and patients [21, 31-33].  Recently AURKA inhibitors 
have been identified as synthetic lethal with defective RB1 [34]. In 
chondrosarcoma 33% of tumors show a defect in the RB1 pathway [35], 
meaning that in these tumors treatment with AURKA inhibitors might be 
good treatment option.  
Chondrosarcoma cell lines were sensitive for inhibition of PLK1 using 
Volasertib, but no clear cell cycle effects were observed after 24 hours of 
treatment. This is surprising because PLK1, just like AURKA, is important 
for entry in M-phase, although multiple other non-cell cycle related 
functions have been proposed as well, for example PLK1 can regulate 
mTORC1 activity [36, 37]. This can influence the effects that we detect on 
the cell cycle. Expression of PLK1 in chondrosarcoma tissue samples was 
low, indicating that targeting PLK1 might not be a good therapeutic strategy 
for chondrosarcoma patients.  
CHK1 is activated by ATM or ATR after the occurrence of DNA damage. Its 
activation will cause the cell to halt cell proliferation in S or G2 and allows 
the cell to repair DNA damage. When CHK1 is inhibited DNA damage will 
accumulate and the cell will die during mitosis. Like AURKA and PLK1, 
CHK1 is also overexpressed in different types of cancer. Like AURKA and 
PLK1, CHK1 is also overexpressed in different types of cancer. Using 
LY2603618 CHK1 was inhibited in a panel of chondrosarcoma cell lines, 
which resulted in an increased phosphorylation of CHK1 at position S345, 
which is in agreement with previous reports [38]. Possibly single CHK1 
inhibition already leads to activation of the DNA damage response, and IC50 
concentrations are not high enough to completely prevent phosphorylation 
by ATM/ATR. A subset of chondrosarcoma cell lines was responding to the 
treatment, and an increase in S phase was observed in JJ012 cells, but not 
in CH2879 cells treated with LY2603618. In addition, JJ012 and SW1353 
could be sensitized for chemotherapy using CHK1 inhibition. Previous 
studies already showed the importance of CHK1 in Ewing, Osteo- and soft 
tissue sarcomas [39-41] and its use in single and combination treatment in 
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pre-clinical models. In addition, we also found a correlation between overall 
survival and CHK1 RNA expression in chondrosarcoma patient tissues, 
indicating that more aggressive chondrosarcomas show higher expression 
of CHK1. Second generation CHK1 inhibitors, showing less toxicity 
compared to first generation inhibitors are currently tested in the clinic in 
combination with chemotherapy in advanced cancers [42-44].  
Cells with defective P53 protein function have been shown to be more 
sensitive to inhibitors for CHK1 [45] as well as AURKA and PLK1 compared 
to cells with intact P53 [46, 47]. Inactivation of P53 will lead to a 
compromised G1 checkpoint, which makes mutated cells more dependent 
on the G2 checkpoint to be able to repair DNA damage. In our study we do 
observe a difference in sensitivity between TP53 wildtype and TP53 mutant 
chondrosarcoma cell lines; cell lines with intact P53 are less sensitive to 
inhibition of AURKA, CHK1 or PLK1. However, these cells also grow slower 
compared to the other cell lines, which could confound the observed 
difference in response. Mutations in TP53 have been observed in 20% of 
chondrosarcomas [35], indicating that inhibitors of cell cycle regulators 
might be of interest especially for these patients.  
In conclusion, we performed a kinase focused siRNA and compound screen 
and identified cell cycle regulators AURKA, CHK1 and PLK1 as interesting 
targetable proteins for follow up studies. RNA expression analysis revealed 
expression of AURKA and CHK1 in a subset of chondrosarcoma patients, 
while PLK1 expression was minimal, compared to normal cartilage tissue. 
In addition high CHK1 expression was correlated towards a decrease in 
survival time. Also inhibition of CHK1 could sensitize a subset of 
chondrosarcoma cells towards chemotherapy. Future studies should 
determine the role of cell cycle proteins in chondrosarcoma, however based 
on our results CHK1 seems to be a promising therapeutic candidate for 
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Supplementary table 1. Patient and control samples included in RNA expression 
analysis. 
 




Low (grade 1) 11 
High (grade 2+3) 19 
Growth plate N/A 3 
Cartilage N/A 3 
 
Supplementary table 2. Sequences of primer pairs used for RNA expression 
analysis. 
 
PLK1 F AGAGACCTACCTCCGGATCAA 
PLK1 R GCAGCTCGTTAATGGTTGGG 
CHK1 F CTTACTGCAATGCTCGCTG 
CHK1 R GAGCTAGAGGAGCAGAATCG 
AURKA F CTCCAGTCACAAGCCGGTTC 
AURKA R GCCAGTTCCTCCTCAGGATTAT 
 
Supplementary table 5. IC50 values and 95% confidence intervals for nine different 
chondrosarcoma cell lines treated with inhibitors for AURKA (MK-5108), CHK1 
(LY2603618) or PLK1(Volasertib). 
 
 MK-5108 (AURKA) LY2603618 (CHK1) Volasertib (PLK1) 
JJ012 513.4 (464.2-570.1) >1000 10.98 (10.31-11.73) 
SW1353 >1000 441.2 (386.6-502.8) 33.67 (31.76-35.66) 
CH2879 847.6 (723.3-1049) 449.3 (401-504.6) 24.28 (20.69-28.18) 
CH3573 >1000 815.2 (730.2-918.4) 8.382 (7.083-9.809) 
L835 >1000 >1000 >1000 
L2975 520.8 (440.5-631) 826.1 (781.3-875.8) 11.33 (9.109-13.92) 
Ndcs1 >1000 442.6 (420.5-465.8) 3.166 (2.54-4.003) 
L3252 >1000 >1000 252.4 (187.1-363.9) 
MCS170 >1000 >1000 276.1 (181.2-482) 
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Abstract  
Chondrosarcomas are malignant cartilage-producing tumors showing 
mutations and changes in gene expression in metabolism related genes. In 
this study we aimed to explore the metabolome and identify targetable 
metabolic vulnerabilities in chondrosarcoma. 
A custom-designed metabolic compound screen containing 39 compounds 
targeting different metabolic pathways was performed in chondrosarcoma 
cell lines JJ012, SW1353 and CH2879. Based on the anti-proliferative 
activity, six compounds were selected for validation using real-time 
metabolic profiling. Two selected compounds (rapamycin and sapanisertib) 
were further explored for their effect on viability, apoptosis and metabolic 
dependency, in normoxia and hypoxia. In vivo efficacy of sapanisertib was 
tested in a chondrosarcoma orthotopic xenograft mouse model. 
Inhibitors of glutamine, glutathione, NAD synthesis and mTOR were 
effective in chondrosarcoma cells. Of the six compounds that were validated 
on the metabolic level, mTOR inhibitors rapamycin and sapanisertib showed 
the most consistent decrease in oxidative and glycolytic parameters. 
Chondrosarcoma cells were sensitive to mTORC1 inhibition using 
rapamycin. Inhibition of mTORC1 and mTORC2 using sapanisertib resulted 
in a dose-dependent decrease in viability in all chondrosarcoma cell lines. 
In addition, induction of apoptosis was observed in CH2879 after 24h. 
Treatment of chondrosarcoma xenografts with sapanisertib slowed down 
tumor growth compared to control mice. 
mTOR inhibition leads to a reduction of oxidative and glycolytic metabolism 
and decreased proliferation in chondrosarcoma cell lines. Although further 
research is needed, these findings suggest that mTOR inhibition might be a 
potential therapeutic option for patients with chondrosarcoma. 
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Introduction 
Chondrosarcomas, a group of malignant cartilage producing tumors, can be 
divided into different subtypes of which conventional chondrosarcoma is the 
most frequent (85%) followed by dedifferentiated chondrosarcoma (10%). 
The remaining 5% of chondrosarcomas consist of the rare subtypes 
mesenchymal chondrosarcoma, clear cell chondrosarcoma and periosteal 
chondrosarcoma. Conventional central chondrosarcomas are found in the 
medulla of the bone and histological grading is the most important 
prognostic factor. Atypical cartilaginous tumors (ACT) / chondrosarcomas 
grade I show a ten years survival rate of 83%, Grade II chondrosarcomas 
64% and grade III chondrosarcomas only 29% [1]. Chondrosarcomas are 
treated by surgery, since these tumors show limited response to 
conventional chemo- and radiotherapy [2, 3]. This means that patients with 
inoperable disease do not have any treatment options with curative intent, 
emphasizing the need to develop novel targeted therapies.  
Increasing evidence has shown the importance of metabolic processes and 
their relation to the activation of oncogenes or inactivation of tumor 
suppressor genes in cancer cells [4]. Therefore, targeting the cancer 
metabolism has been explored and has resulted in several potential 
therapeutic targets that are currently tested in the clinic [5]. In 
chondrosarcoma cells metabolic processes are deregulated as well.  cDNA 
microarrays showed an up-regulation of glycolysis and down regulation of 
oxidative phosphorylation related genes in high grade central 
chondrosarcomas compared to low grade central chondrosarcomas [6]. In 
addition, hypoxia related genes HIF1A and its downstream target carbonic 
anhydrase (CA) IX were found to be up-regulated in high grade compared to 
low grade chondrosarcomas, and high expression was correlated with a 
shorter metastasis free survival [7]. Moreover,  activation of the mTOR 
pathway, which plays a central role in a variety of different metabolic 
processes, was suggested  in 69% of conventional and 44% of 
dedifferentiated chondrosarcoma based on immunohistochemistry [8]. Next 
to differences in expression levels also mutations in genes involved in 
metabolism are found in chondrosarcoma. Mutations in isocitrate 
dehydrogenase 1 and 2 (IDH1 and IDH2) are found in ~50% of central and 
dedifferentiated chondrosarcomas [9-12]. IDH1 and IDH2 are enzymes that 
convert isocitrate to alpha ketoglutarate (αKG) in the Krebs cycle. Mutations 
in IDH1 or IDH2 genes lead to the production of high levels of the 
oncometabolite D2-hydroxyglutarate (D2HG) as well as changes in the 
cellular metabolome through changes in levels of amino acids, glutathione 
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metabolites, choline derivatives and TCA intermediates [13-15]. TP53 
mutations have been identified in ~20% of chondrosarcomas especially of 
higher histological grade [16-18]. P53 is a tumour suppressor protein with 
important functions in controlling cell proliferation and apoptosis as well as 
being a regulator of several metabolic processes including glycolysis and 
mitochondrial metabolism [19]. 
To explore the metabolic changes that play a role in chondrosarcoma we 
performed a metabolic compound screen including, amongst others, 
compounds targeting glycolysis, glutamine metabolism, glutathione, HIF1a, 
mTOR and fatty acid metabolism. Compounds that targeted metabolic 
pathways most important for survival of chondrosarcoma cells were selected 
for further analysis on metabolic level using the Seahorse XFe analyzer. This 
led to the identification of mTOR as most promising metabolic compound 





Conventional central chondrosarcoma cell lines JJ012 (IDH1 mutant, 
R132G) [20] CH2879 (IDH wildtype) [21] and SW1353 (IDH2 mutant, R172S) 
(ATCC) were cultured in RPMI 1640 medium (Thermo Fisher Scientific) 
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS) (F7524, 
Sigma Aldrich, Saint Louis, Missouri, USA). TP53 mutations are present in 
all cell lines, although CH2879 shows a pathogenic TP53 mutation in only 
part of the cells, as determined previously [22]. Cell lines were cultured at a 
temperature of 37⁰C in a humidified incubator in normoxic conditions (5% 
CO₂). Identity of cell lines was confirmed using the Cell ID GenePrint 10 
system (Promega Benelux BV, Leiden, The Netherlands) before and after 




A detailed list of all compounds included in the metabolic compound screen 
is available in supplementary table 1. mTOR inhibitor rapamycin (S1039, 
Selleckchem), BH3 mimetic ABT-737 (S1002, Selleckchem) and general 
caspase inhibitor Z-vad-FMK (550377 BD biosciences) were dissolved in 
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DMSO according to the manufacturer’s instructions. Chemicals for the 
Seahorse experiments oligomycin A (11342), trifluoromethoxy 
carbonylcyanide phenylhydrazone (FCCP, 15218), antimycin A (19433), 
rotenone (13995), UK5099 (16980), Etomoxir (11969) and BPTES (19284) 
were all purchased from Cayman Chemical (Massachusetts, USA) and 
dissolved in DMSO according to the manufacturer’s instructions. 
Doxorubicin and cisplatin in a 0.9% NaCl solution were obtained from the 
in-house hospital pharmacy.  
 
Metabolic Compound Screen 
39 compounds targeting different metabolic pathways were selected 
(supplementary table 1), and concentrations were chosen based on 
literature. In addition, possible synergistic effects with rapamycin and 
doxorubicin were investigated. Chondrosarcoma cell lines were seeded 
3000/well (JJ012 and SW1353) or 5000/well (CH2879) in 96 well plates. 
Cells were cultured overnight to attach and then treated with four different 
concentrations of compound or control for 72 hours. Cells were 
simultaneously treated with either doxorubicin, rapamycin or PBS. 
Combination treatments were carried out with concentrations that did not 
induce any toxicity on its own (>90% of cell viability): doxorubicin 10 nM, 2 
nM and 1 nM for CH2879, SW1353 and JJ012 cell lines respectively. 
Rapamycin was added in a 2 pM concentration for all cell lines. As a positive 
control 5 µM of doxorubicin was included. After 72h incubation, presto blue 
viability assays (Life-Technologies, Scotland, UK) were carried out according 
to the manufacturer’s instructions and fluorescence was measured at 590 
nM using a fluorometer (Victor3V, 1420 multilabel counter, Perkin Elmer, 
Netherlands). This was followed by fixation of the cell with phosphate 
buffered 4% paraformaldehyde and nuclei counting after staining with 
Hoechst using the Cellomics Array Scan High content system (Thermofisher 
Scientific). Compounds were selected for further metabolic characterization 
based on their ability to decrease viability more than 50% for the two highest 
concentrations in at least one of the three cell lines.  
 
Metabolic Characterization  
A Seahorse XFe 96 analyzer (Seahorse Bioscience, Agilent) was used to 
measure both oxygen consumption rate (OCR) and the extracellular 
acidification rate (ECAR) in chondrosarcoma cell lines JJ012, SW1353 and 
CH2879 after 24 hours of treatment. 30 hours prior to the assay cells were 
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plated in custom Seahorse 96 well plates in optimized densities being 15000, 
13000 and 30000 for JJ012, SW1353 and CH2879, respectively. After 6 
hours cells were treated with the selected compound for 24 hours. 
Concentrations were chosen based on the results of the compound screen 
(AOA 1mM, BSO 100 µM, bardoxylone methyl 0.5 µM, CB-839 500 nM, 
sapanisertib 100 nM, lovastatin 5 µM and rapamycin 10 nM). Before the 
measurement, cells were incubated for 1 hour in glucose-free RPMI-1640 
supplemented with 5% FBS. A customized assay was performed to measure 
both oxidative as well as glycolytic characteristics in a single run. During 
the assay, sequential injections of 10 mM glucose (Sigma-Aldrich), 2.0 µM 
oligomycin A, 2 µM FCCP and 0.5 µM 1:1 rotenone : antimycin A  established 
the metabolic profile. Data was normalized to cell numbers measured in 
each individual well using the Cellomics platform after Hoechst staining and 
data represented as the average +/- SD of duplicate or triplicate 
measurements of treated cells and 5-7 replicates for controls. Cell line 
characteristics were determined by calculating the basal and maximal 
respiration as well as the glycolysis and glycolytic capacity. Basal 
respiration, the oxidative rate of cells at rest, was calculated by subtracting 
the final measurement value (non-mitochondrial oxygen consumption) from 
the value after glucose injection. Maximal respiration, the oxidative 
respiration rate of cells treated with 2 µM FCCP, was calculated by 
subtracting the non-mitochondrial oxygen consumption from the highest 
value after FCCP injection. Glycolysis was determined from ECAR values, 
subtracting the final value (non-glycolytic acidification) from the value after 
glucose injection. The glycolytic capacity was calculated by subtracting the 
non-glycolytic acidification from the highest ECAR value after oligomycin 
injection. 
 
Metabolic Flexibility after mTOR Inhibition 
To measure the metabolic fuel dependency, the OCR and ECAR were 
measured after using the MitoFlex assay on the Seahorse XFe 96 analyzer 
according to the manufacturer’s instructions. Briefly, cells were prepared for 
analysis as described above and treated for 24 hours with mTOR inhibitor 
rapamycin or sapanisertib and during the assay with 3 µM BPTES, 4 µM 
Etomoxir and 2 µM UK5099. During the assay 10 mM glucose was injected 
followed by alternating a single inhibitor and a mixture of the remaining two 
inhibitors to measure metabolic dependency. Data was normalized to cell 
numbers measured in each individual well using the Cellomics platform and 
data represented as the average +/- SD of 6 replicate measurements. 
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Metabolic dependency was calculated by taking the last OCR value before 
injection (baseline OCR) and calculating the drop in OCR after injection of a 
single inhibitor by subtracting the lowest value after the single inhibitor 
injection and dividing this by the difference between baseline OCR and the 
lowest value after the injection of the remaining two inhibitors. 
 
Cell Viability and Proliferation Assays 
Chondrosarcoma cell lines JJ012, CH2879 and SW1353 counting seeded in 
previously optimized densities (JJ012 and SW1353 3000cells/well, CH2879 
5000cells/well) were allowed to adhere overnight before treatment with 
increasing concentrations of mTOR inhibitors rapamycin and sapanisertib 
for 72 hours. Cell viability was measured using presto blue viability reagent 
(Life-Technologies, Scotland, UK) and proliferation was measured using 
Hoechst staining as discussed previously. Experiments were performed in 
normoxic as well as hypoxic conditions by incubating cells in a MCO-19M 
O2 /CO2 incubator (Panasonic) using nitrogen to simulate a 1% O2 
environment and in combination with doxorubicin or cisplatin 




Quantification of apoptosis induction was performed using the caspase-glo 
3/7 assay from Promega (Madison, USA) as described previously [23]. 
Briefly, JJ012, SW1353 and CH2879 cells were plated in white walled 96 
well plates (Corning B.V. Life Sciences, Amsterdam, the Netherlands) and 
after overnight adherence incubated with either rapamycin, sapanisertib, or 
DMSO or pan-caspase inhibitor z-vad as control conditions. After 24 hours 
incubation, substrate was added in a 1:1 dilution in culture medium and 
incubated at room temperature (30 min). Cells treated with a combination 
of ABT-737 and doxorubicin were taken along as a positive control. 
Luminescence was measured using a luminometer (Victor3V, 1420 
multilabel counter, Perkin Elmer, Netherlands). Experiments were 
performed three times in duplicate. 
 
Western blot 
Protein expression of Hif1α (Clone D2U3T, Cell signaling), PS6 (Clone 
DS7.2.2E, Cell signaling) and P-akt (ser473) (Clone D9E, Cell signaling) was 
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determined after 24 hours of treatment with rapamycin, or sapanisertib in 
normoxic as well as hypoxic conditions. To prevent reversal of hypoxic 
conditions, lysates were obtained immediately after removal of the culture 
flasks from the incubator, using hot-SDS buffer (1% SDS, 10 mM Tris/EDTA 
with complete inhibitor and phosSTOP) as previously described [24]. For 
each sample, 10 µg of protein was loaded on the gel. As loading control, α-
tubulin (clone DM1A, Sigma-Aldrich Chemie B.V. Zwijndrecht, the 
Netherlands) expression was determined. Blocking was performed using 5% 
milk and primary antibodies were diluted in 5% bovine serum albumin (BSA) 
solution and incubated overnight. Proteins were blotted on a PVDF 
membrane and detected using enhanced chemo luminescence (PierceTM 
ECL Western Blotting Substrate, Thermo Fisher Scientific, Waltham, MA, 
USA) followed by exposure and development of the film (ECL hyperfilm, 
Amersham, GE Healthcare, Chicago, IL, USA). 
Mouse Experiments 
Animal procedures (AVD116002016574) were approved by the Central 
Committee of animal experiments (CCD, The Hague, The Netherlands) 
conform the European legislation (EU 2010/63/EU) and performed under 
permission of the Leiden University animal experimental committee. 
Athymic mice (BALB/c nu/nu 6 weeks old) were acquired from Jackson 
(Janvier-labs, France), and housed at the animal facility of the Leiden 
University Medical Center. A total of 12 female mice were used, using 6 mice 
per group. Orthotopic injection of the luciferase expressing CH2879 LUC10 
clone (1x105 cells in 10 μL PBS) was performed in all mice under isoflurane 
anesthetics as described previously [25]. In brief, two small holes (∼0.35 mm 
each) 4–5mm apart were created in the bone cortex of the upper right tibiae 
using needles (25GA 5/8 0.5 x16). A reservoir for the cells was created by 
flushing out the bone marrow from the proximal end of the shaft. After 
inoculation of the CH2879 Luc10 cells the skin was sutured with wound 
clips. Tumor growth was analyzed by measuring the luciferase activity by 
Bioluminescence Imaging (BLI) 10min. after i.p. injection of 150 mg/kg D-
luciferin (Synchem UG & Co Kg, 60mg/ml in PBS stock solution). Micro 
Computed Tomography (mCT) (Skyscan 1076 Micro CT scanner (Bruker 
Microct, Kontich, Belgium) was performed to determine exact location of the 
tumor and the bone loss at the start of the experiment, in the middle and at 
the end of the experiment. Weekly, mice were weighted and tumor growth 
(BLI) was analyzed under isoflurane anesthetics on the IVIS Spectrum 
Xenogen (Perkin Elmer, Hopkinton, MA) and quantified in 
photons/s/cm2/sr within a standardized ROI using Living Image 3.0 
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(Caliper LifeSciences, Hopkinton, MA). Treatment was started as soon as 
tumor BLI signal reaches 105 P/s/cm2 (4 out of 16 mice failed to develop 
tumors). The 12 mice were divided into even sized control and treatment 
groups. In order to investigate the effect of mTOR inhibitor sapanisertib on 
tumor growth, sapanisertib (MLN0128, Selleckchem) was dissolved in 
30%PEG400 (Bufa) / 0.5%Tween80 (Sigma)/ 5%Propyleenglycol (Bufa) in 
water conform the datasheet and further diluted in PBS. Six mice were 
treated by oral gavage of 100 µl 2.5 mg/kg sapanisertib in PBS for 3 days a 
week (Monday/Wednesday/Friday) for 8 weeks, while the control group of 
six mice was given only 100µl dissolvent 
30%PEG400/Tween80/Propyleenglycol in PBS by oral gavage 3 days a week 
and monitored for 8 weeks. After 8 weeks of treatment or when BLI signal 
reached 108 P/s/cm2 mice were sacrificed. Both tibiae were collected and 
cut longitudinally in half. One part was fixated overnight in formalin and 
decalcified and embedded in paraffin for histological assessment and the 
other part was snap frozen and stored in -80oC. For histological assessment 
of possible metastases or toxicity of the treatment, lungs, liver and kidneys 
were embedded in paraffin. Furthermore, whole blood cell analysis (Sysmex 




On all mouse tumors that were collected, protein expression was evaluated 
for P-S6 (clone D57.2.2E, Cell signaling), Ki-67 (clone D2H10 Cell Signaling), 
Cleaved caspase 3 (Cell signaling #9661) and LC3B (Clone D11 Cell 
signaling). In supplementary table 2 all the specifics of the antibodies are 
described. Immunohistochemistry was performed using standard laboratory 
methods as described previously [26]. Slides were scored using Q-Path 
software or by manually counting positive cells (Cleaved caspase-3). Tumors 
were selected, and positive cell detection was used to calculate the 
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Results 
Compound screen identifies glutamine, glutathione, mTOR, NAD synthesis 
and fat metabolism as important metabolic regulators in chondrosarcoma 
cells. 
The custom designed compound screen indicated that chondrosarcoma cell 
lines were most sensitive for compounds targeting glutamine, glutathione, 
mTOR and NAMPT (Figure 1). In addition, cholesterol inhibitors simvastatin 
and lovastatin were effective in the chondrosarcoma cells, especially in the 
JJ012 cell line. Furthermore, JJ012 demonstrated high sensitivity towards 
treatment with buthionine sulfoximine (BSO), while the other two cell lines 
were resistant. Interestingly, no sensitivity was observed for any of the 
compounds targeting the glycolysis pathway. Combination treatment with 
low concentrations of doxorubicin or rapamycin did not suggest additive of 
synergistic effects (supplementary table 3). Twelve compounds fulfilled the 
selection criteria as they decreased viability more than 50% for the two 
highest concentrations in at least one of the three cell lines. When multiple 
compounds targeting the same pathway met the selection criteria, one was 
chosen for further validation. Moreover, the inhibition of NAD+ biosynthesis 
using GMX1778 was already previously explored within our group [27] and 
was not selected for further validation as we used this as a positive control 
to validate proper workings of the screen. This way, six compounds were 
selected for further study; CB-839, AOA, bardoxylone methyl, BSO, 
sapanisertib and Lovastatin (figure 1). In addition, even though everolimus 
was tested in the compound screen and has shown higher selectivity for 
mTORC1 compared to rapamycin, rapamycin was taken along as a second 
mTOR targeting compound since it is currently in clinical trials for the 
treatment of chondrosaromca (NCT02821507) and targets only mTORC1, 
while sapanisertib is targeting both mTORC1 and mTORC2.  
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Figure 1: Viability of in vitro metabolic drug screen in three different 
chondrosarcoma cell lines. Four different concentrations were used per compound 
as indicated. Of all 39 tested compounds twelve compounds decreased cell viability 
more than 50% for the two highest concentrations in at least one of the three cell 
lines (indicated in bold). Six compounds were selected for further study; BSO, 
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Inhibition of metabolic pathways leads to effects on both oxidative and 
reductive metabolism  
Using the Seahorse XFe96 metabolic analyzer, we evaluated the effect of the 
seven selected compounds on the oxidative and glycolytic respiration in 
JJ012, SW1353 and CH2879. The maximal respiration of all cell lines was 
found to decrease for all seven selected compounds (figure 2A) while the 
basal respiration was lowered in all but the BSO and lovastatin treated cells 
(figure 2B). In contrast, glycolysis and glycolytic capacity was only decreased 
in cells treated with AOA, bardoxylone methyl, sapanisertib and rapamycin 
(figure 2C-D). Combining these parameters, we found that inhibition of the 
aspartate aminotransferase enzyme, an important chain in the aspartate 
synthesis pathway, using AOA as well as the inhibition of mTOR (using 
rapamycin and sapanisertib) led to consistent decreases in all measured 
oxidative and glycolytic parameters. All compounds were confirmed to 
decrease viability after treatment similar to the compound screen 
(supplementary figure 1. A). When comparing IDH mutant with IDH wild type 
cells, no large differences were found. Moreover, pre-treatment of JJ012 with 
AGI-5198, and CH2879 with cell permeable D2-HG, did not reverse the 
effect of the compound on basal and maximal respiration (supplementary 
figure 1B). This suggests that the metabolic vulnerabilities seen are 
independent of the IDH mutation status. 
 
Changes in metabolic fuel dependency upon inhibition of mTOR. 
Since aspartate amino transaminase inhibitor AOA is not suitable for 
clinical use due to a high incidence of side effects [28] we decided to further 
investigate the mechanism of mTOR inhibition in chondrosarcoma. A 
mitoFlex test was performed to measure the dependency on metabolic fuels 
glutamine, fatty acids and glucose after mTOR inhibition. All three cell lines 
depended mostly on glucose for energy production (Figure 2E). We found an 
increase in dependency on glutamine and fatty acids after sapanisertib 
treatment in JJ012 (p=0.0001 and p=0.0016, respectively). This effect was 
more pronounced with sapanisertib as compared to rapamycin. An opposite 
trend was however seen in CH2879 in which the dependency on fatty acid 
and glucose decreased (p=0.0036 and p=0.0026). SW1353 was largely 
unaffected except for lower glucose dependency after sapanisertib treatment 
(p=0.0414). In summary, mTOR inhibition using rapamycin or sapanisertib 
decreases oxidative and glycolytic metabolism and influences the underlying 
metabolic fuel dependency on glutamine (JJ012), fatty acids (JJ012, 
CH2879) and glucose (SW1353, CH2879).  
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Figure 2: Real-time metabolic analysis of three chondrosarcoma cell lines after 
treatment with the compounds selected from the screen.  
Maximal respiration (A), Basal Respiration (B), Glycolysis (C) and Glycolytic capacity 
(D) of all cell lines after 72h of treatment with selected compounds. Maximal and 
Basal respiration are most decreased in all cell lines after treatment with 
Bardoxylone methyl or sapanisertib (P<0.0001). Glycolysis and Glycolytic capacity 
are most decreased after treatment with AOA, sapanisertib and rapamycin 
(P<0.0001). E) MitoFLEX test shows metabolic dependency on fuels glutamine, fatty 
acids and glucose after treatment. JJ012 shows an increased dependency on 
glutamine and fatty acids and CH2879 shows an increased dependency on fatty 
acids and glucose after rapamycin or sapanisertib treatment. Significant changes 
towards control (figure A, B, C and D) or other indicated conditions (figure E) are 
presented by asterisks. *: P<0.05, **: P<0.01, ***: P<0.001, ****: P<0.0001. P values 
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Inhibition of mTOR leads to a decrease in proliferation in chondrosarcoma cell 
lines. 
Inhibition of mTORC1 with rapamycin led to a maximum reduction in 
viability of 50% in all three chondrosarcoma cell lines which was 
independent of dose; 0.5 nM led to the same reduction in viability compared 
to 500 nM (Figure 3A). Chondrosarcoma cell lines treated with dual 
mTORC1 and mTORC2 inhibitor sapanisertib showed a dose dependent 
decrease in viability after 72h with an IC50 of 9nM, 26nM and 27nM for 
JJ012, SW1353 and CH2879 respectively. However, at higher 
concentrations the viability remained 10-30% (Figure 3B). We therefore 
investigated possible synergistic effects by combination treatment with 
doxorubicin or cisplatin. However, combination treatment did not suggest 
any additive or synergistic effects (supplementary figure 2). Induction of 
apoptosis measured by caspase 3/7 activity was increased after 24h of 
treatment with sapanisertib in CH2879 but not in the other two cell lines 
(Figure 3C). In contrast, rapamycin treatment did not result in induction of 
caspase dependent apoptosis in any of the cell lines. Culturing cells under 
hypoxic conditions, to mimic the hypoxic chondrosarcoma 
microenvironment more closely [29], led to an increase in levels of Hif1α. 
However, hypoxia did not alter the response to mTOR inhibition as 
compared to normoxia (figure 3D-E). As expected, treatment with mTORC1 
inhibitor rapamycin does not result in a reduction in p-Akt, while inhibition 
of mTORC1 and mTORC2 by sapanisertib reduces expression of p-AKT 
(figure 3E). Furthermore, treatment with both inhibitors led to a decrease in 
P-S6, but no clear differences in HIF1α expression. 
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Figure 3: Inhibition of mTORC1 or mTORC1 and C2 in chondrosarcoma cell lines. 
A) Inhibition of mTORC1 using rapamycin for 72h led to a 50% reduction in viability 
in JJ012, SW1353 and CH2879 irrespective of the concentration. B) mTORC1 and 
mTORC2 inhibition using sapanisertib for 72 hours leads to a dose dependent 
decrease in viability in chondrosarcoma cell lines JJ012, SW1353 and CH2879. C) 
Caspase 3/7 activity in chondrosarcoma cell lines after 24h treatment with 
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sapanisertib or rapamycin. Only CH2879 cells treated with sapanisertib show an 
increase in caspase 3/7 activity. As a positive control cell lines were treated with 
ABT-737 and doxorubicin simultaneously. Results shown are mean and standard 
deviation of three individual experiments in duplicate. Points indicate individual 
measurements. D) No difference in response towards mTOR inhibitors sapanisertib 
or rapamycin between chondrosarcoma cells cultured in normoxia or hypoxia for 
72h E) Western blot analysis for Hif1α, p-Akt and P-S6 of chondrosarcoma cell lines 
cultured in normoxia (N) or hypoxia (H) treated with either sapanisertib or rapamycin 
for 24 hours compared to control. Α-tubulin expression is determined as a loading 
control.  
 
Treatment with sapanisertib leads to a delay in tumor growth in vivo 
Oral administration of sapanisertib to tumor bearing mice resulted in a 
delay in tumor growth compared to control conditions as measured by 
bioluminescence luciferase imaging (BLI) (Figure 4A, 4B). During the 
treatment period two control mice had to be sacrificed and excluded from 
the analysis. One due to an acquired infection and the other due to tumor 
growth outside of the bone. In the control group all mice reached a 
bioluminescence signal of 108 and a strong increase in percentage tumor 
growth within four weeks after start of treatment, while tumors of mice 
treated with sapanisertib showed a delay in tumor growth and a slower 
increase in tumor formation (figure 4B and supplementary figure 3). After 4 
weeks of treatment tumor growth decreased, with tumor regrowth at week 
6. No difference was observed in white blood cell counts and weight 
measurements between sapanisertib treated and control mice 
(supplementary figure 4). Furthermore, no metastases in the lungs were 
identified in any of the mice and no signs of toxicity of the compound were 
observed in liver, kidney and spleen of a selection of three treated and three 
control mice (data not shown). Immunohistochemical analysis of Ki-67, P-
S6, cleaved caspase 3 and LC3B revealed a small increase in ki-67 positive 
cells in control compared to treated tumors (P=0.03571). No significant 
differences were observed in the other markers between treated and control 
tumors (see supplementary figure 5 and supplementary table 4). In addition, 
no morphological differences were observed in tumors of control and 
sapanisertib treated mice (Supplementary figure 6).  
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Figure 4: Inhibition of mTORC1 and mTORC2 using sapanisertib in an orthotopic 
chondrosarcoma xenograft mouse model leads to a delay in tumor growth.  
A) Bioluminescent signal (photons/sec/cm2/sr) within standardized ROI of control 
mice compared to mice treated with sapanisertib after three weeks of treatment. B) 
Fold increase in tumor growth in control compared to mice treated with sapanisertib 
showing a delayed tumor fold increase in sapanisertib treated mice compared to 
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Discussion  
In this study, metabolic vulnerabilities of three chondrosarcoma cell lines 
with different mutational backgrounds were investigated by a custom-made 
metabolic compound screen targeting a multitude of metabolic pathways. 
Targeting the glutamine-, glutathione-, NAD synthesis-, and mTOR 
pathways decreased viability in all cell lines, of which the glutamine pathway 
has been previously determined to be important in chondrosarcoma with 
similar effects on viability of chloroquine and CB-849 [30]. Seven 
compounds were further investigated by metabolic profiling using the 
Seahorse XFe analyzer, measuring both the oxidative and glycolytic 
characteristics of the cells to see how the overall metabolism of these cells 
was affected. Compounds that caused a decrease in oxygen consumption 
rates showed either decreases or very minor increases in glycolytic rates, 
thus cells were not compensating the loss in oxidative metabolism by up 
regulating their glucose metabolism. This indicates that glycolysis is also 
affected by most treatments or cells try to compensate through other 
metabolic pathways. Interestingly, in the compound screen none of the cell 
lines were sensitive to the inhibition of glycolysis, while previous reports 
suggest that this can be an effective strategy in chondrosarcoma either as a 
single treatment or in combination with chemotherapy [31-33]. Previous 
studies have shown that drug resistance has an impact on the metabolism 
of cells, which explains the difference in sensitivity to glycolytic inhibitors 
that we observed in the compound screen. In our study we used previously 
untreated chondrosarcoma cells while all the aforementioned studies used 
cells that were cultured on low doses of cisplatin or doxorubicin for extended 
periods of time. This leads to the emergence of drug resistance and can 
influence the cellular metabolism. [34] Based on the Seahorse observations 
and the fact that we do not see any differences in viability after inhibiting 
the glycolysis pathway, both in the presence and absence of low 
concentrations of doxorubicin and cisplatin, we hypothesize that glycolysis 
is not essential for chondrosarcoma metabolism. High levels of reactive 
oxygen species (ROS) in tumors have been associated with the 
reprogramming of energy metabolism, which can lead to differences in 
activity of the glycolysis, fatty acid, pentose phosphate and serine one-
carbon pathways [35, 36]. Interestingly, JJ012 was far more responsive to 
glutathione synthesis inhibitors BSO and AOA treatment compared to 
SW1353 and CH2879. Recently, our group described a metabolic 
vulnerability in the NADH synthesis pathway of the JJ012 cell line [27]. This 
might provide a rationale as to why JJ012 is more responsive, as decreased 
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efficiency of the electron transport chain conveys a higher ROS production 
as well as a dependence on NAD dependent aspartate synthesis through the 
GOT1 enzyme, of which AOA is an inhibitor [37, 38]. Further evidence of 
ROS involvement was found upon bardoxylone methyl treatment. The exact 
mechanism of bardoxylone methyl is under debate as its fluctuating effects 
on Nrf2 and NF-kβ seem to depend heavily on the available concentrations 
within the cell and thus might explain the high variance found in the 
glycolytic parameters [39].  
Treatment of chondrosarcoma cell lines with rapamycin or sapanisertib 
showed consistent decreases in viability, coupled to a decrease in both 
oxidative and glycolytic metabolism, highlighting the importance of the 
mTOR pathway in chondrosarcoma cell lines. mTOR is the central regulator 
of many metabolic pathways as well as autophagy and is regulated by a 
multitude of stimuli related to metabolism, DNA damage, growth and 
hypoxia [40]. It can be found in two different complexes mTORC1 and 
mTORC2, with rapamycin inhibiting only the mTORC1 complex, while 
sapanisertib is inhibiting both mTORC1 and mTORC2. In our study we show 
that chondrosarcoma cell lines are responsive to both inhibitors, however 
treatment with the dual inhibitor sapanisertib led to the largest decrease in 
cell viability. The combination treatment of both inhibitors did not suggest 
any synergistic effects (supplementary figure 1). This can be related to the 
binding specifics of the drugs as the inhibition of the whole kinase domain 
(both the S6K and 4EBP1 by sapanisertib negates the effects of rapamycin 
induced via inhibition of the S6K domain only (through complex formation 
with the FKBP12 protein). [41, 42] This is consistent with other pre-clinical 
studies in multiple tumor types including sarcomas, in which sapanisertib 
was shown to be more potent [43]. Furthermore, this increased efficacy was 
also seen in the metabolic characterization where sapanisertib treated cells 
had lower metabolic rates compared to rapamycin. Measuring the 
dependency on underlying fuel pathways showed differences in glutamine, 
fatty acid and glucose dependency. We found increased glutamine and fatty 
acid dependency in JJ012 but a decreased dependency on fatty acids in 
CH2879. Furthermore, lower glucose dependency was observed in SW1353 
and CH2879. Interestingly, all differences in dependency were more 
profound in sapanisertib treated cells compared to rapamycin treatment. 
Although the cells were treated with different concentrations of rapamycin 
and sapanisertib, all data was normalized to cell numbers directly after the 
dependency assay, eliminating the possibility of dose-related effects. 
Therefore, the observed changes are most likely related to the effects of the 
compounds as the inhibition of both mTORC complexes by sapanisertib 
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leads to a stronger metabolic reaction compared to the inhibition of only the 
single mTORC1 complex from rapamycin. However, the cellular metabolism 
is highly intertwined with all other cellular processes and while we observed 
differences in metabolic dependency upon mTOR inhibition further studies 
should be performed to elucidate whether this is a direct effect or from the 
result of changes that occur in other mTOR regulated processes upon its 
inhibition. mTOR is involved in many physiological processes ranging from 
metabolism to muscle mass and brain function. On the cellular level this is 
mainly regulated through protein synthesis and turnover, autophagy and 
lipid/glucose/nucleotide metabolism. Changes in for instance the activity of 
protein turnover can have a secondary effect on the metabolism, therefore 
measuring the activity of activators and downstream targets might provide 
more insight into the exact workings.  
A number of studies have found chondrosarcoma to be a hypoxic tumor with 
increased HIF1α and VEGF signaling [44]. We found higher levels of HIF1α 
in cells under hypoxia but found no difference in cell viability after mTOR 
inhibition with rapamycin and sapanisertib in hypoxic conditions compared 
to normoxia. Thus, in chondrosarcoma cell lines hypoxia does not increase 
sensitivity to mTOR inhibition.  
Sapanisertib has been found as a potent treatment option in mouse models 
of several tumor types, amongst them xenograft models of osteosarcoma [43, 
45, 46]. Using an orthotopic xenograft mouse model of chondrosarcoma we 
established a delay in tumor growth upon treatment with sapanisertib. 
Interestingly, tumor growth was severely delayed up until 5 weeks after start 
of the treatment. From week 5 onwards, increased tumor growth was 
observed, although with a high variance, suggesting a possible resistance 
mechanism. This is in line with the in vitro data, where a decrease to around 
10-30% viability is observed. Furthermore, rapamycin or everolimus based 
interventions have, in spite of favorable pre-clinical data, not progressed 
through phase II clinical trials in chondrosarcoma yet [47-49]. A possible 
solution would be to look into a combination treatment approach to 
circumvent resistance. A phase I study investigating the combined effect of 
rapamycin and cyclophosphamide in 10 chondrosarcoma patients showed 
stable disease in 6 patients and a partial response in one patient indicating 
a predominantly cytostatic effect. Currently a phase II study is on-going to 
confirm these results in a larger cohort (NCT02821507). Furthermore, 
resistance might also explain the lack of difference in expression of cleaved 
caspase, LC-3B, KI67 and p-S6 markers in the tumor tissue harvested at 
the end of the experiment, when tumors were growing again. To further 
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investigate the effects of sapanisertib in vivo, a larger cohort study should 
be set up where it would be of interest to analyze the expression of different 
markers such as Ki67, caspase, LC-3B and p-S6 at multiple time points 
during the experimental period to observe possible changes in these markers 
at earlier stages of treatment. Furthermore, the analysis of metabolic 
pathways, combinational treatment with different drugs and mTOR-related 
pathway analysis would provide great insight into the working and 
secondary resistance mechanism of sapanisertib in vivo. 
Using a screening-based approach we identified glutamine, glutathione, 
mTOR and NAD synthesis as the most essential metabolic pathways in 
chondrosarcoma cells. Metabolic respiration was most affected when mTOR 
was inhibited using sapanisertib, a dual mTORC1 and mTORC2 inhibitor. 
Cell lines showed a dose dependent decrease in viability after treatment with 
sapanisertib; however, a plateau of 10-30% cell viability remained after 
treatment. Treatment of a chondrosarcoma orthotopic xenograft mouse 
model resulted in a decrease in tumor formation, however resistance was 
observed after several rounds of treatment. These results indicate that 
inhibition of mTORC1 and mTORC2 can be a possible therapeutic option for 
chondrosarcoma patients in combination strategies. Further investigation is 
needed to determine possible candidates for combination. 
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Supplementary Figure 1: A) Viability of compounds used in Seahorse metabolic 
characterization after 24 and 72 hours treatment. After 24h no drastic effects (>50% 
decrease) are observed after treatment, indicating that viable cells were still present 
when performing the seahorse assay. After 72h of incubation all compounds showed 
a similar effect as observed in the compound screen. Significant changes towards 
control are presented by asterisks for 24h treatment periods. *: P<0.05, **: P<0.01, 
***: P<0.001, ****: P<0.0001. For 72h treatment periods all values are significantly 
different compared to the control (P<0.0001). P values were calculated using Tukey’s 
multiple comparisons test. B) Maximal respiration and basal respiration parameters 
of cell lines JJ012 and CH2879 after 72-hour treatment with AGI-5198 (JJ012) or 
D2-HG (CH2879) normalized towards control conditions. Treatment with Agi-5198 
or D2HG both resulted in a decrease in metabolic parameters compared to control. 
Significant changes towards control were calculated using Sidaks multiple 
comparison and are presented by asterisks *: P<0.05, **: P<0.01, ***: P<0.001, ****: 
P<0.0001. 
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Supplementary figure 2. No synergistic effects after combined treatment of mTOR 
inhibitors sapanisertib or rapamycin and doxorubicin(DXR) or cisplatin(CDDP) in 
chondrosarcoma cell lines SW1353 and CH2879 
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Supplementary figure 3. Blood count and weight of control compared to 
sapanisertib treated mice. A) No difference between WBC, RBC, HGB, Platelets and 
lymphocyte count in sapanisertib compared to control mice. B) Weight normalized 
towards week 0 of mice treated with sapanisertib compared to control mice. No 
difference is observed between the two groups. Each point indicates one mouse. 
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Supplementary figure 4. No difference is observed between percentages of positive 
cells for ki-67, p-S6, cleaved caspase 3 and LC3B in tumors harvested from mice 
treated with sapanisertib compared to control mice. Each dot represents one tumor, 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
 
Supplementary Table 2. Conditions of Immunohistochemical staining on mouse 
tumor tissue 
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Radiotherapy resistance in chondrosarcoma 
cells; a possible correlation with alterations in 
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Abstract 
Conventional chondrosarcomas are malignant cartilage tumors considered 
radioresistant. Nevertheless, retrospective series show a small but 
significant survival benefit for patients with locally advanced disease treated 
with radiotherapy. And, in daily practice when considered inoperable their 
irradiation is an accepted indication for proton beam radiotherapy. 
Therefore, we investigated the sensitivity of chondrosarcoma cell lines and -
tissue samples towards radiotherapy and screened for biomarkers to identify 
predictors of radiosensitivity. 
Proliferation and clonogenic assays were performed in chondrosarcoma cell 
lines after γ-radiation in combination with mutant IDH1 inhibitor AGI-5198. 
In addition, glutathione levels were measured using mass spectrometry. 
Chondrosarcoma tumor explants were irradiated after which γ-H2AX foci 
were counted. Mutation analysis was performed using the Ion AmpliSeq™ 
Cancer Hotspot Panel and immunohistochemical staining’s were performed 
for P-S6, LC-3B, P53, Bcl-2, Bcl-xl and survivin. Results were correlated 
with the number of γ-H2AX foci. 
Chondrosarcoma cell lines were variably γ-radiation resistant. No difference 
in radiosensitivity, nor glutathione levels was observed after treatment with 
AGI-5198. Irradiated chondrosarcoma patient tissue presented a variable 
increase in γ-H2AX foci compared to non-radiated tissue. Samples were 
divided into two groups, high and low radioresistant, based on the amount 
of γ-H2AX foci. All four highly resistant tumors exhibited mutations in the 
pRb pathway, while none of the less radioresistant tumors showed 
mutations in these genes. 
Chondrosarcoma cell lines as well as primary tumors are variably 
radioresistant, particularly in case of a defective Rb pathway. Whether 
selection for radiotherapy can be based upon an intact Rb pathway should 
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Introduction 
Chondrosarcomas are a heterogeneous group of cartilage producing tumors 
of which the most prevalent subtype (85%) is conventional chondrosarcoma. 
More rare subtypes include dedifferentiated chondrosarcoma (10%), 
mesenchymal chondrosarcoma (2%), clear cell chondrosarcoma (2%), and 
periosteal chondrosarcoma (1%). Conventional chondrosarcoma can be 
subdivided into three histological grades, representing the most important 
prognostic factor. Atypical cartilaginous tumors (previously referred to as 
grade I) have a relatively good prognosis, exhibiting a 10 years survival of 
83%. Probability of surviving 10 years is about 64% for grade II 
chondrosarcomas and about 29% for grade III chondrosarcomas [1-3]. 
Based on their location conventional chondrosarcoma can be further 
subdivided into central (85%) and peripheral (15%) subtypes. Rare 
chondrosarcoma subtypes dedifferentiated, mesenchymal and clear cell 
chondrosarcoma occur also centrally in the bone [4-6], while periosteal 
chondrosarcoma is located and originates from the periosteal surface of the 
bone [3]. In this study, we focused on central chondrosarcomas, as these 
are of highest prevalence. Central chondrosarcomas carry mutations in the 
genes encoding the enzymes Isocitrate dehydrogenase 1 or -2 (IDH1 or IDH2) 
[7-9] in approximately 50% of cases, resulting in production of the 
oncometabolite D-2-hydroxyglutarate (D-2HG).  
The only curative treatment for patients with chondrosarcoma is radical 
surgery, since they are considered resistant towards conventional chemo- 
and radiotherapy. For this reason, linear accelerator based (conventional) 
radiotherapy is only given to patients with metastatic disease, incomplete 
resection or inoperable tumors in difficult sites like the base of skull or the 
sacrum [2, 10]. Several causes have been suggested for chondrosarcoma 
radioresistance, such as the relative hypoxic chondrosarcoma 
microenvironment impairing the induction of reactive oxygen species (ROS) 
and DNA damage, or their relatively slow dividing rate (though not applicable 
to high grade tumors).  Additionally, knock down of anti-apoptotic Bcl-2 
family members Bcl-2, Bcl-xl and XIAP has been shown to increase cell 
death after radiation in chondrosarcoma cell lines [11]. Furthermore, 
restoration of p16 activity sensitized chondrosarcoma cell lines to 
radiotherapy [12]. More recently, a role for IDH mutations has been found 
in predicting radiotherapy response in glioma due to altered redox responses 
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A recent retrospective analysis suggested that a subgroup of 
chondrosarcoma patients with locally advanced, unresectable disease 
showed a favorable overall survival after conventional radiotherapy [10]. As 
chondrosarcoma patients are not commonly treated with radiotherapy, 
prognostic biomarkers for radiosensitivity were investigated using in vitro 
and ex vivo methods. Therefore, the aim of our study was to examine 
whether sensitivity to γ-radiation can be observed in central conventional 
chondrosarcoma cell lines by determining clonogenic survival and γ-H2AX 
foci induction after radiation. In addition, radiosensitivity of 
chondrosarcoma patient samples was determined by counting γ-H2AX foci 
after ex vivo radiation [14, 15]. Mutation and expression analyses were 
performed to investigate prognostic biomarkers for radiosensitivity which 




Conventional chondrosarcoma cell lines JJ012 (Grade II, IDH1 mutant) [16], 
SW1353 (Grade II, IDH2 mutant) (ATCC) and CH2879 (Grade III, IDH wild 
type) [17] were cultured in RPMI-1640 (Gibco, Invitrogen Life-Technologies, 
Scotland, UK) supplemented with 10% Fetal Calf Serum, at 37˚C in a 
humidified incubator (5% CO2). Short tandem repeat analysis was 
performed before and after completion of experiments to confirm identity of 
the cell lines by using the Cell ID Gene Print 10 system (Promega Benelux 
BV, Leiden, The Netherlands). Mycoplasma tests were performed on a 
regular basis.  
 
Compounds 
The specific mutant IDH1 inhibitor AGI-5198 (14624, Cayman Chemicals, 
Michigan, USA) was dissolved in DMSO according to the manufacturer’s 
instructions and stored in -20˚C. AGI-5198 was used at a concentration of 
10 µM since our group previously showed that this leads to a complete 
inhibition of D-2HG production [18]. (2R)-Octyl-α-hydroxyglutarate (16366, 
Cayman Chemicals), a cell-permeable derivative of D2-HG, was freshly 
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Chondrosarcoma cell lines SW1353 and JJ012 were plated in optimal cell 
densities to obtain sufficient colonies after treatment. Cells were allowed to 
adhere overnight before treatment with a wide range (0, 1, 2, 4 or 6 Gy) of γ-
radiation using a 137Cs source (YXLON, Comet technologies USA). Colony 
formation was assessed after 14 days of treatment by fixing and staining 
with 0.5% crystal violet/6% glutaraldehyde. Colonies were counted 
manually and the surviving fraction (SF) was calculated by normalizing 
towards the plating efficiency of untreated controls. The α/β ratios were 
calculated based on the linear quadratic model. α/β ratios describe the slope 
of the cell-survival curve; acute responding tissues show a higher ratio 
compared to late responding tissues. 
 
Viability assay 
Chondrosarcoma cells were counted using a Burker Turk counting chamber 
and seeded in optimized cell densities in 96 well plates. After attachment 
overnight cells were irradiated with increasing doses. Seventy-two hours 
after radiation cell viability was measured using PrestoBlue viability reagent 
(Invitrogen, Life-Technologies, Scotland, UK) according to the 
manufacturer’s instructions. Fluorescence was measured at 590 nM using 
a Wallac plate reader (Victor3V, 1420 multilabel counter, Perkin Elmer, the 
Netherlands). Experiments were performed three times in triplicate. 
 
Cell proliferation measurement 
To measure cell proliferation in real time the RTCA xCELLigence system 
(Roche Applied Sciences, Almere, the Netherlands) was used. JJ012, 
SW1353 and CH2879 cells were pre-treated for 72h with either 10 µM AGI-
5198 or 0.1% DMSO in T25 flasks. Thereafter, cells were plated in the 
presence of AGI-5198 or DMSO and left for 20 hours to attach to the wells 
before low-dose (2 Gy) or high dose (4 Gy) γ-radiation. After 125 hours the 
measurement was stopped, and the results were analyzed using RTCA 
software. Normalized cell index was calculated by normalizing against the 
amount of cells in each well after 20 hours. Experiments were performed in 
duplicate and repeated at least two times. 
 
γ-H2AX staining of chondrosarcoma cell lines 
Optimal cell amounts for JJ012 (550.000 cells), SW1353 (500.000 cells) and 
CH2879 (1000.000 cells) cell lines were cultured on alcohol sterilized APES 
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coated slides in a culture dish. IDH mutant chondrosarcoma cell lines 
SW1353 and JJ012 were pre-treated with 10 µM AGI-5198 or 0.1% DMSO 
for 72h, in order to inhibit mutant activity, and IDH wild type 
chondrosarcoma cell line CH2879 was pre-treated with 250 µM D-2HG for 
24h, in order to mimic mutant activity. After overnight attachment cells were 
radiated to 5 Gy, in order to achieve highest response without significant 
damage to sample, and fixed after 2 or 24h with buffered 4% formaldehyde 
(VWR Chemicals) at 37°C. The procedure was performed as described 
previously [19]. Slides were stained with γ-H2AX antibody (JBW301, 
Millipore) for 60 minutes, washed, then a mixture of Alexa fluor 657 labelled 
secondary antibody and 0.5 µM Hoechst33342 was applied for 60 minutes. 
Slides were covered with ProLong Gold antifade reagent and were examined 
using a confocal microscope by taking tile scans of areas of interest using 
ZEN light software. Pictures were exported in TIF format and loaded into 
FoCo, a previously published format using Image J and Matlab software [20]. 
 
Mass spectrometry measurements of glutathione  
Chondrosarcoma cell lines JJ012, SW1353 and CH2879 were seeded in 
triplicate in T25 culture flasks and allowed to adhere overnight. IDH mutant 
chondrosarcoma cell lines JJ012 and SW1353 were pre-treated with 10 µM 
AGI-5198 for 72h, while IDH wildtype cell line CH2879 was pre-treated with 
250 µM D-2HG for 24h. Samples were treated with 0 or 5 Gy, in order to 
correlate with γ-H2AX results. Cells were harvested by scraping after one 
hour. For each individual replicate 1x105 cells  were fixed overnight using 
ice-cold acetone. The supernatant was then removed and dH2O added (10 
µL), followed by a freeze-thaw cycle (10 seconds dry ice-cooled MeOH, 2 
minutes 37oC heating block). After 2 freeze thaw cycles glutathione was 
extracted with EtOH (50 µL) and the supernatant was mixed 1:1 (v:v) with 
matrix solution (N-(1-naphthyl) ethylenediamine dihydrochloride in 70% 
MeOH) for analysis. Samples were measured using a 9.4T SolariX XR 
Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer 
(Bruker Daltonics, Bremen, Germany) equipped with a CombiSource™ and 
a dynamically harmonized ParaCell™. The mass spectrometric analysis was 
performed in negative ion mode in the m/z-range 101.7-1000 Da, with a 1M 
data point transient (0.3670 second duration) and an estimated resolving 
power of 66000 at m/z 400. Spectra were acquired of 10 averaged scans, 
acquired in a random pattern covering the entire spot, where each scan 
consisted of 500 laser shots (laser power 70%, 1000 Hz frequency). Spectra 
were analyzed using DataAnalysis version 4.2 (Bruker Daltonics, Bremen, 
Radiotherapy resistance 
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Germany). Using a custom algorithm, intensities of the compounds of 
interest were extracted and exported to Excel 2016 (Microsoft) for further 
analysis. 
 
Chondrosarcoma tissue samples 
Chondrosarcoma patient samples (n=9, see table 1) were obtained at surgery 
and collected in RPMI-1640 medium supplemented with 20% FBS and 1% 
P/S. All samples were coded according to the Dutch code of proper 
secondary use of human material as accorded by the Dutch society of 
pathology (Federa), and as approved by the LUMC ethical board (B17.019). 
Samples were processed by manual dissection into approximately 2 mm 
fragments and incubated on a rotation shaker at 37˚C in a humidified 
incubator (5% CO2). The tissue was treated to 5 Gy, consistent with the cell 
line treatment, and incubated for 2 or 24 hours on a rotation shaker at 37˚C 
in a humidified incubator as described previously [21]. After overnight 
fixation with formalin, tissue was processed, embedded in paraffin and 
sections were cut and stained for γ-H2AX foci.  
 
γ-H2AX staining and quantification of paraffin embedded chondrosarcoma 
tissue 
Sections were deparaffinized and antigen retrieval was performed using 
DAKO antigen retrieval solution pH 9.0 by boiling the slides in a microwave 
for 12 minutes. After cooling, slides were washed with TBS and blocking was 
performed using TBS/5% normal goat serum/1% BSA and 0.2% Triton-x-
100. Anti γ-H2AX antibody (Millipore 2310355) was applied in a 1:1000 
dilution and incubated overnight at 4⁰C. Slides were washed with TBS and 
incubated with secondary labelled GAM Alexa fluor 647 antibody. Mounting 
was performed with ProLong Gold containing DAPI (Thermofisher Scientific, 
Waltham, Massachusetts, USA). Positive control slides consisted of JJ012 
cells radiated at 4 Gy as these displayed a consistent, high γ-H2AX signal. 
The cells were embedded in paraffin with the use of ShandonTM 
CytoblockTM Cell Block Preparation system (Thermofisher Scientific). Slides 
were analyzed using a confocal microscope by taking tile scans of areas of 
interest using ZEN light software. Pictures were exported in TIF format and 
loaded into FoCo, a previously published format using Image J and Matlab 
software [20]. The settings to quantify the foci were first optimized using the 
positive control slides, after which the complete series was analysed using 
the same settings.  
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Protein expression of Bcl-2, Bcl-xl, Survivin, P-S6, P53 and LC-3B were 
evaluated in irradiated control patient samples (see supplementary table 1). 
Immunohistochemistry was performed according to standard laboratory 
methods as previously described [22]. All Slides were scored by two 
independent observers (JVMGB,YDJ) using a scoring system assessing 
staining intensity (0= no, 1=weak, 2=moderate, 3=strong) as well as 
percentage of staining (0=no, 1=1-24%, 2=25-49%, 3=50-74%, 4=75-100%) 
[23] This scoring system was used for all the different proteins. 
 
Mutation analysis  
Frozen tissue of chondrosarcoma patients was collected at surgery and DNA 
was isolated using the wizard genomic DNA purification kit (Promega, 
Madison, WI, USA) according to the manufacturer’s instructions. Samples 
were subjected to next generation sequencing using the in-house developed 
Ion AmpliSeq™ Cancer Hotspot Panel v2 (Life Technologies, Thermo Fisher 
Scientific, USA, catalog number 4475346) as described previously [24, 25]. 
The following genes and regions were analysed on an Ion Torrent 
PGM/Proton for all samples (exons between brackets): ARAF (7,10); CTNNB1 
(1,2,4,7,8,12,15); KRAS (2-4); NRAS (2-4); HRAS (2-3); BRAF (11,15); EGFR 
(3,7,15,18-21); GNAQ (5); GNAS (8-9); H3F3A (2); H3F3B (2); IDH1 (4); IDH2 
(4); KIT (2,9-18); MYD88 (3b,5), MUTYH (7,13); PDGFRA (12,14,15,18,23); 
PIK3CA (2,5,6-10,14,18,21); POLE (9,11,13,14); RET (10-12,15,16); TP53 (1-
11). In addition hotspot regions in the following genes were also included: 
ABL1; AKT1; ALK; APC; ATM; CARD11; CD79A; CD79B; CDH1; CDKN2A; 
CSF1R; CTNNB1; ERBB2; ERBB4; EZH2; FBXW7; FGFR1; FGFR2; FGFR3; 
FLT3; GNA11; HNF1A; JAK2; JAK3; KDR; MET; MLH1; MPL; NOTCH1; NPM1; 
PTEN; PTPN11; RB1; SMAD4; SMARCB1; SMO; SRC; STK11; VHL. Libraries 
were prepared with 10 ng of genomic DNA, and each sample was uniquely 
barcoded. Ion Proton chips were prepared using the Ion Chef System. The 
unaligned bam files generated by the Proton sequencer were mapped against 
the human reference genome (GRCh37/hg19) using the TMAP 5.0.7 
software with default parameters (https://github.com/iontorrent/TS). The 
Torrent Variant Caller (TVC)-5.0.2 was used for variant calling and variant 
interpretation was done using Geneticist Assistant 
(http://softgenetics.com/GeneticistAssistant_2.php) as described. 
Chromosomal gains and deletions were assessed by calculating the median 
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base coverage per amplicon, which was normalized using the median value 
of all amplicons in that sample. 
 
Results 
Chondrosarcoma cell lines are variably resistant to γ-radiation 
Clonogenic assay SF2 values (surviving fraction of cells after 2 Gy radiation) 
suggested that JJ012 cells (SF2 0.55) were more radiosensitive compared to 
SW1353 (SF2 0.88) (Figure 1A). JJ012 cells showed a high α/β ratio of 
38.47, in contrast to SW1353 with a very low α/β ratio of -0.75, suggesting 
that SW1353 cells may benefit from hypofractionation. CH2879 cells were 
unable to form colonies and were therefore not included in this assay. In 
addition, dose response curves were made to assess viability after 72h. 
JJ012 cells were most sensitive followed by the CH2879 and SW1353 cells 
(Figure 1B). An X-CELLigence assay was performed to determine the effect 
on proliferation in real time after 2 or 4 Gy of radiation. All cell lines showed 
a reduction in proliferation after radiation. However, CH2879 cells showed 
a similar response when irradiated to 2 or 4 Gy, while JJ012 and SW1353 
showed a dose response relationship (Figure 1C). The amount of double 
strand breaks was determined by quantifying γ-H2AX foci 2 and 24 hours 
after radiation treatment.  JJ012, SW1353 and CH2879 cells exhibited an 
increase in foci after 2 hours, which was decreased again after 24 hours in 
SW1353 and CH2879 cells (Figure 1D-E). Conversely JJ012 cells still 
showed a substantial significant amount of foci compared to non-radiated 
cells, indicating this cell line is less proficient in repairing double strand 
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Figure 1. Chondrosarcoma cell lines exhibit variable γ-radioresistance.  
A) Colony forming assay of SW1353 and JJ012 chondrosarcoma cells. B) Viability of 
JJ012, SW1353 and CH2879 cells, 72h after treatment with increasing doses of γ-
radiation measured using presto blue viability reagent. C) Normalized cell index of 
CH2879, JJ012 and SW1353 cells irradiated to 0 (black), 2 (blue) or 4 Gy (green) 
radiation. D,E) γH2AX foci/cell in CH2879, JJ012 and SW1353 cells 2 and 24h after 
5 Gy radiation.**** indicates P values <0.0001, * indicates P values <0.05  
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γ-radiosensitivity of chondrosarcoma cell lines is not correlated with IDH 
mutation status 
Inhibition of D-2HG production by JJ012 cells using the mutant IDH1 
inhibitor AGI-5198 did not show any difference in radiosensitivity 
(Supplementary figure 1A). In addition no differences were observed in 
proliferation capacity and foci formation between cells treated with AGI-
5198 and radiation or cells treated with radiation only (Supplementary 
figure 1B, C). Since previous reports [13] suggest that IDH mutant cells have 
a reduced capability of producing GSH, GSH levels were measured 1 hour 
after radiation in combination with AGI-5198, for the mutant cell lines or D-
2HG (oncometabolite resulting from an IDH mutation) for the wild type cell 
line. The most radioresistant SW1353 cells displayed the highest baseline 
levels of GSH, followed by CH2879 and JJ012, however no differences were 
observed between different treatment conditions, indicating that GSH levels 
are not influenced by D-2HG inhibition (Supplementary figure 1D). These 
results suggest that IDH and D-2HG do not play a role in chondrosarcoma 
radiosensitivity. 
 
Chondrosarcoma samples that are more resistant towards radiotherapy have 
an increased incidence of mutations in cell cycle regulators  
Chondrosarcoma patient samples showed an increase in γ-H2AX foci after 
5 Gy radiation treatment. In table 1, 2 and supplementary figure 2 
quantified results are shown for nine chondrosarcoma explant tissue 
samples analyzed 2 or 24 hours after treatment with 5 gy of radiation. 
Radiation response was heterogeneous across the samples; the largest 
difference between control and radiated samples was 11,2 foci (sample 
L5213, figure 2A,B), while the smallest difference was 0,9 foci. Samples 
analyzed 24 hours after radiation treatment in general showed a lower 
amount of foci compared to samples analyzed 2 hours after radiation 
treatment.  Samples that showed a difference of 4 or more foci were 
subjected to the less radioresistant group, while samples that showed <4 
foci difference were designated as radioresistant for further analysis. This 
cutoff value was taken for both the 2h and 24h groups and both time points 
were analyzed together since sample size impeded separate analyses. The 
division between more or less radioresistant was made prior to mutation 
analysis. No correlation was observed between histological grade or IDH 
mutation status and the amount of γ-H2AX foci, consistent with the results 
obtained in the chondrosarcoma cell lines (table 1). Mutation analysis was 
performed on 50 known cancer related genes and expression of Bcl-2, Bcl-
8
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xl, survivin, P-S6, LC3B and P53, previously identified to play a role in 
chondrosarcoma [26-30], was determined using immunohistochemistry. No 
significant difference was observed in protein expression of selected markers 
(figure 2C, supplementary figure 3), however three CDKN2A deletions (3/4) 
and one RB1 deletion (1/4) were found in the highly radioresistant group 
and none in the less radioresistant group indicating that a defective Rb 
pathway may be able to impair the response to γ-radiation in 
chondrosarcoma (Figure 2D, Table 1 and 2). Interestingly a mutation in 
CDKN2A was also identified in the SW1353 cell line (supplementary table 
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Figure 2. γ-radioresistance in chondrosarcoma tissues correlates with mutations in 
cell cycle related genes.  
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A) L5213 chondrosarcoma tissue sample showing a large induction of γH2AX foci 
after 5 Gy (right) compared to controls (right). B) Amount of foci/cell in sample L5213 
after 5 Gy radiation compared to controls. C) Protein expression of Bcl-2, Bcl-xl, 
Survivin, P-S6, LC3B and P53 in highly radioresistant (<4 foci difference) compared 
to less radioresistant (>4 foci difference) chondrosarcomas. D) Difference between 
mean amount of γH2AX foci before and after radiation in chondrosarcomas with and 
without alterations in RB1 or CDKN2A Each dot represents one sample. Samples in 



























































































































































































































































































































































































































































































































































































































































































































Chondrosarcomas are relatively radioresistant tumors and therefore, after 
multidisciplinary discussions, very few of these patients are offered 
radiotherapy [10]. In this study we investigated the sensitivity of 
chondrosarcoma cells and tumor explants to γ-radiation. In addition, we 
screened for biomarkers that could select patients that might benefit from 
γ-radiation. Chondrosarcoma cell lines showed a heterogeneous response to 
radiotherapy with relatively high SF2 values [31]. JJ012 cells presented a 
SF2 value of 0.55, while SW1353 were more resistant showing a SF2 value 
of 0.88. Compared to cell lines of other tumor types, these values are 
relatively high, confirming chondrosarcoma radioresistance. A previous 
published study by Hamdi et al. showed a SF2 value of 0.64 for the SW1353 
cell line [32]. This difference might be attributed to the fact that different 
methods were used to perform the clonogenic assay. In our study the cells 
were seeded prior to radiation, while in the study of Hamdi et al. the cells 
were subconfluently seeded in culture flasks and subsequently radiated and 
seeded. In addition the differences in culture conditions (normoxic vs 
hypoxic) can very well influence how cells respond to radiation treatment. 
Quantification of γ-H2AX foci showed that SW1353 and CH2879 cells were 
able to repair double strand breaks within 24 hours after radiation while 
JJ012 cells were less capable of doing so, in line with the lower SF2 values 
observed in JJ012 cells.  
In contrast to published studies in glioma [13, 33], we did not observe a 
correlation between radiosensitivity and IDH mutation status in 
chondrosarcoma. Inhibition of mutant IDH1 using AGI-5198 did not lead to 
any changes in radiosensitivity, nor in altered GSH levels. Also, no difference 
was observed in γ-H2AX foci formation between IDH mutant and IDH wild 
type chondrosarcoma explants. This indicates that, unlike the observations 
in gliomas, IDH1 or IDH2 mutations in chondrosarcoma do not correlate 
with radiosensitivity. This is in line with our previous results in which we 
also did not find any correlation between IDH1 or -2 mutation status in 
sensitivity for inhibitors of glutaminolysis [34], NAD synthesis [35] or Bcl-2 
family members in chondrosarcoma cells, while in other tumor types there 
was a clear difference in sensitivity [36-38]. This difference indicates that 
IDH mutations may have a tissue specific effect rather than a more general 
effect in different tumour types.  
Our results suggest that deletions in cell cycle regulators CDKN2A and RB1 
are associated with increased radioresistance in chondrosarcoma explant 
tissue. In line with this, the most resistant SW1353 cells harboured a 
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mutation in the splice site region of CDKN2A in addition to mutations in 
TP53 and a kRAS mutation [39]. CDKN2A is a gene encoding p16(INK4A) 
and p14(ARF), which are two tumor suppressor proteins controlling the cell 
cycle. P16 inhibits CDK4 and CDK6, two inhibitors of Rb1 phosphorylation, 
while p14-ARF protects p53 from being broken down by inhibiting MDM2. 
Alterations in the pRB pathway have been described in the majority of high 
grade conventional chondrosarcomas [40-43]. Previous studies in 
chondrosarcoma cell lines (CS-7, CS-8, CS-9) showed that restoring P16 
expression, and thereby increasing Rb1 phosphorylation, resulted in an 
increased radiosensitivity [12], in line with our results. Although we see a 
clear difference in the amount of foci in tumors with and without deletions 
in CDKN2A or RB1, this study is based on a small heterogenous group of 
chondrosarcomas and measurements are taken after 2 or 24 hours. In 
addition the threshold of 4 foci/cell is taken arbitrarily. This complicates 
making firm conclusions based on this data and further studies should 
focus on; including more patients and analyze amount of foci after 24 hours 
to determine the damage remaining after DNA repair. In addition when 
radiotherapy is included in the treatment plan, follow the response towards 
radiation and correlate this towards mutation status. 
In contrast to our findings in chondrosarcoma, deletion of RB1 has been 
described to enhance radiosensitivity in breast, prostate and bladder cancer 
[44-47]. This observation might therefore be tissue and context specific; only 
a limited number of cancer types have been investigated. In addition, pRb 
has multiple functions, not only in the cell cycle but also in chromatin 
organization, transcription patterns, metabolic pathways and the proteome 
[48]. Several studies found that loss of pRB expression resulted in an 
increase in glutamine consumption and an increased glutamine 
incorporation into GSH. Upon RB knock down cells increased the expression 
of glutamine transporters and upregulated glutaminase activity, indicating 
that the pRB pathway can regulate glutamine metabolism and that cells with 
inactivated pRB are potentially more sensitive for targeted anti-glutamine 
treatment [49-51]. Interestingly, we recently reported that interfering with 
glutamine metabolism can be a therapeutic target for high grade 
chondrosarcoma [34]. The SW1353 chondrosarcoma cell line was 
particularly sensitive for inhibition of glutaminase, which is in line with the 
high basal GSH levels measured in this cell line. We can hypothesize that 
the mutation in CDKN2A observed in this cell line might contribute to the 
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In addition to conventional radiotherapy, research has been focusing 
increasingly on proton [1H] and carbon [12C] therapy, which have several 
advantages compared to γ-radiation. Both these beam qualities have dose 
distribution advantages, causing less damage to surrounding healthy 
tissues, making it possible to deliver higher doses to the tumor. 
Chondrosarcomas of the skull base and spine are increasingly treated with 
proton beam radiation, showing promising results [52]. Whether 
chondrosarcoma radiosensitivity differs between photon (γ-) beams and 
proton beams is subject for further investigation. 
In conclusion, this study confirms a heterogeneous radiosensitivity of 
chondrosarcoma cell lines and fresh explant tissue. In addition, we 
identified alterations in CDKN2A/RB1 as predictors of decreased double 
strand break formation after radiotherapy in chondrosarcoma tissue, and 
although further research is necessary in a larger group, this suggests that 
these patients might benefit less from radiation therapy. 
 
Acknowledgements 
We would like to thank Matty Meijers and Maaike Vreeswijk for technical 
assistance with the tumor culture model and Ben Floot (The Netherlands 
Cancer Institute, Amsterdam) for his help with the colony formation assay. 
In addition we would like to thank Liam McDonnell for his advice and 
discussions on the optimization of the glutathione measurements. Also we 
would like to thank Francois Chevalier and Yannick Saintigny for fruitful 
discussions. We are grateful to Dr JA Block (Rush University Medical Centre, 
Chicago, IL, USA), who provided us with the JJ012 cell line and Professor A 
Llombart Bosch (University of Valencia, Spain) for the CH2879 cell line. This 
work was financially supported by the Dutch Cancer Society (UL2010-4873 





- 221 - 
 
References 
1. Evans HL, Ayala AG, Romsdahl MM: Prognostic factors in chondrosarcoma 
of bone: a clinicopathologic analysis with emphasis on histologic grading. 
Cancer 1977, 40:818-831. 
2. Gelderblom H, Hogendoorn PCW, Dijkstra SD, van Rijswijk CS, Krol AD, 
Taminiau AH, Bovee JV: The clinical approach towards chondrosarcoma. 
Oncologist 2008, 13:320-329. 
3. Hogendoorn PCW, Bovee JVMG, Nielsen GP: Chondrosarcoma (grades I-III), 
including primary and secondary variants and periosteal chondrosarcoma. 
In WHO Classification of Tumours of Soft Tissue and Bone. Edited by 
Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F2013: 264-268 
4. Inwards C, Hogendoorn PCW: Dedifferentiated chondrosarcoma. In WHO 
Classification of Tumours of Soft Tissue and Bone. Edited by Fletcher CDM, 
Bridge JA, Hogendoorn PCW, Mertens F2013: 269-270 
5. McCarthy EF, Hogendoorn PCW: Clear Cell Chondrosarcoma. In WHO 
classification of Tumours of Soft Tissue and Bone. Volume 42013: 273-274 
6. Nakashima Y, de Pinieux G, Ladanyi M: Mesenchymal chondrosarcoma. In 
WHO Classification of Tumours of Soft Tissue and Bone. Edited by Fletcher 
CDM, Bridge JA, Hogendoorn PCW, Mertens F2013: 271-272 
7. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, 
O'Donnell P, Grigoriadis A, Diss T, et al: IDH1 and IDH2 mutations are 
frequent events in central chondrosarcoma and central and periosteal 
chondromas but not in other mesenchymal tumours. JPathol 2011, 
224:334-343. 
8. Damato S, Alorjani M, Bonar F, McCarthy SW, Cannon SR, O'Donnell P, 
Tirabosco R, Amary MF, Flanagan AM: IDH1 mutations are not found in 
cartilaginous tumours other than central and periosteal chondrosarcomas 
and enchondromas. Histopathology 2012, 60:363-365. 
9. Pansuriya TC, van ER, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J, 
Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, et al: Somatic 
mosaic IDH1 and IDH2 mutations are associated with enchondroma and 
spindle cell hemangioma in Ollier disease and Maffucci syndrome. NatGenet 
2011, 43:1256-1261. 
10. van Maldegem AM, Gelderblom H, Palmerini E, Dijkstra SD, Gambarotti M, 
Ruggieri P, Nout RA, van de Sande MA, Ferrari C, Ferrari S, et al: Outcome 
of advanced, unresectable conventional central chondrosarcoma. Cancer 
2014, 120:3159-3164. 
11. Kim DW, Seo SW, Cho SK, Chang SS, Lee HW, Lee SE, Block JA, Hei TK, 
Lee FY: Targeting of cell survival genes using small interfering RNAs (siRNAs) 
enhances radiosensitivity of Grade II chondrosarcoma cells. J Orthop Res 
2007, 25:820-828. 
12. Moussavi-Harami F, Mollano A, Martin JA, Ayoob A, Domann FE, Gitelis S, 
Buckwalter JA: Intrinsic radiation resistance in human chondrosarcoma 
cells. Biochem Biophys Res Commun 2006, 346:379-385. 
13. Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, Henneman 
P, Khurshed M, Lenting K, Mul AN, et al: Radioprotection of IDH1-Mutated 
Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. Cancer Res 2015, 
75:4790-4802. 
14. Menegakis A, De Colle C, Yaromina A, Hennenlotter J, Stenzl A, Scharpf M, 
Fend F, Noell S, Tatagiba M, Brucker S, et al: Residual gammaH2AX foci 
8
 
- 222 - 
  
after ex vivo irradiation of patient samples with known tumour-type specific 
differences in radio-responsiveness. Radiother Oncol 2015, 116:480-485. 
15. Menegakis A, von Neubeck C, Yaromina A, Thames H, Hering S, 
Hennenlotter J, Scharpf M, Noell S, Krause M, Zips D, Baumann M: 
gammaH2AX assay in ex vivo irradiated tumour specimens: A novel method 
to determine tumour radiation sensitivity in patient-derived material. 
Radiother Oncol 2015, 116:473-479. 
16. Scully SP, Berend KR, Toth A, Qi WN, Qi Z, Block JA: Marshall Urist Award. 
Interstitial collagenase gene expression correlates with in vitro invasion in 
human chondrosarcoma. ClinOrthopRelat Res 2000:291-303. 
17. Gil-Benso R, Lopez-Gines C, Lopez-Guerrero JA, Carda C, Callaghan RC, 
Navarro S, Ferrer J, Pellin A, Llombart-Bosch A: Establishment and 
characterization of a continuous human chondrosarcoma cell line, ch-2879: 
comparative histologic and genetic studies with its tumor of origin. Lab 
Invest 2003, 83:877-887. 
18. Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, 
Waaijer CJ, Wijers-Koster PM, Briaire-de Bruijn IH, Haazen L, et al: 
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting 
tumorigenic properties of chondrosarcoma cell lines. Oncotarget 2015, 
6:12505-12519. 
19. Corver WE, Demmers J, Oosting J, Sahraeian S, Boot A, Ruano D, Wezel TV, 
Morreau H: ROS-induced near-homozygous genomes in thyroid cancer. 
Endocr Relat Cancer 2018, 25:83-97. 
20. Lapytsko A, Kollarovic G, Ivanova L, Studencka M, Schaber J: FoCo: a simple 
and robust quantification algorithm of nuclear foci. BMC Bioinformatics 
2015, 16:392. 
21. Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers 
M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, et al: Functional 
ex vivo assay to select homologous recombination-deficient breast tumors 
for PARP inhibitor treatment. Clin Cancer Res 2014, 20:4816-4826. 
22. Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovee 
JV, Hogendoorn PC, Danen EH: Aven-mediated checkpoint kinase control 
regulates proliferation and resistance to chemotherapy in conventional 
osteosarcoma. J Pathol 2015, 236:348-359. 
23. van Oosterwijk JG, Meijer D, van Ruler MA, van den Akker BE, Oosting J, 
Krenacs T, Picci P, Flanagan AM, Liegl-Atzwanger B, Leithner A, et al: 
Screening for potential targets for therapy in mesenchymal, clear cell, and 
dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFbeta 
as potential targets. AmJPathol 2013, 182:1347-1356. 
24. Sibinga Mulder BG, Mieog JS, Handgraaf HJ, Farina Sarasqueta A, Vasen 
HF, Potjer TP, Swijnenburg RJ, Luelmo SA, Feshtali S, Inderson A, et al: 
Targeted next-generation sequencing of FNA-derived DNA in pancreatic 
cancer. J Clin Pathol 2017, 70:174-178. 
25. van Riet J, Krol NMG, Atmodimedjo PN, Brosens E, van IWFJ, Jansen M, 
Martens JWM, Looijenga LH, Jenster G, Dubbink HJ, et al: SNPitty: An 
Intuitive Web Application for Interactive B-Allele Frequency and Copy 
Number Visualization of Next-Generation Sequencing Data. J Mol Diagn 
2018, 20:166-176. 
26. de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, 
Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, 
Radiotherapy resistance 
 
- 223 - 
 
Danen EH, Bovee JV: Targeting survivin as a potential new treatment for 
chondrosarcoma of bone. Oncogenesis 2016, 5:e222. 
27. Perez J, Decouvelaere AV, Pointecouteau T, Pissaloux D, Michot JP, Besse 
A, Blay JY, Dutour A: Inhibition of chondrosarcoma growth by mTOR 
inhibitor in an in vivo syngeneic rat model. PLoSOne 2012, 7:e32458. 
28. Terek RM, Healey JH, Garin-Chesa P, Mak S, Huvos A, Albino AP: p53 
mutations in chondrosarcoma. DiagnMolPathol 1998, 7:51-56. 
29. van Oosterwijk JG, Herpers B, Meijer D, Briaire-de Bruijn IH, Cleton-Jansen 
AM, Gelderblom H, van de Water B, Bovee JVMG: Restoration of 
chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: 
BCL-2 family members cause chemoresistance. AnnOncol 2012, 23:1617-
1626. 
30. Zhang YX, van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, van WT, 
Buehnemann C, Hassan AB, Demetri GD, Bovee JV, Wagner AJ: Functional 
profiling of receptor tyrosine kinases and downstream signaling in human 
chondrosarcomas identifies pathways for rational targeted therapy. 
ClinCancer Res 2013. 
31. Fertil B, Malaise EP: Intrinsic radiosensitivity of human cell lines is 
correlated with radioresponsiveness of human tumors: analysis of 101 
published survival curves. Int J Radiat Oncol Biol Phys 1985, 11:1699-1707. 
32. Hamdi DH, Barbieri S, Chevalier F, Groetz JE, Legendre F, Demoor M, 
Galera P, Lefaix JL, Saintigny Y: In vitro engineering of human 3D 
chondrosarcoma: a preclinical model relevant for investigations of radiation 
quality impact. BMC Cancer 2015, 15:579. 
33. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, 
Lou JJ, Everson RG, et al: Overexpression of isocitrate dehydrogenase 
mutant proteins renders glioma cells more sensitive to radiation. 
NeuroOncol 2013, 15:57-68. 
34. Peterse EFP, Niessen B, Addie RD, de Jong Y, Cleven AHG, Kruisselbrink 
AB, van den Akker B, Molenaar RJ, Cleton-Jansen AM, Bovee J: Targeting 
glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation. Br J 
Cancer 2018. 
35. Peterse EF, van den Akker B, Niessen B, Oosting J, Suijker J, de Jong Y, 
Danen EH, Cleton-Jansen AM, Bovee J: NAD Synthesis Pathway 
Interference is a Viable Therapeutic Strategy for Chondrosarcoma. Mol 
Cancer Res 2017. 
36. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, 
Zhao F, Medeiros BC, Tyvoll DA, Majeti R: Isocitrate dehydrogenase 1 and 2 
mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 
2015, 21:178-184. 
37. Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, 
Slocum KL, Pu M, Lin F, Vickers C, et al: IDH1 mutations alter citric acid 
cycle metabolism and increase dependence on oxidative mitochondrial 
metabolism. Cancer Res 2014, 74:3317-3331. 
38. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, 
Wiederschain D, Bedel O, Deng G, Zhang B, et al: Extreme Vulnerability of 
IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell 2015, 28:773-784. 
39. Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, 
Cerniglia GJ, Muschel RJ, McKenna WG: Direct evidence for the 
contribution of activated N-ras and K-ras oncogenes to increased intrinsic 




- 224 - 
  
40. Schrage YM, Lam S, Jochemsen AG, Cleton-Jansen AM, Taminiau AH, 
Hogendoorn PC, Bovee JV: Central chondrosarcoma progression is 
associated with pRb pathway alterations: CDK4 down-regulation and p16 
overexpression inhibit cell growth in vitro. JCell MolMed 2009, 13:2843-
2852. 
41. Asp J, Brantsing C, Benassi MS, Inerot S, Sangiorgi L, Picci P, Lindahl A: 
Changes in p14(ARF) do not play a primary role in human chondrosarcoma 
tissues. IntJCancer 2001, 93:703-705. 
42. Asp J, Sangiorgi L, Inerot SE, Lindahl A, Molendini L, Benassi MS, Picci P: 
Changes of the p16 gene but not the p53 gene in human chondrosarcoma 
tissues. IntJCancer 2000, 85:782-786. 
43. van Beerendonk HM, Rozeman LB, Taminiau AH, Sciot R, Bovee JV, Cleton-
Jansen AM, Hogendoorn PC: Molecular analysis of the INK4A/INK4A-ARF 
gene locus in conventional (central) chondrosarcomas and enchondromas: 
indication of an important gene for tumour progression. JPathol 2004, 
202:359-366. 
44. Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, 
Knudsen ES: The retinoblastoma tumor suppressor modifies the therapeutic 
response of breast cancer. J Clin Invest 2007, 117:218-228. 
45. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES: 
RB-pathway disruption in breast cancer: differential association with 
disease subtypes, disease-specific prognosis and therapeutic response. Cell 
Cycle 2010, 9:4153-4163. 
46. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ: 
Abnormal bcl-2 and pRb expression are independent correlates of radiation 
response in muscle-invasive bladder cancer. Clin Cancer Res 1997, 3:1823-
1829. 
47. Sharma A, Comstock CE, Knudsen ES, Cao KH, Hess-Wilson JK, Morey LM, 
Barrera J, Knudsen KE: Retinoblastoma tumor suppressor status is a 
critical determinant of therapeutic response in prostate cancer cells. Cancer 
Res 2007, 67:6192-6203. 
48. Dyson NJ: RB1: a prototype tumor suppressor and an enigma. Genes Dev 
2016, 30:1492-1502. 
49. Clem B: RB in glutamine metabolism. Oncoscience 2014, 1:304-305. 
50. Nicolay BN, Gameiro PA, Tschop K, Korenjak M, Heilmann AM, Asara JM, 
Stephanopoulos G, Iliopoulos O, Dyson NJ: Loss of RBF1 changes glutamine 
catabolism. Genes Dev 2013, 27:182-196. 
51. Reynolds MR, Lane AN, Robertson B, Kemp S, Liu Y, Hill BG, Dean DC, Clem 
BF: Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 
2014, 33:556-566. 
52. Frisch S, Timmermann B: The Evolving Role of Proton Beam Therapy for 
Sarcomas. Clin Oncol (R Coll Radiol) 2017, 29:500-506. 
Radiotherapy resistance 
 




Supplementary figure 1. No relation between IDH mutation and radiosensitivity in 
chondrosarcoma cell lines A) clonogenic assay of JJ012 cells with or without 10 µM 
mutant IDH1 inhibitor AGI-5198.B) normalized cell index of JJ012 cells treated with 
0, 2 or 4 Gy radiation in combination with 10 µM mutant IDH1 inhibitor AGI-5198 
or DMSO as a control. Black indicates 0 Gy, Red 0 Gy + AGI-5198, blue 2 Gy, Purple 
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2 Gy + AGI-5198, green 4 Gy, Orange 4 Gy + AGI-5198. C) Amount of yH2ax foci in 
CH2879, JJ012 and SW1353 after 2 and 24h of treatment with 5 Gy radiation with 
and without 10 µM AGI-5198 or 250 µM D-2HG D) glutathione levels of 
chondrosarcoma cells treated with 10 µM AGI-5198 or 250 µM D-2HG  measured 1h 
after radiation. 
  
Supplementary figure 2. y-H2ax staining quantification of chondrosarcoma patient 

















































































































































































































Supplementary figure 3. Representive images of HE and Immunohistochemical 
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Supplementary table 2. Mutation analysis of chondrosarcoma cell lines. Results 
on IDH and TP53 mutation status were published previously (de Jong et al. 2016).  
 
# only found in 17% of cells  










Bcl-2 1:100 - Tris-EDTA Tonsil Dako clone 124 
Bcl-xl 1:400 5% Milk Citrate Prostate Cell signalling 
clone 54H6 
Survivin 1:100 - Citrate Placenta Cell signalling 
clone 71G4B7 
P-S6 1:800 - Citrate Melanoma Cell signalling 
clone D57.2.2E 
P53 1:800 - Citrate Tonsil Dako clone DO-7 




 IDH1 IDH2 TP53 CDKN2A KRAS PTEN 
SW1353 - R172S V203L 9:21971209 
A-C* 
 
G12C  - 
JJ012 R132G - G199V - - - 
CH2879 - - S366A 
R273C# 
- - R233Ter 
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Discussion 
The studies presented in this thesis describe the use of compound and 
siRNA screens to identify new targeted treatment options for patients with 
chondrosarcoma. Using available chondrosarcoma cell lines as a model we 
investigated apoptotic proteins, kinases and metabolic regulators in a non-
biased way to identify most promising hits. In addition the role of individual 
Bcl-2 family members Bcl-2, Bcl-xl and Bcl-w was investigated. Results 
reveal a role for Bcl-2 family member Bcl-xl, anti-apoptotic and cell cycle 
regulator Survivin, Cell cycle regulators AURKA, CHK1 and PLK1 and mTOR 
as important survival proteins in chondrosarcoma. Moreover treatment with 
Bcl-xl or CHK1 inhibitors could chemo-sensitize a subset of 
chondrosarcoma cell lines. Furthermore alterations in the Rb1 pathway 
have been identified as a marker for radioresistance in chondrosarcoma 
patient samples. In this chapter these findings are discussed in a broader 
perspective. 
 
Bcl-xl as most important Bcl-2 family member in chondrosarcoma 
The apoptosis pathway is an attractive target in the treatment of cancer, and 
has been studied extensively. Cancer cells can develop several mechanisms 
to evade apoptosis including upregulation of anti-apoptotic proteins or 
downregulation/inactivation of pro-apoptotic proteins or pore-forming 
proteins Bax and Bak [1]. The mechanism that has now been shown for all 
chondrosarcoma subtypes, except for periosteal chondrosarcoma, is 
upregulation of anti-apoptotic Bcl-2 family members [2-4]. In chapter 3 of 
this thesis we confirmed this also for mesenchymal chondrosarcoma and 
showed that these cells can be sensitized towards conventional 
chemotherapy by inhibiting Bcl-2 family members. In chapter 4 we looked 
at the individual Bcl-2 family members and showed that particularly Bcl-xl 
is important and might be most promising in targeted treatment of 
chondrosarcoma [5]. We showed that Bcl-2 family members Bcl-2 and Bcl-
xl were highly expressed in chondrosarcoma tissue samples and showed a 
correlation of expression with histological grade. Selective inhibition of Bcl-
2 did not result in any decrease in viability in a panel of ten chondrosarcoma 
cell lines, nor a decrease in tumour growth in an orthotopic rat 
chondrosarcoma model. However selective Bcl-xl inhibition was effective in 
a subset of chondrosarcoma cell lines and in vivo tumour growth was slowed 
down. In addition a sensitizing effect was observed with chemotherapy in a 
subset of chondrosarcoma cell lines, but not in vivo. These data indicate 
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that Bcl-xl is the dominant/most important anti-apoptotic family member 
in chondrosarcoma. 
No correlation between protein expression levels and response rate of 
chondrosarcoma cell lines to specific inhibitors was observed in our study, 
which can complicate selection of eligible patients. The group of Letai et al 
developed a method called BH3 profiling to determine the dependency of a 
certain tumour on individual anti-apoptotic proteins. Mitochondria of 
cancer cells are isolated and exposed to a panel of different pro-apoptotic 
synthetic BH3 peptides after which the initiation of MOMP and/or apoptosis 
is measured. How well these mitochondria respond to the different peptides 
can be measured and can give an indication of the threshold to achieve 
apoptosis in these cells, as well as identification of the anti-apoptotic 
proteins they are most dependent on [6]. In addition a modified version of 
this method can also be used to predict cytotoxic responses of cancers to 
different treatment strategies [7] and already showed its predictive value in 
pre-clinical models of different types of hematologic malignancies [8-10]. 
This strategy is an attractive method to determine chondrosarcoma 
dependency on Bcl-2 family members and to predict responses to apoptosis 
inducing treatments. Further research should determine whether this 
method is also suitable for solid tumours. 
Selective targeting of Bcl-2 family members is highly advantageous in terms 
of toxicities, compared to combined inhibition using for example ABT-737 or 
its orally equivalent ABT-263 (navitoclax). However targeting of Bcl-xl seems 
more problematic compared to targeting Bcl-2 or Mcl-1 due to its expression 
on platelets. This might be solved by careful dosing and timing of drug 
administration. In addition, combinations with other treatments might lower 
the effective dose and consequently also toxicity [11]. 
In our study we showed that single inhibition of Bcl-2 is ineffective in pre-
clinical models, but we did not specifically look into Mcl-1 as a possible 
important anti-apoptotic protein in chondrosarcoma. Previous studies 
showed RNA as well as protein expression of Mcl-1 in chondrosarcoma cell 
lines and several pre-clinical studies suggest it can play a role in resistance 
mechanisms in solid tumours. It would be interesting to study its role in 
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Survivin; a pro-survival protein with a broad range of functions  
As discussed in chapter 5, Survivin was identified as an important survival 
protein in chondrosarcoma cells by performing an apoptosis focussed siRNA 
screen [16]. Survivin has multiple functions based on its location in the cells. 
It’s cytoplasmic function is mainly preventing apoptosis, while its nuclear 
function is regulating mitosis as part of the chromosomal passenger complex 
(CPC) [17]. Survivin was found to be highly expressed in a large panel (>200) 
of chondrosarcoma tissue samples of all different subtypes. Expression was 
found in the nucleus as well as in the cytoplasm, indicating that the 
apoptotic as well as its cell cycle related function is important in 
chondrosarcoma cells. No expression was observed in normal articular 
cartilage. 
The exact mechanism by which Survivin inhibits apoptosis is not well 
understood. The current hypothesis is that Survivin has most inhibitory 
activity when in complex with XIAP (X-linked inhibitor of apoptosis) and 
HBXIP (hepatitis B X-interacting protein). Survivin is a member of the IAP 
family, which consists of eight different members. Only the canonical 
member XIAP can directly inhibit caspase activity, however interaction with 
other IAPs can improve its stability and increase its inhibitory effect [17]. 
When in complex with XIAP and HBXIP, Survivin can inhibit caspase 9, 8 
and 3/7 activation [18] and increase the activity of other IAP family members 
acting in the extrinsic apoptosis route [19]. In addition Survivin has been 
shown to prevent apaf1 release from mitochondria and bind to the IAP 
inhibitor Smac/Diablo [20].  
The function of Survivin in the cell cycle is essential for mitosis. It is a 
member of the CPC and ensures that chromosomes are properly aligned by 
targeting the CPC towards the centrosomes in prometaphase. This process 
is highly dependent on interaction with BUBR1 and AURKB (Aurora kinase 
B). In addition the CPC coordinates chromosome segregation and 
cytokinesis. 
How Survivin is regulated is not completely understood. The main pathways 
that have been shown to regulate its expression are EGFR, IGF-1R or 
HER2/3 tyrosine kinase receptors, which will lead to activation of RAS 
and/or AKT and downstream signalling activation of mTOR and NF-kb. HIF-
1α and STAT3 can function as a transcriptional activator of Survivin 
expression. Several reports suggest that wild type P53 can transcriptionally 
repress Survivin expression, which will lead to (amongst others) an increase 
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in apoptosis [21]. In addition, post-translational modifications, during 
different phases of mitosis, are regulating Survivin function and stability. 
Since Survivin is regulated by a variety of different pathways and 
mechanisms it is hard to speculate which one is most important or most 
active in chondrosarcoma, however based on available literature and the 
results described in this thesis the  hypothesis is that mTOR can play an 
important role. In addition, since chondrosarcomas are hypoxic tumours, 
its connection to HIF-1α would be interesting to investigate further, for 
example in 3D models that more closely mimic the patient situation. 
A positive correlation between Survivin and P53 overexpression (suggestive 
for mutated TP53) was shown in conventional chondrosarcoma (chapter 5). 
In addition, chondrosarcoma cell lines with mutant TP53 were more 
sensitive for Survivin inhibitor YM155, indicating that especially TP53 
mutant chondrosarcomas might be eligible for treatment with Survivin 
inhibitors. YM155 is an indirect inhibitor of Survivin; it inhibits the 
transcription of Survivin by disrupting the RNA binding protein ILF3/NF110 
[22]. In addition, the binding of zinc transcription factor SP1 to the Survivin 
promoter is prevented by YM155 [23]. Since the SP1 transcription factor has 
more binding regions that activate transcription of genes involved in 
proliferation and cell cycle progression, there will likely be additional effects 
of YM155 [24]. This is also reflected in the different responses of cell lines 
towards YM155 treatment. 
Phase I and II clinical trials show that YM155 is well tolerated, but minimal 
anti-tumour effects have been observed in mono- as well as combination 
treatment strategies [24, 25]. New Survivin inhibitors have been under 
development, of which the most promising one is the development of 
vaccines for cancer immunotherapy. Promising results have been achieved 
for glioblastoma multiforme and other solid tumours [26-28]. 
 
Cell cycle proteins as therapeutic targets 
Besides Survivin other cell cycle regulators that might be important in 
chondrosarcoma have been identified using a combined siRNA screen and 
compound screen focussed at kinases, as described in chapter 6 of this 
thesis. Hits that were identified in both screens were selected for further 
validation. Using this unbiased approach we identified AURKA (aurora 
kinase A), PLK1 (Polo like kinase 1) and CHK1 (Checkpoint kinase 1) as 
important kinases for chondrosarcoma cell survival [29]. These kinases are 
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all involved in cell cycle regulation, and are essential for proper cell division 
[30]. Cancer cells show aberrant cell cycle activity, which can be caused by 
deregulation of cell cycle proteins, or upstream cell signalling pathways [30]. 
This gives an opportunity to target cell cycle proteins specifically in cancer 
cells in mono treatment or in combination with chemotherapy [31].  
PLK1 and AURKA are both involved in the progression from G2 to S phase 
during the cell cycle and are important for mitosis and cytokinesis [32]. 
CHK1 is activated in response to DNA damage by ATM or ATR, and cells will 
halt the cell cycle in S or G2 to repair the damage. Overexpression of these 
three cell cycle regulators has been shown in a variety of different tumours 
and correlates with a worse prognosis [33-35]. 
A subset of chondrosarcoma patients showed RNA expression of AURKA and 
CHK1, while PLK1 expression was low compared to normal cartilage. This 
indicates that PLK1 might not be a good target for chondrosarcoma 
treatment. AURKA was expressed in chondrosarcoma patient samples, and 
inhibitors for AURKA are already in clinical trials [30]. Monotherapy with 
alisertib, the most developed AURKA inhibitor was tested in different solid 
tumours including sarcoma, and showed a partial response in one out of six 
patients with dedifferentiated chondrosarcoma [36]. Although first results 
seemed encouraging [37], a large Phase III trial in lymphoma was 
discontinued due to lack of clinical response compared to the comparator 
arm [38]. Combination treatment studies show conflicting results, 
depending on the dose and tumour type, regarding adverse effects, 
maximum tolerated dose and efficacy [39-42]. Larger phase III randomized 
control studies should determine whether combination therapy is superior 
over standard treatment. High CHK1 RNA expression was correlated 
towards a worse overall survival, and inhibition of CHK1 sensitized 
chondrosarcoma cell lines towards conventional chemotherapy treatment. 
This was also previously shown in other sarcoma types [43-45]. CHK1 is 
part of the DNA damage pathway, and combination treatment with DNA 
damaging agents will lead to synthetic lethality. This means that a 
combination of the two treatments will lead to cell death, while treatment 
with only one of the two will not cause any or only minimal effect. First 
generation inhibitors of CHK1 were discontinued due to toxicity, however 
second generation inhibitors show less toxicity and are currently tested in 
combination with chemotherapy [34, 46, 47].  
Defects in cell cycle regulators and DNA damage pathways are a general 
hallmark of cancer. The three cell cycle related kinases that we found in this 
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study are deregulated in a large portion of cancers. In chondrosarcoma 
specifically CHK1 might be the most interesting and most potent target to 
investigate further, since this was correlated to overall survival and 
synthetic lethality with chemotherapy was shown. A correlation was 
observed between TP53 mutation status and sensitivity, which is also 
reported in the literature [48-50]. This indicates that the higher grade 
chondrosarcomas, harbouring a mutation in TP53 (20%) [51] might benefit 
most from inhibitors targeting the cell cycle, as monotherapy of in 
combination strategies. 
 
Metabolic vulnerabilities in chondrosarcoma; mTOR as central player 
Another vulnerability investigated in chondrosarcoma was targeting 
metabolism. This might be a therapeutic opportunity since approximately 
50% of the chondrosarcomas shows a mutation in IDH1 or IDH2, which will 
lead to the production of oncometabolite D2HG. IDH1 and IDH2 have an 
important function in the citric acid cycle and mutations in these genes 
might possibly lead to a dysregulated metabolic state and cause 
vulnerability. In chapter 7 the execution of a custom-made metabolic 
compound screen performed in three different chondrosarcoma cell lines is 
described. This was followed by validation of the most promising compounds 
on a metabolic level using the Seahorse analyser. In concordance with a 
recent publication of Zhang et al., we reported that cholesterol inhibitors are 
effective in chondrosarcoma cells, especially in the IDH1 mutant line, and 
lower mitochondrial respiration levels were observed [52]. Dual mTORC1 
and C2 inhibitor sapanisertib was found as the most potent inhibitor of 
oxidative and glycolytic metabolism, and was further validated in a panel of 
cell lines and in an orthotopic mouse model. Cell lines were sensitive for 
treatment with sapanisertib, although a plateau was reached at 10-30% 
viability. Mouse tumours treated with sapanisertib were growing slower 
compared to control tumours, however resistance was acquired after +/- 8 
weeks of treatment [53].  
mTOR can form two different complexes; mTORC1 and mTORC2. They both 
have different functions. mTORC1 is involved in many cellular processes, 
including mRNA translation, autophagy, amino acid signalling and lipid, 
glucose and nucleotide metabolism. Its activation is regulated by growth 
factors and intracellular and environmental stress including energy, oxygen, 
amino acid and DNA damage levels. The function of mTORC2 is less studied, 
but it is involved in cytoskeleton regulation, metabolism and cell survival. 
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mTORC2 is activated by Pi3K regulated mechanisms, but possibly also by 
metabolic signals [54-56]. 
Compared to Rapamycin, which is only inhibiting mTORC1, treatment with 
sapanisertib led to larger decreases in oxidative phosphorylation and 
glycolysis indicating that mTORC1 and mTORC2 both are regulating  
metabolism in chondrosarcoma cells. This was not dependent on IDH1. 
Previous reports suggest that D2HG, the oncometabolite produced by cells 
harbouring a mutation in IDH1 or IDH2, inhibits mTOR signalling [57]. We 
did not observe any difference in metabolic response towards mTOR 
inhibitors between IDH1 mutant cells in which D2HG production was 
inhibited, compared to control conditions. In addition all tested 
chondrosarcoma cell lines had a high basic level of P-S6 and P-AKT 
expression indicating that mTOR signalling is highly active in these cells. 
One of the metabolic pathways that is regulated by mTOR is glutamine 
metabolism. Most cancer cells depend on glutamine for their survival [58]. 
Our lab previously showed that this is also the case for a subset of 
chondrosarcoma cells, which was again independent of IDH mutation status 
[59]. Inhibiting glutamine in chondrosarcoma cells resulted in a dose 
dependent decrease in viability. In addition, chondrosarcoma tissue samples 
showed an increased expression of GLS, the enzyme converting glutamine 
to glutamate, which was correlated with  histological grade, but not with IDH 
mutation status [59]. Both mTORC1 and mTORC2 promote glutaminolysis 
and inhibiting mTOR in chondrosarcoma might be partially effective because 
of its effect on glutamine. Resistance to mTOR inhibition might be caused 
by adapting mechanisms in AKT, which will lead again to an increase in 
glutaminolysis [60]. Previous research in lung squamous cell carcinoma 
xenografts showed that combining dual mTOR inhibition with glutamine 
inhibition overcomes resistance to mTOR inhibitors [61]. Since we also 
observed resistance in our in vivo experiments it would be interesting to 
further explore this combination also in chondrosarcoma.  
In future research it would be relevant to focus on identifying a metabolic 
signature for cancer cells to select patients eligible for treatment with certain 
metabolic inhibitors. This has been done by Momcilovic et al. in lung and 
head and neck squamous cell carcinoma and osteosarcoma. Expression of 
a specific set of proteins combined with PET imaging and histology predicted 
response towards dual mTOR inhibition and glutamine inhibitors in 
xenograft models [61]. In addition an 11 gene signature together with 
expression of GAC, a specific isoform of GLS1, was predictive of glutamine 
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sensitivity in breast cancer. They also showed that upon GLS1 knock down 
TCA and glutathione intermediates were downregulated and ROS 
production was increased in breast cancer cell lines. These observations 
indicate that the combination of glutamine inhibitors together with redox 
modifiers in patients that show a high prediction score might be worthwhile 
to investigate [62]. 
It is important to look into this metabolic signature on a tissue specific, and 
if possible patient specific level. For example in chondrosarcoma no specific 
metabolic profile has been found for IDH mutated chondrosarcomas, while 
gliomas harbouring an IDH mutation do show for example an increased 
sensitivity for glutaminase inhibitors [63].  
 
Defects in CDKN2A/RB1 as a marker of radio resistance?  
Chondrosarcomas are relative radioresistant tumours; conventional  
radiotherapy (linear accelerator based) is only given to patients with 
inoperable tumours, or metastatic disease [64, 65]. A recent retrospective 
study showed that a small group of patients might still benefit from 
conventional radiotherapy [65]. In chapter 8 a study is described to identify 
possible markers for radioresistance or -sensitivity in chondrosarcoma. Our 
cell line panel showed a heterogeneous response towards γ-radiation, which 
was confirmed by a recent publication by Girard et al. [66]. By using an ex 
vivo culture system we identified that alterations in the RB1 pathway might 
correlate with radiotherapy resistance in chondrosarcoma [67]. 
Chondrosarcoma tumour explants were cultured, treated with radiotherapy 
and afterwards analysed for the induction of double strand breaks using a 
previously published γ-H2AX assay [68, 69]. Subsequently, tumour material 
was sequenced and mutations frequently observed in known oncogenes and 
tumour suppressor genes were analysed. Mutations in IDH1 and IDH2 were 
detected in approximately 50% of chondrosarcomas, but were not associated 
with the amount of γ-H2AX foci. This was in concordance with the fact that 
we did not observe a difference in radio sensitivity between IDH1 mutant 
cells, in which production of D2HG was inhibited using AGI-5198, and non-
treated cells. Conversely alterations in CDKN2A and RB1 were associated 
with less γ-H2AX foci after radiation, which indicates radio resistance in 
these patients. In line with our results a previous study described that 
restoring P16 in chondrosarcoma cell lines increased radio sensitivity [70]. 
Other studies report an increase in radio sensitivity in tumours that display 
defects in the RB1 pathway [71-74], indicating a context specific effect. 
Alterations in one of the components of the RB1 pathway have been 
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described in the majority of high grade conventional chondrosarcomas, 
indicating that alterations in this pathway are correlating with a more 
malignant phenotype [75-78].  
The amount of γ-H2AX foci has been shown to be a good marker for the 
number of double strand breaks induced by radiation and correlations with 
patient response and amount of foci have been observed in several studies 
[68, 79-81]. However there are also studies that do not find a correlation 
between γ-H2AX foci and radiosensitivity [82-84], indicating that this might 
also be tissue and context specific. The fact that we observe less γ-H2AX foci 
in RB1 pathway mutated tumours might be explained by an effect of the 
mutation on cell cycle distribution, which will lead to differences in the 
amount of repair and the pathway that will be used to repair the breaks. 
Our study describes the observation that we find more alterations in RB1 
pathway genes in tumours that show less γ-H2AX foci after radiation 
compared to tumours that do not show alterations in RB1 pathway genes. 
Research more focussed on downstream repair pathways might lead to the 
identification of the mechanism behind this observation. In addition our 
panel of chondrosarcoma tissues is very small and heterogenous, and 
further research in a larger cohort is needed to confirm our findings. Besides 
its well-known role in the cell cycle RB1 is also involved in a multitude of 
other cellular processes, including metabolic processes [85]. Cells with 
inactivated RB1 showed upregulated glutaminase activity and glutamine 
incorporation into GSH, indicating that tumours with alterations in the RB1 
pathway are more susceptible for treatment with glutamine inhibitors [86-
88]. We recently published that glutamine can be a potentially therapeutic 
target for patients with high grade chondrosarcoma [59], although the exact 
mechanism remained unclear. The most glutamine sensitive cell line, 
SW1335, also showed the highest GSH levels, and the highest 
radioresistance, as measured by γ-H2AX foci counting. This cell line 
harbours a mutation in CDKN2A, influencing the RB1 pathway. It would be 
interesting to investigate whether alterations in the RB1 pathway might 
predict for sensitivity for glutamine inhibitors in chondrosarcoma. In 
addition inhibition of AURKA has been identified as synthetic lethal in cells 
with defective RB1 [89], suggesting  this might be another therapeutic 
vulnerability for patients with high grade RB1 defective chondrosarcoma. 
Whether alterations in the RB1 pathway can also predict for sensitivity to 
proton or high let radiation treatment will be a subject for further 
investigation.  
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Future perspectives 
In this thesis the use of two focussed siRNA screens to identify new 
therapeutic targets for chondrosarcoma patients is described. Since the time 
the siRNA screens were initiated, several technical improvements have been 
become available, the most important one of which is the discovery of the 
CRISPR technique. Using CRISPR technology genes can be knocked out very 
specifically, with reduced aspecific effects compared to siRNAs. In addition 
to the method used, other improvements are the use of isogenic cell pairs, 
rather than screening a panel of different cell lines, to study the role of a 
specific gene. This rules out cell line specific effects that are not related to 
the effects specific for the cancer type. Furthermore, pooled screening is also 
an option to detect genes that show synthetic lethality with the gene of 
interest. Using pooled screening, all different genes are studied at once, 
cultured for a prolonged period of time and the start and the end population 
of cells is sequenced to detect which genes are important in the specific cell 
line.  
Another important step is creating 3D models that more closely resemble 
the tumour in the patient. Cell lines are easy for large screens, but not 
always good models to do translational research. In our study for example 
we found that chondrosarcoma cell lines are sensitive to certain types of 
chemotherapy, while patients do show resistance. In addition we do show a 
high expression of PLK1 in the cell lines, while expression was absent in the 
chondrosarcoma primary tumour tissues. This illustrates that cell lines 
might not be the best models to validate results. In my opinion cell lines are 
a good model for performing genetic and compound screens, but for 
validation studies, it would be better to use a 3D model, next to the cell lines, 
that more closely resembles the patient situation.  
In the research described in this thesis, one of the most important aims is 
to find therapeutic options for patients with inoperable and metastatic 
disease. In addition, the mechanism behind resistance towards conventional 
chemotherapy remains to be identified, although there have been some clues 
from research in cell line models. In this thesis we describe a role for Bcl-xl 
and CHK1 as potential important proteins in chemoresistance. Since 
previous studies show that cell lines and 3D cultures show differential 
sensitivities towards chemotherapy, it will be an important next step to 
validate these findings in relevant chondrosarcoma 3D models.  
In addition, several other potential targets have been identified, including 
mTOR and Survivin. A clinical trial testing mTOR inhibitors in combination 
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with cyclophosphamide in chondrosarcoma patients is currently ongoing. In 
the chondrosarcoma xenograft model after an initial delay in tumour growth, 
resistance towards mTORC1 and mTORC2 inhibitor sapanisertib was 
observed within a few weeks. Combination treatment using mTOR inhibitors 
with glutamine inhibitors might be an interesting strategy to overcome this 
resistance, and has been shown previously in a lung cancer xenograft model 
[61]. 
In conclusion, we found Bcl-2 family member Bcl-xl, cell cycle regulator 
CHK1 and metabolic regulator mTOR as important mediators of 
chondrosarcoma survival and chemoresistance. The clinical value of these 
findings should be further exploited in future studies. In addition, 
personalized approaches like BH3 and metabolic profiling to select eligible 
patients for specific treatments might hold great value for future exploration, 
since no general marker predicting sensitivity to specific inhibitors is 
available at the moment. 
Future translational studies to identify new therapeutic targets for 
chondrosarcoma patients should focus on CRISPR screens and compound 
screens in either a large panel of chondrosarcoma cell lines, or isogenic cell 
pairs to study a specific genetic defect. The validation of these findings 
should include a 3D based model that most closely resembles the patient 
situation, and genomic and expression analysis in patient material with the 
ultimate goal to bring the findings to the clinic.  
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Summary 
Chondrosarcomas are malignant cartilage producing tumours representing 
20% of malignant bone tumours [1]. They predominantly develop in the 
bones of the pelvis, ribs and extremities and are diagnosed in a broad age 
range, but most commonly around the age of fifty. Chondrosarcoma can be 
subdivided in conventional chondrosarcoma (85%), dedifferentiated 
chondrosarcoma (10%) [2], mesenchymal chondrosarcoma (2%) [3], clear 
cell chondrosarcoma (2%) [4] and periosteal chondrosarcoma (1%) [1]. 
Conventional chondrosarcoma is further subdivided into central (85%) and 
peripheral (15%), based on its location in the medulla or next to the bone. 
Their histological appearance is similar however they show a different 
genetic background; central chondrosarcomas present with mutation in 
IDH1 or IDH2 in +/- fifty percent of the cases while peripheral 
chondrosarcomas show alterations in EXT1 and EXT2 genes. Conventional 
chondrosarcoma can be subdivided in three different grades based on its 
histological appearance (Grade I-III). Grade III chondrosarcomas are most 
malignant and show a 10 years survival rate of 26-29% [1, 5-7]. 
Dedifferentiated chondrosarcoma is a high grade tumour showing IDH1 or 
IDH2 mutations in approximately fifty percent of the cases [8]. It has a very 
low 10 years survival rate of only 10-28% depending on the presence of 
metastasis [9]. Mesenchymal chondrosarcomas are genetically characterized 
by a HEY1-NCOA2 fusion, and 10 years survival rates are reported between 
27 and 67% [10, 11]. Clear cell chondrosarcomas are low grade tumours 
with a mortality rate of 15% [12]. No recurrent initiating genetic alterations 
have been identified in this subtype. Periosteal chondrosarcomas are very 
rare and few studies have been reported investigating this subtype. IDH1 or 
IDH2 mutations have been identified in 15% of the cases [13].  
Treatment of chondrosarcoma patients is mainly by surgery, since tumours 
are relatively resistant toward chemo-and radiotherapy. Several possible 
mechanisms are hypothesized why chondrosarcoma cells are therapy 
resistant, including upregulation of multi-drug resistance pumps and anti-
apoptotic proteins, but likely up regulation of other pro-survival 
mechanisms and down regulation of pro-cell death mechanisms are playing 
a role [14-17].  
The aim of this thesis was to look further into these mechanisms and find 
alternative targetable treatment options for chondrosarcoma patients by 
using a screening based approach. In addition we investigated the role of 
Bcl-2 family members and its use in targeting the apoptosis pathway in 
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chondrosarcoma. Furthermore possible mechanisms of radio-resistance 
were investigated in chondrosarcoma cell lines and explants. In Chapter 2 
a general overview is given about genetic alterations and pathway 
deregulations that have been identified in the different chondrosarcoma 
subtypes. This illustrates the complexity and heterogeneity of the different 
chondrosarcoma subtypes. Chapter 3 describes the characterization of a 
new mesenchymal chondrosarcoma cell line MSC170, which is the first cell 
line that has been reported of this rare chondrosarcoma subtype. We 
confirmed the presence of the characteristic HEY1-NCAO2 fusion. 
Expression of Bcl-2 and especially Bcl-xl was present in this cell line and 
inhibiting Bcl-2 family members using ABT-737 resulted in synthetic 
lethality with doxorubicin as well as cisplatin as was previously shown for 
conventional and dedifferentiated chondrosarcoma [15, 16]. Chapter 4 dives 
deeper into the role of Bcl-2 family members in chondrosarcoma and 
resistance towards conventional chemotherapy. We looked into single 
inhibition of Bcl-2 and Bcl-xl specifically in chondrosarcoma cell lines and 
in a Swarm Rat Chondrosarcoma (SRC) model. Interestingly we found that 
not Bcl-2, but Bcl-xl is most important for chondrosarcoma survival in vitro 
as well as in vivo. A subset of cell lines showed a synergistic response when 
Bcl-xl was inhibited in combination with chemotherapy, indicating that 
involvement of Bcl-xl in chemotherapy resistance is heterogenous across the 
panel of chondrosarcoma cell lines that we studied. This shows that further 
research, and possibly personalized approaches, are needed to assess 
applicability of combination treatments using Bcl-xl inhibitors in 
combination with chemotherapy in chondrosarcoma patients. Chapter 5 
describes the discovery of Survivin as an essential regulator in 
chondrosarcoma. A siRNA screen targeting 51 apoptosis related genes was 
performed, and identified BIRC5, encoding the Survivin protein as essential 
for chondrosarcoma survival. Survivin has multiple functions depending on 
its location in the cell [18]. Nuclear Survivin has a role in the cell cycle, while 
cytoplasmic Survivin is involved in apoptosis. We found nuclear as well as 
cytoplasmic Survivin expression to be correlated with an increased 
histological grade. In addition, nuclear Survivin expression was correlated 
with P53 expression. Of note, TP53 mutant chondrosarcoma cell lines were 
especially sensitive for Survivin inhibition, with no caspase dependent 
apoptosis, but a deregulated cell cycle profile. This shows that Survivin 
might be a potential therapeutic option for patients with TP53 mutated 
chondrosarcoma. In Chapter 6 the discovery of cell cycle proteins as 
possible therapeutic targets for chondrosarcoma is described. A kinase 
focussed siRNA (n=779) and compound screen (n=273) have been performed 
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in chondrosarcoma cells, that resulted in the discovery of PLK1, CHK1 and 
AURKA as important targetable kinases of chondrosarcoma cell survival. 
Kinase inhibitors targeting these three cell cycle regulators were validated 
in a panel of chondrosarcoma cell lines and dose dependent decreases in 
viability were observed as well as increased sensitivity towards conventional 
chemotherapy after inhibition of CHK1. Expression of AURKA and CHK1, 
but not PLK1 was observed in chondrosarcoma tissue samples, raising the 
question of the importance of PLK1 as a therapeutic target in 
chondrosarcoma. A worse overall survival was observed in patients with 
higher CHK1 expression indicating that high CHK1 expression is correlated 
with a more malignant phenotype. Although more studies are needed to 
confirm these findings, this study points to CHK1 as the most promising 
targetable kinase for treatment of chondrosarcoma patients. Chapter 7 
focusses on the chondrosarcoma metabolome and its vulnerabilities. A 
metabolic compound screen was designed and 39 compounds targeting the 
most important metabolic pathways were included.  This screen was 
executed in three different chondrosarcoma cell lines, using four different 
concentrations of each compound. Six compounds were selected for 
metabolic profiling resulting in the selection of a dual mTORC1 and 
mTORC2 inhibitor sapanisertib as most promising hit. Treatment with 
sapanisertib resulted in a reduction in glycolytic as well as oxidative 
metabolism and a dose dependent decrease in viability. In addition, tumour 
growth was slowed down in an orthotopic chondrosarcoma mouse model, 
indicating that inhibiting mTOR as single or combination treatment might 
be a potential option for chondrosarcoma treatment. Chapter 8 shows a 
possible role for the RB1 pathway in radiotherapy resistance in 
chondrosarcoma. Chondrosarcoma cell lines showed variable resistance 
towards γ-radiation. Contradicting previous results [19], chondrosarcoma 
cell lines treated with mutant IDH1 inhibitor AGI-5198 did not show 
differential sensitivity towards γ-radiation, nor a difference in glutathione 
levels. Chondrosarcoma explants treated with γ-radiation showed  a variable 
response pattern, as measured by γ-H2Ax foci quantification. Explants that 
showed less foci, which were considered more radioresistant, showed 
alterations in the RB1 pathway, while these alterations were absent in 
explants with more foci. Further investigation should be performed to 
determine if patients can be selected for treatment with radiotherapy based 
upon RB1 pathway status. 
In conclusion, this thesis shows the identification of several lead targets that 
might be useful as targeted treatment options for chondrosarcoma patients. 
Future research should focus more on the therapeutic value of these targets 
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in a clinical setting. Novel upcoming techniques, such as CRISPR screening 
and 3D models that more closely resemble the patient situation, will improve 
the selection of targetable pathways and will lead to a better translation of  




Chondrosarcomen zijn kwaadaardige kraakbeenvormende tumoren, die zich 
voornamelijk ontwikkelen in de botten van het bekken, de ribben en de 
ledematen. Deze tumoren worden voornamelijk gevonden rond het vijftigste 
levensjaar. Chondrosarcomen zijn verantwoordelijk voor 20% van al de 
kwaadaardige bottumoren [1] en kunnen onderverdeeld worden in : 
conventioneel chondrosarcoom (85%), gededifferentieerd chondrosarcoom 
(10%) [2], mesenchymaal chondrosarcoom (2%) [3], helder cellig 
chondrosarcoom (2%) [4] en periostaal chondrosarcoom (1%) [1]. Het 
conventionele chondrosarcoom is verder onderverdeeld in centraal (85%) en 
perifeer (15%), op basis van de locatie centraal in het merg (de medulla) of 
aan het oppervlak van het bot. De histologische kenmerken van centrale en 
perifere chondrosarcomen zijn hetzelfde, maar ze vertonen een andere 
genetische achtergrond; centrale chondrosarcomen hebben een mutatie in 
IDH1 of IDH2 in circa vijftig procent van de gevallen, terwijl mutaties in EXT1 
of EXT2 belangrijk zijn bij het ontstaan van perifere chondrosarcomen. 
Conventionele chondrosarcomen kunnen op basis van de histologische 
kenmerken worden onderverdeeld in drie verschillende graden (graad I-III). 
Graad III chondrosarcomen zijn het meest kwaadaardig en patiënten met 
deze tumor hebben een 10 jaars overleving van 26-29% [1, 5-7]. 
Gededifferentieerd chondrosarcoom is een hooggradige tumor die in circa 
vijftig procent van de gevallen een IDH1- of IDH2-mutatie laat zien [8]. 
Patiënten met gededifferentieerd chondrosarcoom hebben een 10-jaars 
overlevingskans van slechts 10-28%, afhankelijk van de aanwezigheid van 
metastasen [9]. Mesenchymale chondrosarcomen worden genetisch 
gekenmerkt door een HEY1-NCOA2 fusie en overlevingspercentages over 10 
jaar worden gerapporteerd tussen 27 en 67% [10, 11]. Het heldercellig 
chondrosarcoom is een laaggradige tumor met een sterftecijfer van 15% [12]. 
Er zijn geen specifieke genetische veranderingen geïdentificeerd in dit 
subtype. Periostale chondrosarcomen zijn zeer zeldzaam en er zijn weinig 
onderzoeken gerapporteerd waarin dit subtype werd onderzocht. IDH1 of 
IDH2 mutaties zijn geïdentificeerd in 15% van de gevallen [13]. 
In dit proefschrift worden experimenten beschreven waarbij siRNA en 
compound screens zijn gebruikt om nieuwe therapeutische opties te vinden 
voor het behandelen van chondrosarcomen. Verder wordt de rol van 
apoptose eiwitten van de Bcl-2 familie beschreven en een studie waarbij 
gekeken is naar radioresistentie mechanismen in chondrosarcoom cellijnen 
en patiënt weefsel. In Hoofdstuk 2 wordt een overzicht gegeven van 
genetische en andere belangrijke veranderingen die zijn gevonden in de 
verschillende subtypen van het chondrosarcoom. Dit illustreert de 
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complexiteit en heterogeniteit van de verschillende chondrosarcoom 
subtypen. Hoofdstuk 3 beschrijft de karakterisatie van een nieuwe 
mesenchymale chondrosarcoom cellijn MCS170; de eerste cellijn 
beschreven van dit zeldzame chondrosarcoom subtype. We bevestigden de 
aanwezigheid van de karakteristieke HEY1-NCAO2 fusie en detecteerden 
een hoge expressie van apoptose eiwitten Bcl-2 en vooral Bcl-xl. Remmen 
van deze Bcl-2 familie eiwitten met ABT-737 zorgde er voor dat de cellen veel 
gevoeliger werden voor chemotherapie, zoals ook al eerder werd aangetoond 
voor het conventionele en gededifferentieerd chondrosarcoom [14, 15]. 
Hoofdstuk 4 gaat dieper in op de rol van Bcl-2-familie eiwitten in het 
chondrosarcoom en resistentie tegen conventionele chemotherapie. We 
onderzochten de remming van Bcl-2 en Bcl-xl specifiek in chondrosarcoom 
cellijnen en in een rat chondrosarcoom model. Uit deze experimenten 
konden we concluderen dat niet Bcl-2, maar Bcl-xl het belangrijkst is voor 
de overleving van chondrosarcoom cellen zowel in vitro als in vivo. Een 
subset van cellijnen vertoonde een synergistische respons wanneer Bcl-xl 
werd geremd in combinatie met chemotherapie, wat aangeeft dat de 
betrokkenheid van Bcl-xl bij chemotherapieresistentie heterogeen is in dit 
panel van chondrosarcoom cellijnen. Dit toont aan dat verder onderzoek, en 
mogelijk ook een gepersonaliseerde benadering, nodig is om te beoordelen 
of de combinatie van Bcl-xl remmers en chemotherapie toepasbaar is bij 
patiënten met een chondrosarcoom. Hoofdstuk 5 beschrijft de identificatie 
van survivin als een essentiële regulator in chondrosarcoom cellen. Een 
siRNA-screen gericht op 51 apoptose gerelateerde genen identificeerde 
BIRC5, coderend voor het survivin eiwit, als essentieel voor de overleving 
van chondrosarcoom cellijnen. Survivin heeft meerdere functies, afhankelijk 
van de locatie in de cel [16]. Survivin in de kern speelt een rol in de celcyclus, 
terwijl cytoplasmatisch survivin betrokken is bij apoptose. In onze studie 
tonen we aan dat expressie van survivin in zowel de kern als het cytoplasma 
gecorreleerd waren met een hogere histologische graad en dus met 
toegenomen agressiviteit van de tumor. Bovendien was survivin expressie in 
de kern gecorreleerd met P53 expressie. Vooral TP53 gemuteerde 
chondrosarcoom cellijnen waren gevoelig voor het remmen van Survivin. Dit 
resulteerde niet in apoptose, maar wel verstoring van de celcyclus. Dit toont 
aan dat het remmen van Survivin een mogelijke therapeutische optie kan 
zijn voor patiënten met TP53 gemuteerd chondrosarcoom. In Hoofdstuk 6 
wordt de ontdekking van celcyclus eiwitten als mogelijke therapeutische 
optie voor patiënten met een chondrosarcoom beschreven. Door het 
uitvoeren van een specifiek op kinases gerichte siRNA (n = 779) en drug 
screen (n = 273) werden PLK1, CHK1 en AURKA ontdekt als cruciale eiwitten 
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voor de overleving van chondrosarcoom cellen. Kinaseremmers die zich 
richten op deze drie eiwitten werden gevalideerd in een panel van 
chondrosarcoom cellijnen waarbij de vitaliteit van de cellen afnam bij 
toename van de dosis. Tevens werd een verhoogde gevoeligheid voor 
conventionele chemotherapie na CHK1 remming gezien. Expressie van 
AURKA en CHK1, maar niet van PLK1, werd waargenomen in 
chondrosarcoom tumor weefsel, wat vraagtekens zet bij het belang van het 
remmen van PLK1 als behandelingsmethode voor chondrosarcoom 
patiënten. CHK1 expressie was gecorreleerd met een slechtere algehele 
overleving. Hoewel verder onderzoek nodig is om deze bevindingen te 
valideren, lijkt CHK1 de meest veelbelovende kinase om te remmen in 
patiënten met een niet operabel of gemetastaseerd chondrosarcoom. 
Hoofdstuk 7 richt zich op het chondrosarcoom metabolisme en hoe deze 
eventueel te gebruiken als therapeutische optie. Een drug screen met 39 
metabole drugs, gericht tegen verschillende metabole cellulaire systemen 
werd uitgevoerd in chondrosarcoom cellijnen. Na een aantal selectieronden 
werd mTORC1 en mTORC2 remmer sapanisertib geïdentificeerd als meest 
veelbelovende hit. Behandeling met sapanisertib zorgde voor een 
vermindering van zowel het glycolytische als oxidatieve metabolisme en een 
afname van de vitaliteit in chondrosarcoom cellen, bij een toenemende dosis. 
Bovendien werd de groei van de tumor vertraagd in een chondrosarcoom 
muismodel, wat aangeeft dat het remmen van mTOR als enkele of 
gecombineerde behandeling een mogelijke optie voor chondrosarcoom 
behandeling zou kunnen zijn. Hoofdstuk 8 toont een mogelijke rol voor de 
RB1 signaaltransductie route in de ongevoeligheid voor radiotherapie die 
word gezien bij chondrosarcomen. Chondrosarcoom cellijnen vertonen een 
wisselde gevoeligheid voor y-straling. In tegenstelling tot eerdere resultaten 
[17], vertoonden chondrosarcoom cellijnen behandeld met IDH1-remmer 
AGI-5198 geen verlaagde gevoeligheid voor γ-straling en ook geen verschil in 
glutathion levels. Chondrosarcoom tumorweefsels van patiënten, ex vivo 
behandeld met γ-straling, vertoonden een variabele respons, zoals gemeten 
met γ-H2Ax foci kwantificatie. Onze resultaten lieten zien dat tumoren die 
minder foci ontwikkelden na bestraling, en dus als meer radioresistent 
werden beschouwd, genetische veranderingen in de RB1 
signaaltransductieroute vertoonden. Tumoren die meer foci ontwikkelden 
na bestraling lieten deze veranderingen niet zien. Of selectie voor 
radiotherapie kan worden gebaseerd op een intacte RB1 signaaltransductie 
route moet nader worden onderzocht. 
Concluderend beschrijft dit proefschrift de identificatie van verschillende 
eiwitten die belangrijk zijn voor de overleving en chemo- en radioresistentie 
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van chondrosarcoom cellen. Toekomstig onderzoek naar deze eiwitten moet 
uitwijzen of deze geschikt zijn als therapeutische aangrijpingspunten. 
Nieuwe opkomende technieken, zoals CRISPR-screening en 3D-modellen die 
meer op de patiënten situatie lijken, zullen de selectie van relevante targets 
verbeteren en leiden tot een betere vertaling van preklinisch onderzoek naar 
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